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Abstract
Virus filtration is an integral part of the downstream purification of mammalian cell
culture-derived biotherapeutics to assure the viral safety of the products. Virus filtration
membranes remove viruses based on a size-exclusion mechanism. Commercial parvovirus filers
possess unique membrane structure and are designed to remove smaller non-enveloped
parvoviruses with size 18-26 nm. However, some filters face issues, such as pre-mature fouling,
the decline of filtrate flux, and reduction in virus retention. This doctoral dissertation focused on
identifying the factors that influence the filtrate flux and the virus retention capability of
commercial virus filters. The effects of solution pH and ionic strength, buffer type, protein
molecules, and filter properties on virus filters' performance are investigated.
In Chapter 2, virus filtration was performed for an Fc-fusion protein using three
commercial virus filters in solutions with varying buffer type and salt concentrations. A
combined pore blockage and cake filtration model successfully described the three filters' fouling
behavior in all the solution conditions. The model indicates that the blockage of membrane pores
by larger particles (e.g., virus and protein aggregates) occurs in the initial stage of the filtration,
followed by a cake filtration where particles accumulate on the membrane surface. Both the pore
blockage rate and the rate of increase of protein layer resistance over blocked pores are affected
by the solution conditions and membrane properties.
In Chapter 3, an Food and Drug Administration (FDA) recommended model virus,
minute virus of mice (MVM) was spiked into the solution of three different protein molecules
under various solution conditions, then filtered with three commercial virus filters. The log
reduction values (LRV) were determined to systematically evaluate the effects of solution pH,
salt concentration, buffer species, protein molecules' properties, cumulative viral loads, and the

process interruption on the virus retention capability of the virus filters. The results showed that
some virus filter is more prone to virus breakthrough than the others, both during the filtration
and after a process interruption. In some cases, a higher flux is associated with a more significant
LRV decline.
The diffusion interaction parameter, 𝑘𝐷 , is an indicator of colloidal and thermal stability
of proteins in solution and a negative 𝑘𝐷 represents the presence of attractive intermolecular
forces. The 𝑘𝐷 of a monoclonal antibody was determined in various solution conditions and was
found to be affected by the pH, ionic strength, and the buffer species. Besides, a more negative
𝑘𝐷 value is associated with a lower average relative flux of a commercial virus filter. These
results indicate that 𝑘𝐷 can be potentially used as an indicator of virus filter performance. The
comparison between a two-layer membrane and a single-layer module of the same membrane
was made to investigate the cause for their difference in virus retention. Fluorescent labeling of
the virus and the protein was done; confocal imaging of the membranes after filtration was done
as well to visualize the location of the captured virus and protein within the membrane.
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Chapter 1 Introduction
1.1 Production of Biotherapeutics and Downstream Purification

Biotechnology refers to the creation and manufacturing of biological products using living
organisms or molecular engineering methods (Evens & Kaitin, 2015). In the health care field,
human beings have been benefited from biotechnological products for more than two centuries
since the English surgeon Edward Jenner treated a child with a viral smallpox vaccine in 1761.
In the earlier stages, the most common biotechnological products include natural or synthetic
antibiotics (i.e., Penicillin) and hormones (i.e., insulin) (BIO: Making History, 2020). In the
1980s, pharmaceutical and biotech companies started to focus on developing biologics, the largemolecule drugs produced with the engineered form of biological tissue, and the major
biotechnology products include vaccines, recombinant DNA proteins, and monoclonal antibodies
(Evens & Kaitin, 2015). Compared to conventional small-molecule drugs, biologics exhibit high
specificity and activity, rarely cause side effects by targeting only specific molecules. Also, the
success rate of the biotechnology molecules entering clinical trials, getting approved, and
marketed is significantly higher than small molecule drugs (25%-32% VS 10-13% in 1990 and
2000s) (Evens & Kaitin, 2015) (CSDD, 2005) (CSDD, 2009). More and more pharmaceutical
companies devoted to developing biopharmaceuticals and a large number of molecules gained
approval in Europe and U.S regions. With a current growth rate of over 15% annually, the world
market value for biopharmaceuticals is forecasted to reach $305 Billion by 2020 (McAuliffe,
2018). Meanwhile, from the initial discovery, it takes more than 10 years for a new drug to reach
the marketplace with an average development cost of $2.6 billion (PhRMA, 2015).
Several expression systems can be used for biopharmaceutical productions. The small
recombinant proteins, which do not need post-translational modifications, are commonly
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expressed and produced on a large-scale using bacterial expression systems (e.g., E.coli)
(Sanchez-Garcia, et al., 2016); the yeast expression system can provide proper post-translational
modification, while it also produces some undesired hypermannosylation comes with low
product yield (Gupta & Shukla, 2017) (Dalton & Barton, 2014) (Ahmad, Hirz, Pichler, &
Schwab, 2014). Insect cell lines, plant expression systems, and transgenic animals are also used
to express biologics. The cell-free protein synthesis is now getting more attention because it has
many advantages: the system is able to produce difficult proteins, and the expression
environment is not limited by homeostasis conditions to maintain cell viability; additionally, it
can save the efforts from complicated and costly steps such as gene transfection, cell culture and
extensive protein purification (Kesik‐Brodacka, 2018) (Shinoda, et al., 2016). However, due to
its low product yield, the technology is still under development.
Monoclonal antibodies (mAb) and vaccines are the two largest groups of products. From
2015 to July 2018, the monoclonal antibody made up 53% of the first-time approval (Walsh,
2018). mAbs are a group of large (approximately 150 kDa) multimeric (Buss, Henderson,
McFarlane, Shenton, & Haan, 2012) proteins comprising pairs of heavy and light chains
connected with disulfide bonds. Antibody glycosylation is an enzymatic post-translational
modification process that results in the attachment of glycans to the heavy chains of the antibody,
and the glycosylation patterns can affect antibodies’ effector functions and half-life (Buss,
Henderson, McFarlane, Shenton, & Haan, 2012). Traditional antigen-specific murine
monoclonal antibodies can be produced in large quantities by the hybridoma cells developed by
merging a plasma cell and a multiple myeloma cell (Evens & Kaitin, 2015). However, to enable
proper folding and glycosylation, molecularly engineered antibodies with enhanced efficiency
and lessened immune response, such as chimeric (30% components are murine and 70% are
2

human) and humanized (90% human) mAbs need to be produced from recombinant genes that
are reintroduced into mammalian cells (Evens & Kaitin, 2015). Production of mAbs using
animal cells in general or mammalian cells does not require cell lysis to extract the target
proteins since these cells can secret the recombinant proteins. From 2015 to 2018 July, 79% of
the approved biopharmaceutical products are expressed in mammalian cell lines (relative to nonmammalian-based production cells) (BIO: Making History, 2020). The most commonly used cell
lines are human cell lines (e.g., CAP, PER.C6, HT-1080, and HEK293), rodent cell lines (e.g.,
Sp2/0, BHK, and NS0) (Estes & Melville, 2014). Chinses Hamster Ovary cells (CHO) is the
primary choice for recombinant protein, with 7 out of 10 top-selling biopharmaceuticals are
produced in CHO (Kesik‐Brodacka, 2018). Because CHO met all the criteria for an expression
system by providing a close to human glycosylation pattern and a high specific production rate
and accepting foreign DNA, then stably express the desired protein. Furthermore, the cell line
has been extensively studied.
Currently, mAbs and derivative antibodies are used for treating diseases such as cancer,
inflammatory diseases, cardiovascular diseases, organ transplantations, infections, respiratory
diseases, and ophthalmologic diseases (Kesik‐Brodacka, 2018). Studies have shown that these
molecules must be injected in large doses over a long period to achieve clinical efficiency
(Chames, Regenmortel, Weiss, & Baty, 2009). For example, 6-12 g of Rituximab, the drug used
to treat certain autoimmune diseases and types of cancer, is needed per patient and year
(Genentech, n.d.) (Seymour, 2016). According to a demand forecast made by BioProcess
Technology Consultants, the overall kilogram requirements need to meet commercial product
demand will increase to 40 metric tons in 2020 (Seymour, 2016). The increasing demand
requires drug manufacturers to produce and purify these biological molecules with cost and time
3

efficiency. With two decades of intensive research and development in the cell line, media, and
bioreactor condition optimization, high protein titers up to 10 g/L and cell densities over 100
million cells/mL with cell-specific productivity over 20 pg/cell/day can be reached (Li,
Vijayasankaran, Shen, Kiss, & Amanullah, 2010) (Wurm, 2004). The challenge then has shifted
to the downstream to develop and scale purification processes that can yield kilogram quantities
of purified mAb at the lowest possible cost.
mAbs are first produced in upstream in bioreactors through a fermentation process. In
addition to the cells themselves, some additional supplements, as well as a cell culture medium
that contains amino acids, inorganic salts, vitamins, glucose, and other organic substances, are
added into the bioreactors (Sommerfelda & Strube, 2005). Secreted proteins can be separated
and purified from the complex mixture of fermentation broth in downstream. The mixture
includes not only the above-mentioned cell culture medium but also various impurities released
from the cells that are destroyed during fermentation. The presence of both the product-related
and process-related impurities could pose safety and efficacy risks (e.g., immunogenicity,
toxicity, endotoxin shock). The product-related impurities refer to the molecular variants such as
aggregates, fragments, oxidized or deaminated species; the process-related impurities refer to the
ones derived from the manufacturing process, including HCP, endogenous virus-like particles
(RVLP), leachates, and reaction byproducts (Downey, 2017). Some properties of the
contaminants are summarized below (Table 1.1) (Singh, et al., 2016). In downstream,
monoclonal antibodies go through clarification, capturing, purification, and polishing steps to
reach the final purify and quality requirements (e.g., HCP< 100 ppm; host cell DNA<100 ppm)
(Liu, Wickramasinghe, & Qian., 2017) (Chollangi, et al., 2015). Commonly used unit operations
for mAb purification have been summarized in Table 1.2.
4

Table 1.1 Properties and sources of contaminants commonly found in CHO cell harvest and
process intermediates (adapted from a table in (Singh, et al., 2016))
Molecular weight
Isoelectric point (pI)
Contaminant
Hydrophobicity
(M.W.) range (kDa)
range
Host cell proteins
10-200
2-11
Variable
(HCPs)
Host cell DNAs
90-1000
2-3
Low
Protein A
6
4.8-5.2
Low
Endotoxin
3-40
1-4
Variable
Viruses
200-7200
4-7.5
Variable
The final goal of downstream purification is to predictably and reliably produce drug
products suitable for humans. The two significant challenges in current biopharmaceutical
manufacturing are reducing impurity levels and the processing time while achieving high endconcentration (Marichal-Gallardo & Alvarez, 2012).
Centrifugation and depth filtration are commonly coupled to be employed for the primary
harvesting of therapeutic proteins, removing cell debris and host cells. The harvested cell culture
fluid (HCCF) from these steps is clarified, thus suitable for the following chromatography steps.
Centrifugation efficiency is affected by multiple factors, including hardware such as bowl
geometry and G-force, and the cell culture fluid properties such as cell density. Most
biopharmaceutical harvesting operations prefer dis-stack centrifugation over other centrifuge
types because of its lower-shear design and continuous discharge mechanism (Turner, Joseph,
Titchener-Hooker, & Bender, 2018). Centrifuge steps should be modified to achieve higher
sedimentation of submicron particles while minimizing the generation of cell debris and cell
lysis. Depth filter comprises an ionic binder, a cellulose frame, and a porous filter aid (e.g.,
diatomaceous earth). It removes impurities based on several mechanisms, such as sieving and
electrostatic interactions.
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Affinity chromatography, Protein A is applied as a capturing step. It is a powerful and selective
unit operation that can remove most impurities based on the specific affinity between the Fc
region of IgG and Protein A, which is covalently attached to the chromatography matrix. Protein
A is a naturally occurring polypeptide with a molecular weight of 42 kDa from the cell wall of
the bacteria Staphylococcus aureus. The loading onto Protein A occurs pH 6-8 when the histidyl
residues on the Fc remain unchanged and binds to the ligand through hydrophobic interactions;
intermediate washing removes some unbound impurities, followed by an elution occurs at pH
2.5-4 when the histidyl residues become charged and allow the IgG to be detached from Protein
A due to a repulsive force (Marichal-Gallardo & Alvarez, 2012) (Li, Dowd, Stewart, Burton, &
Lowe, 1998). The elution pH is suitable for inactivating some enveloped viruses such as
Xenotropic murine leukemia virus-related virus. Thus, Protein A is always followed by a low pH
hold for virus inactivation.
The elute from the affinity chromatography is typically relatively pure, with 200-3000
ppm HCP, 3-40 ppm Protein A leachates (M.W.: 6-40 kDa), and 0.5-25% HMW aggregates
(Chollangi, et al., 2015) (Kim, Chen, & Fane, 1993) (Carter-Franklin, Victa, McDonald, &
Fahrner, 2007) (Fahrner, et al., 2001). A well-designed polishing step can remove >2 logs
leached protein A, > 3 logs nucleic acids, > 4 logs HCP, > 5 logs retrovirus and 20 folds
reduction in product aggregates (Kelley, Blank, & Lee, 2009). The most commonly used unit
operations for polishing are ion (Liu, Ma, Winter, & Bayer, 2010)-exchange chromatography
(IEX) and hydrophobic interaction chromatography (HIC).
Ion exchange chromatography (IEX): Ion exchange chromatography removes impurities such as
host cell proteins and DNA, leached Protein A, and high molecular weight species, based on the
charge difference between these impurities and the mAbs. For anion exchange chromatography
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(AEX), the functional groups are positively charged and bind to negatively charged processrelated impurities (e.g., host cell protein and DNA) types of impurities at neutral pH conditions.
Both the weakly basic groups (e.g., diethylamino ethyl, DEAE or dimethylamino ethyl, DMAE)
and strongly basic (e.g., quaternary aminoethyl, Q or trimethylammonium ethyl, TMAW or
quaternary aminoethyl, QAE) can be used. AEX can either operate in flowthrough mode, where
impurities get captured, or in bind-and-elute mode. For cation exchange chromatography (CEX),
the functional groups are negatively charged, and they can remove host cell DNA and proteins
and product-related impurities such as oxidized species, N-terminal truncated forms. Both the
weakly acidic groups (e.g., carboxylic group) and strongly acidic (e.g., sulfopropyl, sulfoethyl,
and sulfa isobutyl groups) can be immobilized on the resin backbones (Liu, Ma, Winter, &
Bayer, 2010). CEX often operates in a bind-and-elute mode for the purification of mAbs with
neutral or basic pIs, where the mAbs eluted in with increasing salt condition or increasing pH.
Hydrophobic interaction chromatography (HIC): HIC is used as a complementary technique to
the other steps as it removes impurities based on hydrophobicity difference. As the hydrophobic
regions of proteins are exposed in a high-salt loading condition, they get captured by ligands
such as N-alkyl (C1-C8) and aryl (phenyl). The more hydrophobic impurities like high molecular
weight aggregates are more tightly bound to the ligands. Elution occurs when salt concentration
decreases gradually. Depending on the needs, HIC can operate either in flowthrough or in bindand-elute mode.
Virus Clearance: Virus clearance strategies are discussed in detail in the next section.
Ultrafiltration and diafiltration (UF/DF) is used for concentration and buffer exchange of
proteins, mostly at the end of a purification train as the final formulation step. It can separate
species ranging in molecular weight from 500 Da to 1,000 kDa using membranes with pore size
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1-20 nm (Tutunjian, 1983), with the product protein retained by the membrane while buffer
passes through the pores. Those membranes are typically composed of a thin skin layer,
controlling the selectivity, and a macroporous layer for providing mechanical strength. The
UF/DF step is operated in tangential flow filtration (TFF) mode at constant pressure (retentate
pressure or transmembrane pressure) or constant filtrate flux, where the flow consistently sweeps
the filter surface and preventing the formation of a gel layer. The protein concentration at this
step is typically very high, thus optimizing the operating condition of UF/DF to reduce the loss
of product is critical in downstream process development.
Other options: Flocculation/ precipitation: In some cases, when a larger number of cells and
cell debris are present in the fermentation broth, it requires a much greater depth filter area to
remove those impurities. To reduce the burden of depth filtration, flocculation and precipitation
can be used before the step. As commonly used flocculation (or precipitation) agents, acetic or
cationic polyelectrolytes can adsorb to a particle to create an oppositely charged patch, which
can then adhere to a bare patch on an opposing particle surface due to electrostatic interaction
(Liu, Ma, Winter, & Bayer, 2010) (Wang, 1989) (Dunnill, 1995). Chitosan, calcium chloride,
and potassium phosphate are considered as safe flocculation agents (Liu, Ma, Winter, & Bayer,
2010). However, when flocculants are used, their influence on the efficiency of the following
purification steps, and the ways to remove them from the final drug product should be
considered.
Membrane chromatography (MC) is an alternative to column chromatographies, which presents
some disadvantages such as high pressure drop within the column and slow intraparticle
diffusion (Boi, 2007). MC purifies proteins with a multi-layer microporous membrane with the
functional ligands attached to the internal pore surface. Compared to packed bed
8

chromatography, the binding capacities of membrane chromatography is independent of flow
rates because biomolecules are transported to the binding sites by convection instead of diffusion
(Blank, 2001). Other advantages include the reduced buffer usage due to the smaller void volume
and the reduced revalidation cost because that membrane chromatography is mostly single-use
due to the lower material cost (Liu, Wickramasinghe, & Qian, 2017). The base membranes are
mostly made of polyethersulfone (PES), polyvinylidene fluoride (PVDF), and regenerated
cellulose (RC), while the ligands are the same as the ones of column chromatography. However,
membrane chromatography also has some drawbacks, such as low binding capacities in a bindand-elute mode (Tressel, 2006). Several commercial quaternary amine (Q) membranes are
developed for mAb purification, including Natrix®, Sartobind®, and Mustang®, to remove
negatively charged host cell protein, DNA, and viruses.
Multimodal chromatography and membrane chromatography (MMC & MMM): Multimodal
chromatography provides new solutions to protein purification by binding to the target or
impurities by multiple interaction mechanisms, including hydrogen bonding, van der Waals,
electrostatic and hydrophobic interactions. These interactions are influenced by resin chemistry,
protein molecules, and solution conditions. Ligand development plays a crucial role in MMC
since a right balance between the electrostatic and hydrophobic moieties can offer better salt
tolerance and higher binding capacity than traditional chromatography. For example, Capto™
adhere developed by GE Healthcare, has N-benzyl methyl ethanolamine ligands, and is marketed
as an alternative to conventional IEX and HIC (GE, 2013).
Other chromatography steps: other alternatives are also available, such as weak partitioning
chromatography (WPC), hydrophobic charge induction chromatography (HCIC), ceramic
hydroxyapatite chromatography (CHT) (Liu, Ma, Winter, & Bayer, 2010).
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Table 1.2 An example of a downstream purification train for a monoclonal antibody and the
function, matrix, operation mode/conditions, working mechanisms, and limitations of each unit
operation (Ghose, Tao, Conley, & Cecchini, 2013) (Marichal-Gallardo & Alvarez, 2012)
(Turner, Joseph, Titchener-Hooker, & Bender, 2018) (Liu, Ma, Winter, & Bayer, 2010).

1

2

3

4

Matrix/
Device

Unit operation

Function

Centrifugation

Primary
harvesting
step;
Separation
or retention
of cells and
cell debris
from the
supernatant
containing
target
molecules

Dis-stack
centrifuge

Depth filtration

Secondary
harvesting
step;
removal of
cells, cell
debris, host
cell DNAs,
and
proteins

A porous matrix
(e.g., cellulose
or
polypropylene),
a porous filteraid (e.g.,
diatomaceous
earth), and an
anionically
charged resin
binder

Protein A
affinity
chromatography

Capturing
step:
separate the
target
product
from the
bulk
impurities

Low pH-hold
for viral
inactivation

Inactivation
of
endogenous
or
adventitiou
s virus

Protein A resins
(glass/ silicabased; agarosebased; organic
polymer-based)

Low pH (< pH
3.6 solution
condition
for >30 min, at
≥15°C

Operation
mode/
conditions

Working
mechanism

Limitations

Centrifugatio
n force that
exploits the
density
difference
between
insoluble
solids and a
liquid
medium

A practical
lower limit to
the particle
size exists
(~0.5
microns);
shear damage;
significant
capital
investment

Adsorption
and sizeexclusion

Poor flow
distribution in
the membrane
matrices

Typically,
the
membrane
is single
used

Binding at
pH 6-8,
elution at
pH 2.5-4

Affinity or
hydrophobic
interactions
between the
polypeptide,
Protein A,
and the Fc
region of IgG

Formation of
high
molecular
weight
species due to
acetic elution
conditions;
Protein A
leachates;
high cost;
non-specific
binding of
impurities

Protein A
resins are
typically
used to an
average of
200 cycles
(depends
on the
leachable
and
cleaning
procedure)

Inactivatio
n: Weak
acids

Ionic
destructions
cause
conformation
al changes to
the viral
structural
proteins

Some nonenveloped
viruses are
resistant to
inactivation

Has an
LRV
greater than
6 (robust)

Bowl
speed:
7,0009,000 RPM

Dead-end
filtration
mode,
flow rate
75-135
L/h;
Cell culture
fluid

Comment
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Table 1.2 (Cont.) An example of a downstream purification train for a monoclonal antibody and
the function, matrix, operation mode/conditions, working mechanisms, and limitations of each
unit operation
Step

5

6

7

Function

Matrix/
Device

Operation
mode/
conditions

1st Polishing
chromatography
: e.g., Ion
exchange
chromatography
(IEX)

Removes
Protein A
leaches,
HCP,
DNA,
endotoxin,
viruses,
and HMW
species and
charged
variants

Resin
backbones: the
resin matrix
backbone
includes agarose
and dextran,
glycidyl
methacrylate,
Polystyrenedivinyl
benzene
and
polymethacrylat
e; AEX:
positively
charged
functional
groups.
CEX: negatively
charged
functional
groups

2nd Polishing
chromatography
: e.g.,
Hydrophobic
interaction
chromatography
(HIC)

Remove
product
variants
and
aggregates,
and other
residual
impurities
(HCP, host
cell DNA,
etc.)

Virus filtration

Remove
viruses that
are
resistant to
virus
inactivation

Unit operation

Working
mechanism

Limitations

Comment

AEX: at pH
8.0-8.5 and
low ionic
strength,
operates
mostly in a
flowthrough
mode;
CEX: at pH
4.5-5.5
operates
mostly in a
bind-andelute mode

Electrostatic
interactions
between the
charged resins
and the
oppositely
charged
impurities (or
the target
product)

CEX: at the
operating pH,
protonated
impurities and
phosphorylate
d impurities
(DNA and
endotoxin)
could form
charged
complexes,
making it
difficult to
remove the
impurities

Impurity
removal
efficacy:
1) AEX >
CEX: DNA
and
endotoxin
2) CEX>
AEX: HCP,
leached
Protein A,
HMW

Resins contain
phenyl or butyl
ligands

Loading in
a high salt
buffer;
operates in
bind-andelute or
flowthrough
mode

The
hydrophobic
regions of the
proteins get
exposed in a
high ionic
strength
environment
and bind to
HIC resins
through
hydrophobic
interactions

Limited
binding
capacity; high
salt condition
causes
corrosion of
stainless-steel
tanks

Specially
designed
membrane filters
made of various
polymers

Dead-end
filtration
mode; at
constant
flow or
constant
pressure

Sizeexclusion

High cost;
limited
throughput
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Table 1.2 (Cont.) An example of a downstream purification train for a monoclonal antibody and
the function, matrix, operation mode/conditions, working mechanisms, and limitations of each
unit operation
Step

8

Unit operation

Ultrafiltration/
Diafiltration

Function

Concentrati
on and
buffer
exchange

Matrix/
Device

Ultrafiltration
membranes with
pores ranging
from 1-20 nm
made of
polysulfone,
polyethersulfone
, polyvinylidene
fluoride, and
regenerated
cellulose

Operation
mode/
conditions

Tangential
flow
filtration
mode

Working
mechanism

Limitations

Comment

A pressuredriven
process where
the proteins
are retained
while the old
buffer is
filtered
through (and
a new buffer
is added)

Degradation
of protein and
formation of
aggregation
and
degradation
due to a
combination
of the
physical
stress of
different
origins (e.g.,
pump shear,
flow-induced
shear)

This step
has a high
throughput
and low
resolution

Continuous processing is getting increasing attention from biotherapeutic manufacturers
since it can intensify the purification process by increasing flexibility, improve product quality,
and reduce facility footprint (Somasundaram, Pleitt, Shave, & Baker, 2018). In continuous
chromatography, resins are split into numbers of smaller connected columns, and when some
columns are loaded with the product while the others go through the wash, elution, or
regeneration steps. Several commercial continuous systems are available now, such as the
Cadence™ BioSMB (simulated moving bed) PD system by Pall and AKTA™ PCC 75 (Periodic
countercurrent chromatography) by GE Healthcare. For the primary capturing and the polishing
step, selection of resins, reusability of columns, and the timing (time for loading ≥ time for
wash/regeneration) are critical factors to consider when designing a process (Zydney A. L.,
2016). Continuous unit operations other than chromatography are developed as well.
Alternative tangential flow (ATF) filtration, integrated with perfusion bioreactor, is used for the
clarification step. It reduces the damage to the cells by using a low shear diaphragm pump
(Clincke, et al., 2013). High-performance tangential flow filtration (HPTFF) is an alternative to
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the polishing columns as it can separate proteins from impurities at a high resolution, based on
both the size and charge differences (Zydney & Reis, 2001). Single-pass tangential flow
filtration (SPTFF) can concentrate the protein into the drug substance during the last formulation
step in a continuous process. The ‘single-pass’ refers that the product passes through the
membrane only once, without recirculating back to the retentate tank (Zydney A. L., 2016). A
membrane module with a larger area enables the ‘single-pass.’ For example, the Cadence™
system by Pall concentrated a mAb for 4-5 times within a single pass (Casey, Gallos, Alekseev,
Ayturk, & Pearl, 2011). This was accomplished by a unique set-up where a series of membranes
with sequentially decreasing areas are lined-up in a single module, allowing a higher conversion
rate by compensating for the reducing retentate volume (Zydney A. L., 2016). Virus clearance in
a continuous process has been studied as well and is discussed in the following section.
1.2 Viral Safety of Biopharmaceuticals and Virus Clearance Strategies

In the manufacturing process of biopharmaceutical products that use animal-derived
materials, there is a potential risk of contamination with animal viruses. Throughout history,
many human pathogen contamination incidents had happened to biotherapeutic products that are
administrated for human use, such as human blood- and plasma-derived products. For example,
in the 1970s, the human growth hormone extracted from cadavers led to the death of numerous
people from Creutzfeld-Jacob disease (CJD) because the extract hormone got contaminated with
infectious agents (Brown, Gajdusek, Gibbs, & Asher, 1985). Animal viruses, especially
mammalian viruses, should also be concerned about since approximately 60% of all human
pathogens are zoonic, and about 75% of recently emerging infectious diseases affecting humans
are the disease of animal origin (CDC, n.d.). Numerous routes could cause viral contamination in
biopharmaceuticals, namely endogenous/intrinsic viral load associated with the cell line,
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manufacturing environment (e.g., personnel, equipment, facilities), and the material/reagents
used in production, purification, and formulation (Aranha, 2011). Retrovirus, Minute Virus of
Mice (MVM), Cache Valley virus (CVV), Sindbis, Encephalomyocarditis Virus, and Vesivirus
2117 are proven to be commonly found in CHO cell cultures, the cell line that is commonly used
for mAb production (Berting, Farcet, & Kreil, 2010). Virus contamination in monoclonal
antibody is rare; however, it can be catastrophic once it happens. Contamination with infectious
pathogens could not only directly impact on patients’ safety but also have indirect impacts such
as a shortage of availability of the drug. It could be life-threatening for some patients since many
products are still under patent and single-sourced. Also, contamination events have severe
impacts for the drug manufacturer, such as impacts on public perception, regulatory implications,
facility or production shutdown, financial losses, and losing opportunity due to competition
(Aranha, 2011). In 2009, virus contamination was found in drug manufacturer Genzyme’s
bioreactor that led to a temporary closing of the manufacturing plant and halted the production of
drugs used by 8,000 patients. It was estimated that the incident could cause the company up to
$300 million in lost revenue, a $175 million fine charge by U.S Food and Drug Administration
(FDA) (Shutterstock, 2018).
In the U.S. and Europe, regulatory authorities formulated guidelines designed to
minimize any potential risk of viral contamination. They are ‘(Q5A) Viral Safety Evaluation of
Biotechnology Products Derived from Cell lines of Human or Animal origin’ by the
International Conference on Harmonization (ICH), ‘Points to Consider in the Manufacture and
Testing of Monoclonal Antibody Products for Human Use’ by FDA and ‘Guideline on virus
safety evaluation of biotechnological investigational medicinal products’ by European Medicines
Evaluation Agency (EMEA) (ICH, 1998) (FDA, 1997) (EMA, 2008). There is a so-called ‘viral
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safety tripod’ that comprises the following risk mitigation strategies: 1) appropriate sourcing; 2)
demonstration of viral clearance capacity through the manufacturing processes; 3) in-process
control (Aranha, 2011). The ‘appropriate sourcing’ refers to extensive testing of the cell banks,
unpurified bulk material, and the final product for the presence of infectious agents.
Manufacturers also integrate at least two orthogonal virus clearance steps in the downstream
purification train for adequate removal of viruses. Lastly, appropriately designed virus clearance
validation studies are performed to evaluate the ‘virus clearance capacity’ of an inactivation or
removal step. Log Reduction Value (LRV) is a commonly used term for the characterization of
virus clearance:
𝐿𝑅𝑉 = 𝐿𝑜𝑔10

𝐶𝑓𝑑 ×𝑉𝑓𝑑
𝐶×𝑉

(Eq. 1.1)

Where 𝐶𝑓𝑑 is the virus titer in the feed, 𝑉𝑓𝑑 is the volume of the product processed through the
virus clearance step; 𝐶 and 𝑉 are the virus titer and the volume of the solution after the process,
respectively. Commonly used virus clearance strategies are summarized in the following table.
Table 1.3 Commonly used virus clearance strategies in downstream processing.
Virus clearance strategy

Low pH

<1 for parvovirus;
>5 for retrovirus

Solvent/Detergent

≥ 6 for retrovirus

Virus filtration

>4 for parvovirus;
>5 for retrovirus

Affinity
Chromatography

1-3 for parvovirus;
1-5 for retrovirus

Anion Exchange
Chromatography
Cation Exchange
Chromatography

2-5 for parvovirus;
~4-5 for retrovirus
~1 for parvovirus;
2-3 for retrovirus
0-6 for retrovirus and
parvovirus

Inactivation

Removal

Log Reduction Value
(LRV)

Membrane adsorbers

Mechanism

Limitation

Ionic disruption of the
envelope and
destructive
conformational changes
of structural proteins
Inactivation by lipid
dissolution

Inactivation of
enveloped virus only

Size-exclusion

Low throughput

Protein denaturation
due to low pH

Influenced by feed
stock quality and
composition
Electrostatic interaction
Buffer conditiondependent;
non-robust

15

Viruses either can be inactivated or removed from the product stream. One of the most
commonly used virus clearance methods is low pH inactivation. This method can efficiently
inactivate enveloped viruses. Viral inactivation is conducted between pH 3.0 and 4.0 for at least
10-15 minutes, and some studies have shown that a robust viral inactivation requires a pH 3.6 or
below (Chen, 2014). This inactivation is compatible with mAb downstream purification process
since the Protein A chromatography columns are eluted at low pH conditions. The low pH
conditions are achieved by adding a weak acid (e.g., citric acid or acetic acid) then neutralized by
the addition of weak base solutions. An LRV over 4.6 was achieved when ≤40 mg of protein was
incubated at room temperature with an acetate or citrate buffer with ≤500 mM NaCl at a pH of
≤3.8 for ≥30 min (Brorson, et al., 2003). However, a high concentration of acid could create a
localized low pH environment that would lead to protein denaturation or aggregation.
Inactivation with solvent detergent can be used for the products that cannot tolerate low pH
conditions. It mainly functions by saturating the viral membrane and fully solubilize the lipid
envelope of viruses into mixed micelles. Combinations of tri-n-butyl phosphate (TNBP; 0.11.0%) with detergent (Triton X-100 or Tween 80; 0.5-1.0%) are commonly used (Brorson, et al.,
2003). This step is often conducted at the beginning stages of the downstream processing so that
the chemicals introduced for viral inactivation can be removed in the following steps. Adding
solvent detergent can also help break up cell membranes and cell debris, thus clarify the bulk
harvest.
Non-enveloped viruses are very difficult to inactivate so that additional virus removal
steps should be introduced. Some chromatography steps can provide 2-3 LRV. However, they
cannot be considered robust since the viral clearance efficiency by chromatography is related to
the physicochemical and biochemical properties of an individual virus and strongly depends on
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the solution conditions (e.g., pH and ionic strength). Affinity chromatography and anion
exchange chromatography (AEX) is most commonly identified by drug manufacturers as
potential viral clearance steps. Removal of viruses with Protein A can be achieved when the
virus flows through the column while the mAbs tightly bind to the resins. According to an
analysis of a large virus clearance database extracted from the studies performed at WuXi
AppTec, four virus families (retrovirus, parvovirus, herpesvirus, and retrovirus 3) have
demonstrated LRVs from 1 to 7 with Protein A chromatography, with clearance for retrovirus
reached 3-5 LRV and for parvovirus reached 1-3 LRV (Cipriano, Burnham, & Hughes, 2012).
However, the feedstock composition and the quality significantly affect the virus removal
efficiency of Protein A. AEX has been proven to provide adequate virus clearance for retroviruslike particles, non-enveloped viruses, and enveloped viruses (Curtis, Lee, Blank, Brorson, & Xu,
2003) (Norling, et al., 2005) (Strauss, et al., 2009). AEX operates at a pH below the isoelectric
point of the mAb so that mAbs are net positively charged and flow through the column while
viruses are negatively charged and bind to the column resins (Gagnon, 1996). A clearance study
for over 21 virus families with multiple AEX resins or membrane adsorbers (Sartobind Q and
Mustang Q) has shown that AEX (in flowthrough mode) is robust in most cases: >65% of the
studies have demonstrated >4 logs parvovirus clearance and >75% studies have shown >4 logs
clearance of retrovirus, herpesviruses, and reoviruses (Cipriano, Burnham, & Hughes, 2012).
Compared to AEX, CEX is less commonly used as a virus clearance step, providing only 1 LRV
for parvovirus and 2-3 LRV for retrovirus. To remove viruses using CEX, it requires the virus to
bind to the resins more tightly than the mAbs (Miesegaes, Lute, & Brorson, 2010). Other options
have been tested for VC as well. Zhou et al. have used commercial depth filters, A1HC, and
CUNO ZA90 disposable capsules, for virus clearance and demonstrated consistent removal of
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viruses (MVM, xMuLv, PRV, and Reo-3) (Zhou, Solamo, Hong, Shearer, & Tressel, 2008).
However, it is challenging from the regulatory aspect to implement depth filtration as a virus
clearance step because qualification methods based on integrity and functionality have not been
established for depth filters yet. In recent years, the potential of using adsorptive filters, such as
Millipore Intercept, Pall Mustang, Sartorius Sartobind, for virus clearance has been explored
(Zhou, Solamo, Hong, Shearer, & Tressel, 2008) (Weaver, Husson, Murphy, & Wickramasinghe,
Anion exchange membrane adsorbers for flow‐through polishing steps: Part II. Virus, host cell
protein, DNA clearance, and antibody recovery, 2013) (Weaver, Husson, Murphy, &
Wickramasinghe, 2013) (Miesegaes G. R., Lute, Read, & Brorson, 2014). Membrane adsorbers
have advantages such as being relatively less costly and providing high flow rates and high
throughputs. However, the high dependence of the adsorptive mechanism on buffer chemistry
and process attributes made it non-robust for virus clearance application (Carter & Lutz, 2002).
Besides, the impurity levels also need to be well controlled since other biomolecules could
quench the filter’s adsorptive capacity.
The above-mentioned ‘virus clearance validation study’ is a critical component of risk
mitigation strategies. They are performed by scaling down the unit operation recognized as
having virus clearance potential, adding virus to the starting material (virus spiking), then taking
the virus-spiked material through these steps. The virus titers of the feed and the
filtrate/flowthrough are determined to calculate the amount of viruses cleared by that step.
According to the guidelines, less than one virus particle is allowed per million doses of
mammalian cell-derived therapeutics (ICH, 1998). Any guideline addresses no particular LRV
because factors such as the dosage, the patient population, and the nature of the cell line must be
considered in the assessment. A typical reasonable goal to target is 3-5 logs reduction value
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higher than the estimated viral particles in one dose, which is approximately equal to 12-18 logs
of endogenous virus and 6 logs of the adventitious virus (Kern & Krishnan, Virus removal by
filtration: points to consider, 2006). LRV of two clearance steps can be added only when the
mechanism of the two steps is different (so-called orthogonal steps) so that at least one robust
viral clearance step should be included in the downstream purification process. A step is
considered robust only when it can be scaled down accurately and reproducibly, and also can
effectively remove/inactivate a wide variety of potential viral contaminants under a wide variety
of process conditions (Darling, 2002). The viruses used for virus clearance validation studies are
selected based on the type of cell-substrate used for mAb production and the potential risk of
introducing adventitious viruses. So that at least one relevant virus, which has been identified as
a potential contaminant of the starting material and one model virus, which represents the
spectrum of different physicochemical characteristics of viruses, should be selected for the virus
clearance validation studies (Darling, 2002). As shown in table 1.4, viruses have various
characteristics regarding their genome (DNA/ RNA; single-stranded or double-stranded),
presence of lipid envelop, size, and resistance to inactivation.
Table 1.4 The viruses that are commonly used for virus clearance validation studies.
Virus
Minute Virus of Mice (MVM)
Hepatitis A Virus
SV 40 virus
Bovine Viral Diarrhea Virus
(BVDV)
Murine Leukemia virus (xMuLv)
Herpes Simplex Virus
Parainfluenza Virus

Envelope
No
No
No

Genome
DNA
RNA
DNA

Size (nm)
18-24
25-30
40-50

Yes

RNA

50-70

Yes
Yes
Yes

RNA
DNA
RNA

80-110
120-200
150-300

Assessment of virus filters with one or two viruses is required for clinical phase
submission, and spiking studies with three to five model viruses are expected to support
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commercial submission of a biopharmaceutical product (Stuckey, et al., 2014). Porcine
parvovirus (PPV), minute virus of mice (MVM), retrovirus type 3 (Reo-3), pseudorabies virus
(PRV), and xenotropic murine leukemia virus (xMuLv) are commonly used for Biological
License Application (BLA) filing. MVM is a small, non-enveloped single-stranded DNA virus.
It is known to contaminate rodent production cell culture. Gefroh et al. made a comprehensive
review of the literature and experimental data from Amgen to provide a rationale for using MVM
as a single-worst case model virus for parvovirus filter validation (Gefroh, Dehghani, McClure,
Connell-Crowley, & Vedantham, 2014). Stucky et al. have summarized a large set of
experimental data from Eli Lily to achieve a modular retrovirus clearance for parvovirus filters
(Stuckey, et al., 2014). According to their review, Planova™ 20N completely retained retrovirus
even when parvovirus breakthrough occurs, and Viresolve® Pro and Virosart® CPV were able to
provide full retention for large viruses (Reo-3 and xMuLv). So, using MVM only for virus filter
validation studies can not only eliminate the need for extra validation with large retroviruses but
also allow us to better understand the robustness of the unit operation and the mechanism behind
the clearance. In this dissertation, MVM has been used as a model virus for all the studies.
1.3 Virus Filtration and virus filtration membranes

Using at least two orthogonal virus clearance steps that employ complementary mechanisms
can give a higher assurance for viral safety because viruses resistant to the first mechanism may
be cleared by the second (Carter & Lutz, 2002). During membrane filtration, retention occurs
when the particles are too large to pass through membrane pores. This mechanism is called sizeexclusion or sieving (Grant, Liu, Fisher, & Bowling, 1989). Size-exclusion is generally
considered the dominant functioning mechanism of virus filtration to complement other virus
clearance steps working based on specific electrostatic or chemical interaction mechanisms (e.g.,
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AEX). Viruses travel along with the fluid, approach, and pass through the porous membrane;
some encounter membrane pores that are too small to penetrate through, thus retained by the
membrane. Size-exclusion is considered a robust mechanism because, in traditional
understanding, it is not easily affected by operating conditions and the feed solution conditions.
In addition to the size-exclusion mechanism, virus particles also can be captured by the virus
filters through other mechanisms such as adsorption, which involves a variety of different forces
on the membrane surface or within membrane pores. These forces include van der Waals forces,
hydrogen bonding, steric entrapment. However, all these mechanisms are not dominant.
Membrane-based separation is preferable because it is simple to operate and causes little
damage to the protein products. Table 1.5 shows currently available commercial virus filters.
They have different membrane characteristics, including various membrane material, surface
modification, structure, module, pore-size distribution, pore structure, virus retention capacity,
protein transmission, and adsorption properties (Sofer, et al., 2005). These commercial virus
filters are all single-use because disposable systems are cost-effective and user-friendly, without
the need for cleaning and further validation.
Table 1.5 Commercial virus filtration membranes (Kern & Krishnan, 2006) (LaCasse, et al.,
2013) (Asahi-Kasei, 2018).
Vendor

Product
Viresolve® NFP

Millipore

Viresolve® NFR
Viresolve® Pro
Ultipor® DV20

Pall
Ultipor® DV50

Membrane
structure

Material

Asymmetric
with 3 layers
Asymmetric
with 3 layers
Asymmetric
with 2 layers
Symmetric
with 2 layers

Hydrophilic
PVDF
Hydrophilic
PES
Hydrophilic
PES
Hydrophilic
PVDF

Symmetric
with 3 layers

Hydrophilic
PVDF

Operation
Mode

Target Virus

Virus size
(nm)

NFF

Parvovirus

28

NFF

Retrovirus

80-130

NFF

Parvovirus

18-24

NFF

Parvovirus

26

NFF

Retrovirus

26;
76-88

Virus retention
claimed by the
vendor
>4 log фX-174
bacteriophage
>6log
retrovirus
≥ 4 log MVM
>3log PP7
bacteriophage
>3 log PP7
bacteriophage;
>6 log PR772
bacteriophage
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Table 1.5 (Cont.) Commercial virus filtration membranes.
Vendor

Membrane
structure

Material

Operation
Mode

Target Virus

Virus size
(nm)

Planova® 15N

Asymmetric;
hollow fiber

Hydrophilic
CRC

TFF/NFF

Parvovirus

18-26;
28-30

Planova® 20N

Asymmetric;
hollow fiber

Hydrophilic
CRC

TFF/NFF

Parvovirus

18-26;
28-30

Planova® 35N

Asymmetric;
hollow fiber

Hydrophilic
CRC

TFF/NFF

Retrovirus

40-70;
80-130

Planova® BioEX

Asymmetric;
hollow fiber

Modified
PVDF

TFF/NFF

Parvovirus

18-24

>4.8 log MVM

Virosart®

Symmetric
with 2 layers

Hydrophilic
PES

Parvovirus

80 ;
80-130

>4 log PP7
bacteriophage
;>6 log PP7
retrovirus

Asahi Kasei

Sartorius

Virus retention
claimed by the
vendor
>6.2 log
parvovirus;
>6.7 log
Poliovirus
>4.3 log
parvovirus;
>6.7 log
polivirus
>5.9 logs
bovine viral
diarrhea virus;
>7.3 log HIV

Product

CPV

NFF

Note: PVDF: Polyvinylidene fluoride; PES: Polyethersulfone; CRC: Cuprammonium
Regenerated Cellulose. TFF: Tangential flow filtration; NFF: Normal flow filtration.
Current virus filtration membranes are ultrafilters or very tight microporous filters. The pore
size rating of the virus filter is vendor-specific. Asahi Kasei uses the average pore size
measurement; for example, Planova™ 15N, 20N, and 75N are filters with pore size15 nm, 19
nm, and 72 nm, respectively. Millipore names their virus filters by the types of viruses retained;
for example, Viresolve® NFR and NFP are normal flow filters for removing retrovirus and
parvovirus, respectively. Pall names by the size of the virus retained by the filters; for example,
Ultipor® DV20 removes viruses as small as 20 nm. Some first-generation virus filters also have
used the nominal molecular weight cut-off (MWCO) for naming, such as Viresolve® 70 and 180
(Millipore) and Omega™ 100K and 300K (Pall).
Two different filtration modes are used for virus filtration: tangential flow filtration (TFF)
and normal flow filtration (NFF). In TFF, the fluid flow occurs parallel to the membrane surface,
and the bulk fluid is recirculated on the upstream side of the filter. In this mode, the ‘tangential
flow’ sweeps the surface of the filer and reduces the pore plugging rates. However, NFF virus
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filtration membranes are now more commonly adapted due to their lower cost and less
complicated design. In NFF, the complete feed flow is pressed through the membrane,
accompanied by an accumulation of the matters on the surface of the membranes.
Virus filters are made of polymers such as Polyvinylidene fluoride (PVDF),
Polyethersulfone (PES), and Cuprammonium Regenerated Cellulose (CRC). The base
membranes are mostly modified to render the filter hydrophilic. Surfactants or humectants can be
added to enhance wettability; preservatives can be added to prevent microbial growth during
storage. Virus filtration membranes typically possess an asymmetric structure. They are
composed of an open porous substructure, which provides mechanical stability, and a thin skin
layer, which provides the retention characteristics for the filter. These virus filters are designed to
be ‘void-free,’ which eliminates defects that can arise from the penetration of finger-like voids
from the substructure through the skin layer (Brorson, Sofer, & Aranha, Nomenclature
standardization for “large pore size” virus-retentive filters, 2005). So, traditional ultrafiltration
membranes cannot be used for virus filtration because of the presence of a small number of
defects. Viresolve® Pro by Millipore has an asymmetric structure and operates in an orientation
where the dense skin side faces away from the feed stream (skin-side down). Planova™ 15N,
20N, and 35N by Asahi Kasei has a multi-layer, capillary-void structure with a thick effective
layer (approximately 35 µm in thickness) with high porosity and possesses a hollow fiber
configuration (Hongo-Hirasakia, Yamaguchib, Yanagidaa, & Okuyamaa, 2006). With the
capillary-void structure, protein molecules can flow through the capillary-void pore structure
while viruses are captured within the void pores and excluded from passing through the capillary
structures. In addition, the multi-layer structure can reduce the risk of virus passage caused by a
deformity in the retentive skin layer.
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Extensive studies done with the earlier generation virus filters, such as Viresolve® 70,
Viresolve® 180, Viresolve® NFP, and Viresolve® NFR can still provide useful insights into the
protein fouling and virus retention mechanism of current-generation virus filters.
1.4 Current Challenges with Virus Filtration
1.4.1 Membrane Fouling and Flux Decay
The filtrate flux of a membrane is calculated by the following equation:
𝑃−𝜎∏

𝐽𝑣 =𝜇(𝑅

𝑚 +𝑅𝑐 )

(Eq. 1.2)

Where 𝐽𝑣 is the volumetric filtrate flux, 𝑃 is the transmembrane pressure, 𝜎 is osmotic reflection
coefficient, ∏ is the osmotic pressure differential. 𝜇 is the solution viscosity. 𝑅𝑚 is the
membrane resistance, which is determined by the membrane characteristics such as thickness,
pore shape, and pore size distribution; 𝑅𝑐 is resistance from the fouling layer, includes the effects
of pore blockage, pore constriction, gel layer formation, and concentration polarization. ∏ is
related to the concentrated protein layer that is immediately upstream of the membrane surface.
𝜎, being equal to 0 for solute with no retention and 1 for the fully retained solute, determines the
magnitude of the influence of osmotic pressure differential on filtrate flux. However, since in
virus filtration feed, there are both protein and virus particles present thus, this equation can not
be directly applied. This is discussed in Chapter 2 of this dissertation in more detail.
The parvovirus diameter is around 18-26 nm, while a typical mAb has a hydrophobic
diameter around 8-12 nm. To provide an efficient virus retention (>4 LRV) as well as a sufficient
protein passage (>98%), parvovirus filters are required to have a very fine pore-size distribution
(PSD). Because of this narrow PSD, virus filters are susceptible to impurities that cause protein
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fouling, which refers to an irreversible alteration of the membrane structure due to interactions
between the proteins and the membrane matrix (Bakhshayeshirad, 2011). This physical
deposition or adsorption of proteins onto or within pores increases Rc, causing flux decline and
capacity reduction. Since virus filtration is the second-most costly purification step in the
downstream process, the developers must understand the fouling mechanism to mitigate filter
pre-mature fouling and reduce the processing time and the costs for membrane consumption.
Many parameters could influence filter fouling, such as the aggregation profile of the feed,
protein solution properties like pH, ionic strength, and buffer type, filter properties like surface
chemistry, pore size distribution, and pore size gradient. It is also important to understand protein
adsorption to solid surfaces.
The fouling species should be removed from the feed before loading onto the virus filter.
Various prefiltration options have enabled increased mass throughput of virus filters, and
analyses of the entrapped species in the pre-filter also allow us to understand the fouling
mechanism of virus filters. Bolton et al. have found that the application of a pre-filter with
entrapped diatomaceous earth, which can hydrophobically bind to fouling species, could increase
the capacity of Viresolve® NFP (normal flow parvovirus) significantly (Bolton, Spector, &
LaCasse, Increasing the capacity of parvovirus‐retentive membranes: performance of the
Viresolve® Prefilter, 2006). The analysis of the fouling species with combined methods
(SDS/PAGE, isoelectric-focusing, size-exclusion chromatography, CD and ANS (1anilinonaphthalene-8-sulphonate titration)) has revealed that oxidized/degraded IgG species or a
subset of IgG molecules with the more hydrophobic antigen-binding surface are responsible for
the flux decay of virus filters. In another study, the application of Viresolve pre-filter (VPF), a
depth filter comprising diatomaceous earth, cellulose fibers, and a negatively charged resin
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binder, has protected Viresolve® NFP from fouling under an adjusted pH (optimal pH: 7-8) and a
high salt condition. In this case, the cellulose backbone and the charged resin binders with ionic
properties contributed to charge-specific bindings, and diatomaceous earth exhibited
hydrophobic binding for the foulants (Ireland, Bolton, & Noguchi, 2005). Using a combination
of a depth filter A1HC, which contains diatomaceous earth and cationic binding groups, and a
virus filter, Viresolve® Pro, which was used as a size-based pre-filter here, has improved the
mass throughput of virus filters Planova™ 20N, Viresolve® Pro and Virosart® CPV (Bolton,
Basha, & LaCasse, 2010). In this particular case, virus filter plugging is primarily caused by
hydrophobic foulants that can be removed by adsorptive filters and larger-particle foulants that
can be removed by a size-retentive pre-filter. However, an increased pre-filter loading, increased
flux, or decreased residence time reduces the pre-filter capacity to protect the virus filter,
suggesting the importance of optimizing those parameters.
Brown et al. preferred ion exchange (IEX) adsorptive filters for prefiltration over depth
filter because the depth filters are not stable in caustic conditions (e.g., sanitization with 0.5 N
NaOH), and the diatomaceous earth generates more leachables than membrane-based filters
(Brown, et al., 2010). IEX membrane adsorber is clean, well-defined, and chemically stable.
After testing IEX filters including Mustang® S, Sartobind® S, Sartobind® Q, and Viresolve®
Shield, they found both anion exchange (AEX) and cation exchange (CEX) membrane adsorber
can improve the capacity of Viresolve® Pro during the filtrations for acetic or basic mAb
respectively. The solution pH and conductivity have a strong influence on the performance of
CEX because foulants removal relies on the electrostatic interactions between the foulants and
the adsorbers. The authors also have analyzed the adsorbers’ elutes with SEC and sedimentation
velocity analysis and found that soluble trace levels of high molecular weight species (HMWS)
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ranging from 8 to 13 nm in the hydrodynamic radius are mainly responsible for VF filter fouling.
In contrast, the filter scale and adsorber brand do not have a significant effect on foulant
adsorption.
Using a novel high throughput filtration screening system, Bieberbach et al. have
characterized the feed stream of virus filters and classified the aggregates into two groups:
reversible and irreversible aggregates (Bieberbach, et al., 2019). They observed that irreversible
aggregates cause irreversible fouling of the membrane, resulting in continuously increasing pore
clotting and continuous reduction of the flux. Those irreversible aggregates can be removed with
hydrophobically interacting pre-filters. On the other hand, reversible aggregates cause reversible
fouling, resulting in concentration-dependent initial flux decay with no further flux decline.
Dilution of the feed can mitigate those flux reductions caused by concentration-dependent
reversible protein oligomer formation. However, this only applies when the virus titer in the feed
solution is high.
The studies mentioned above show that deformed protein molecules are mostly
responsible for virus filter fouling. Proteins deformation/denaturation occurs when exposed to
physical and chemical destabilizing factors, such as covalent bond modification, deamination
reactions, oxidation reactions, cleavage of peptide bonds, adsorption to surfaces, aggregation,
precipitation, and changes in secondary or tertiary structures (Rosenberg, 2010). The virus
filtration step is often placed close towards the end of a mAb purification train, mostly right
before the final formulation (UF/DF) and sterile filtration steps, where the feed stock is relatively
pure (Carter & Lutz, 2002). Nevertheless, proteins still can be exposed to plenty of physical
stresses, such as air-liquid interfaces, solid faces of different hydrophobic or hydrophilic
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materials, and temperature variation, as well as different chemical stresses, including varying pH,
ionic strength, buffer species, and protein concentrations.
Types of salts added can influence the conformational stability of the protein and the
colloidal stability of the system, while pH and ionic strength affect electrostatic interactions, thus
related to the self-association of protein molecules (Rosenberg, 2010). Bakhshayeshi et al.
demonstrated that the Viresolve® 180 membrane capacity for BSA and the protein yield were the
lowest at protein isoelectric point (pI) and increased monotonically with pH above the pI of the
protein (Bakhshayeshi & Zydney, 2008). The authors attributed this to the greater degree of
concentration polarization associated with the smaller diffusion coefficient at the pH. HongoHirasaki et al. have systematically analyzed the effect of solution conditions (ionic strength, pH
and IgG concentration, buffer composition, etc.) on the filter performance of Planova™ 20N
(Hongo‐Hirasaki, Komuro, & Ide, 2010). They found that the optimum protein concentration for
filtration is 10-20 g/L. When the ionic strength is kept higher than 10 mM NaCl, a consistent
high flux was maintained at pH 4-8 under a typical buffer composition (citrate, acetate, and
phosphate buffer), indicating that the ionic strength threshold is 10 mM. Also, by measuring the
zeta potential of the membrane and the protein solution, they concluded that the electrostatic
interactions between the membrane and the antibodies have a dominant influence on the flux and
capacity. The addition of amino acids, such as arginine and histidine, can increase the filter flux
and capacity because it reduces the surface charge of antibodies, thus reduces the electrostatic
interactions. Higuchi et al. have done a series of studies to understand how the presence of DNA,
a common contaminant in the mAb product stream, could influence the performance of
Planova™ 15N, Planova™ 35N, and Planova™ 75N during the filtration of Y-globulin
(Higuchi, et al., 2001) (Higuchi, et al., 2002) (Higuchi, et al., 2004). They found a trace amount
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of DNA in the Y-globulin protein solution can drastically decrease flux. Using Dynamic Light
Scattering (DLS), they observed that flux decline is due to the formation of DNA-protein
complex with size 135 nm-225 nm. An Addition of sodium chloride or treatment with DNase has
enhanced the filter flux and the transmission of y-globulin through the membrane
Interactions between the solid surface/membrane and the protein molecule can affect
filter fouling as well. Two mechanisms are proposed to explain those interactions: a) the proteinsurface interaction leads to adsorption of the protein onto the membrane surface, then reduce the
effective size of the membrane pores and cause the formation of a cake layer; b) the proteinprotein interaction leads to the stacking of aggregated protein molecules on the membrane
surface (Jones & O’Melia, 2000) (Nakamura & Matsumoto, 2006) (Babu & Gaikar, 2001)
(Mueller & Davis, 1996). To understand the interactions between immunoglobulin G (IgG) and
cellulose, Hamamoto et al. have fabricated sensors coated with cellulose for surface plasmon
resonance (SPR) and quartz crystal microbalance with energy dissipation measurements (QCMD) (Hamamoto, et al., 2018). They observed that virus filtration flux for IgG varied in a NaCl
concentration-dependent manner and didn’t come back with a post-filtration buffer flush,
indicating a formation of a salt concentration-dependent irreversible membrane fouling. The IgG
adsorption kinetics determined with cellulose-coated SPR showed immediate adsorption of IgG
onto the cellulose surface in solution with lower salt concentration. An analysis of the interaction
energy revealed that attractive interactions between the surface and the protein markedly
increased at a distance less than 5 nm, suggesting that the protein molecules were adsorbed by
the cellulose membrane when passing through the pores. Also, the viscoelasticity data of the
adsorbed IgG determined with QCM-D shown that proteins present more conformational
changes at lower salt concentrations. So that post-adsorption protein conformational changes
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promoted the irreversible protein-protein and protein-surface interactions and lead to further flux
decay.
Filter properties also influence virus filtration performance. Resistance to fouling can be
achieved by fabricating filters with a low interacting base material such as regenerated cellulose
or rendering higher interacting base material (e.g., PES or PVDF) low interacting by a separate
surface modification step. Virus filters have separation-active layers (SALs) with up to 30micron thickness, contributing to the high selectivity and a porous support structure. It has been
shown that fouling resistance increases when the membranes were oriented with the SAL facing
away from the feed because the porous support structure acted as a pre-filter and protected SAL
from ‘trace levels of submicron-sized’ particles (Bohonak & Zydney, 2005). The pore size
gradient (PSG) of a virus filter also significantly affects membrane fouling. Current commercial
virus filters exhibit a wide range of PSGs. Membranes with steep PSGs have high water
permeability. However, they are more susceptible to fouling because only a small section of the
filter has a pore size of protein aggregates, acting as an internal pre-filter. Membranes with
shallow PSG possess higher robustness against fouling because a large part of the membrane
structure can retain foulants. However, they have lower water permeability because the majority
of the membrane contributed to the hydraulic resistance. Membranes with very shallow PSGs are
susceptible to fouling since a large part of the foulants could be retained directly on the outer
membrane surface facing the feed (Ho & Zydney, Effect of membrane morphology on the initial
rate of protein fouling during microfiltration, 1999). Kosiol et al. have challenged a wide range
of different commercial and non-commercial parvovirus filters with gold nanoparticles (GNPs)
to determine their PSG (Kosiol, et al., 2018). To reduce the interference of the adsorption effects,
the membrane and the GNPs were equilibrated with sodium dodecyl sulfate (SDS). In the virus
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filtration of model protein IVIG, they found the major foulants are trace amounts of small
aggregates, mostly in the size range of 16-30 nm. Also, the membranes with shallower PSG were
less susceptible to fouling than those having steeper PSGs.
Membrane morphology is another factor that affects fouling behavior. Viresolve virus
filters have a complex multi-layer structure, and current membranes operate with skin-side
facing down. This is because fouling mechanisms differ in a different orientation, and the
operation with skin-side down had shown a much robust performance under various flux and
pressure. Using cysteinylated bovine serum albumin (BSA) as a model protein, Syedain et al.
have quantitively investigated the effects of operating conditions and membrane orientation on
the fouling behavior and system capacity of Viresolve® 180 membranes (Syedain, Bohonak, &
Zydney, 2008). When the skin-side faces up, the osmotic pressure effect caused by concentration
polarization significantly affects membrane fouling; thus, the filter performance strongly
depends on both the operation mode (constant pressure VS constant flux) and operation
conditions (TMP and flux). While when the skin-side faces down, fouling occurs throughout the
membrane thickness, and the total resistance was entirely determined by the filtrate volume per
unit membrane area, so that the rate of fouling is independent of both the operation mode and
conditions. In contrast to the composite structure of Viresolve® filters, Planova™ filters remove
viruses with a thick functional layer composed of a succession of voids and capillaries
(Yamamoto, Hongo‐Hirasaki, Uchi, Hayashida, & Nagoya, 2014). Small proteins can pass
through the thin capillaries; however, large particles (>1 micron) such as viruses and protein
aggregates can be retained by the filter mechanically or physicochemical (Herzig, Leclerc, &
Goff, 1970).
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Viral clearance validation studies are designed to reproduce actual manufacturing scale
production; however, the laboratory scale is not always scalable for many reasons, including the
virus spiking itself. In a virus spiking study, the feed solution comprises two distinct biological
solutions, a protein product and a virus stock, with each one of them has their buffer, pH,
conductivity, and contaminants. A product solution could contain contaminants such as
multimers and host cell proteins/lipids/DNAs, while a virus stock could have contaminants such
as aggregated virus particles and the cellular component from the host cell used to produce the
virus. When the two solutions got mixed, there is a potential interaction between particles,
leading to further filter fouling. The volumetric throughput achieved during a virus spiking study
is used for sizing virus filters for manufacturing scale. The virus filter area needed for
manufacturing could be overestimated because more fouling could occur during a virus spiking
study than the actual manufacturing process. This can lead to an increase in filtration costs and
process complexity (Cabatingan, 2005). A variety of approaches have been employed to address
this issue. Slocum et al. have investigated what quality attributes of a virus stock are essential to
or indicative of the performance of the Viresolve® Pro filtration device (Slocum, et al., 2013).
They prepared virus stocks of different grades and found the overall levels of protein and DNA
are closely related to filter performance, with the virus stock with the lowest DNA and protein
content outperformed the other stocks. To minimize the potential adverse impact of virus spike
on filter capacity, they suggested spiking less of impure virus or using highly purified virus
stock. Khan et al. have proposed performing a filter preconditioning (also referred to as
‘RUNspike’), which entails processing non-spiked protein solution to a volumetric throughput
target before processing virus-spiked feed to a final flux decay endpoint (Khan, Parrella, Genest,
& Colman, 2009). This approach allowed a Viresolve® NFP filter to demonstrate a high
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throughput and an LRV comparable to the LRV obtained with a conventional method. However,
to assure viral safety, they suggested performing filter preconditioning alongside a conventional
validation study. In addition, this RUNspike approach has been proven to be suitable only for
Viresolve® NFP filter, whose virus retention decreases as a function of flux decay, and it may not
be suitable for other virus filters. Some virus filters require in-line pre-filters to improve
throughput because they are susceptible to trace amounts of process impurities. In virus spiking
studies, a standard approach is to batch filter the protein solution using the pre-filter, spike the
virus into the prefiltration filtrate, then perform virus filtration. However, this type of batch
filtration leads to a much lower throughput than in-line filtration. To resolve this difference, Lutz
et al. have proposed an in-line spiking approach, where the virus spike was continuously
injected, mixed with pre-filtered feed, sampled, and fed to the virus filter (Lutz, et al., 2011).
This approach maintains a high throughput even with virus spiking by mirroring the inline
prefiltration operation that is used in manufacturing and avoided prefiltration removing the
spiked viruses. However, some virus filters do not need to use this method since their filtration
performance is not significantly affected by virus spiking. Hongo‐Hirasaki et al. have
investigated the effect of virus spiking conditions (virus stock quality and spike percentage) on
filter performance (flux and virus retention) of Planova™ 20N and found its performance was
minimally affected by virus spiking (Hongo-Hirasaki, Yamaguchi, Yanagida, Hayashida, & Ide,
2011). In most cases, having a high-quality virus stock is critical for accurately evaluating virus
filtration unit operation.
In addition to knowing what parameters are related to virus filter fouling, it is also critical
to understand how these factors affect filter fouling. Process modeling, where a set of
mathematical equations represent the physical phenomena involved in a process, has been widely
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used in both industry and academia to describe a process. Based on limited sets of experimental
data, these models can predict the behavior of a process and identify which parameters are
critical and which interactions between parameters are essential. In normal flow filtration, there
are four classical filtration models for the analysis of flux decline data: standard pore blocking
(pore constriction), intermediate pore blocking, complete pore blocking (pore blockage), and
cake filtration (Hermia, 1982). All four blocking models can be expressed as the following
equation:
𝑑2 𝑡
𝑑𝑉 2

𝑑𝑡

= 𝛼(𝑑𝑉)𝛽

(Eq. 1.3)

Where 𝑡 is the filtration time; 𝑉 is the filtrate volume; 𝛼 and 𝛽 are model-dependent fitting
constants. Filtration data were fitted into the formula above to determine the  value for each
filtration experiment. The value of  is 0, 1, 1.5, and 2 for cake filtration, intermediate blocking,
standard blocking, and complete blocking.
The linearized form of the standard blocking model (=1.5) is
𝑡
𝑉

= 𝐴𝑡 + 𝐵

(Eq. 1.4)

where t is the filtration time; V is the corresponding volume filtered up to that time; A and B are
the fitting slope and intercept on the y-axis. When volume (V) is solved and time (t) goes to
infinity, then (Giglia & Straeffer, Combined mechanism fouling model and method for
optimization of series microfiltration performance, 2012):
1

𝑉 = 𝑉max = 𝐴

(Eq. 1.5)
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The Vmax can be used to predict the membrane capacity of a virus filter (Badmington, Wilkins,
Payne, & Honig, 1995).
However, it has been shown that there are significant discrepancies between the
predictions with classic pore blocking models and the actual filtrate flux data. Ho and Zydney
developed a mathematical model in which they assumed the initial fouling was caused by pore
blockage, and the subsequent fouling occurs due to the growth of a protein cake or deposit over
these initially blocked regions (Ho & Zydney, 2000). Bolton et al. developed five fouling models
that accounted for the combined effects of the pore constriction, pore blockage, and cake
formation (Bolton, Boesch, & Lazzara, 2006). They derived the equations from Darcy’s law,
which relates volume to time during constant pressure operation and pressure to time during
constant flow filtration. Their models were able to accurately predict sterile filtration of IgG and
virus filtration of BSA, and they concluded that the combined compete blocking-cake filtration
model was the most useful as it was able to provide good fits for a range of data sets. In 2006,
Bolton et al. proposed a new model to account for the constriction of membrane pores caused by
foulants adsorption combined with fouling by one of the three classical mechanisms
(intermediate, cake filtration, and complete blocking) (Bolton, Boesch, & Lazzara, 2006). The
filtration behavior of IgG with Viresolve® 180 was successfully predicted with the adsorption
and intermediate pore blockage model. A well-validated model is important and useful since it
could allow us to understand a process better, reduce the number of experiments needed in
establishing robustness, and facilitate various aspects of process development.
1.4.2 Virus Breakthrough
Virus filtration is a dedicated step for virus removal, considered as an efficient and robust
unit operation. The mechanism of virus retention by virus filter is mostly based on size
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exclusion. However, several studies have shown that virus retention is also affected by
parameters other than particle sizes, such as filter properties, flow rate, transmembrane pressure,
and the adsorption interaction between virus, protein, and the membranes.
The high selectivity of the virus filtration membranes is achieved by the very narrow pore
size distribution (PSD) in the separation-active layer of the membranes. Using a newly
developed technique, Kosiol et al. determined the PSD for highly diverse commercial and noncommercial parvovirus retentive filters, then correlated the cut-off pore diameters to the virus
retention performance of those filters (Kosiol, Hansmann, Ulbricht, & Thom, 2017). They
developed a method based on the solute rejection of rigid and monodisperse gold nanoparticles
(GNP). The GNP was first equilibrated with an SDS solution before the experiment to overcome
the interfering adsorptive retention of GNPs to the membranes. The application of SDS shifted
the mechanism of retention from adsorption to a size exclusion dominated mechanism. They
found the second-generation commercial virus filters, which have increased virus retention
robustness compared to the first-generation filters, exhibited narrower PSDs. Liquid-liquid
displacement porosimetry (LLDP) is one of the most reliable and appropriate porosimetric
methods. Peinador et al. used a fully automated and precise LLDP equipment developed in the
surface and porous materials group (SMAP) in Valladolid, Spain, to determine critical structural
parameters, including the pore-size distribution and the porosity of virus filters (Peinador, et al.,
2011). They observed that the maximum pore size of a filter is related to the LRV of
bacteriophage. Giglia et al. made a quantitative prediction of virus retention performance from
PSD of virus filters and virus size using a mechanistic mathematical model, which is based
solely on the sieving mechanism (Giglia, Bohonak, Greenhalgh, & Leahy, 2015). They found a
close agreement between the observed and the predicted virus retention, supporting that the size36

exclusion is the primary mechanism for virus removal with VF filters. Even though sizeexclusion plays a major role in virus retention, the effects of other factors, such as the membrane
surface chemistry and the adsorption between virus/protein and the membrane, should also be
considered.
Solution conditions, such as the buffer species, pH, and ionic strength, could affect many
aspects, including interactions between molecules/particles and the membrane properties.
Considering that the primary mechanism of virus retention is size-exclusion, Jorba et al.
reasoned that the ionic strength could affect virus retention because it can change virus shape and
size (Jorba, Shitanishi, Winkler, & Herring, 2014). They assessed the ability of Viresolve® Pro to
remove eight (relevant or model) viruses with different sizes during the filtration of coagulation
factor IX at different ionic strengths. They observed that the virus removal with Viresolve® Pro
kept consistent over a two-fold range of salt concentration, indicating that minor shape/size
changes caused by ionic strength do not affect the virus retention capability of Viresolve® Pro.
Besides, solution pH and ionic strength also affect the interactions between the membrane and
the virus, thus affect virus retention; for example, Viresolve® NFP filter had shown greater virus
retention at lower pH and lower ionic strength when there is an attractive electrostatic interaction
between the positively charged bacteriophage Phi-X174 and the negatively charged membrane
(Dishari, et al., 2015).
Planova™ filters have a unique pore structure consisting of voids and capillaries. They
remove viruses with three mechanisms: 1) size exclusion; 2) constraint by hydrodynamic force;
3) multistep filtration. Yamatomo et al. have studied virus behavior in Planova filters using
numerical simulations and experimental studies (Yamamoto, Hongo‐Hirasaki, Uchi, Hayashida,
& Nagoya, 2014). They found viruses are constrained by hydrodynamic forces at the entrances
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of capillaries with diameters smaller than their own, while with lower hydrodynamic force,
viruses could drift away to neighboring capillaries with a larger diameter, thus cause virus
breakthrough. Considering this mechanism, they concluded a higher flow rate, higher operating
pressure, and greater solution viscosity could reduce virus breakthrough. Several recent studies
also have found similar patterns that lower pressure or pressure interruption can potentially affect
the parvovirus removal capacity. Tested a range of operating pressure for Planova™ 20N (7.3 psi
to 16 psi) and Planova™ BioEx (10.0 psi-49.7 psi), Strauss et al. concluded that both the filters
have a robust removal of viruses over the wide range of operating pressure, while some reduction
of MVM clearance occurred with Planova™ 20N under lower pressure (Strauss, et al., 2017).
They also observed that this LRV reduction is related to solution conditions, including pH and
conductivity, which could potentially affect interactions between the virus, protein, and the
membranes.
Protein fouling could also potentially alter the virus retention characteristics of the virus
filters; however, this is membrane specific. Using electron microscopy (SEM), Fallahianbijan et
al. observed how the fouling of Viresolve® NFP membrane and Viresolve® Pro membrane by
human immunoglobulin G (IgG) affects the capture location of 20 nm gold nanoparticles within
these membranes (Fallahianbijan, Giglia, Carbrello, Bell, & Zydney, 2019). In Viresolve® Pro,
20 nm nanoparticles shifted away from the virus retentive skin layer after protein fouling,
indicating that protein fouling reduces the effective pore size in the region close to the virus
retentive skin layer; however, in Viresolve® NFP filter, the capture location of 20 nm
nanoparticles was not affected even by fouling caused 90% flux decline, indicating protein
fouling occurs first in the smaller pores in NFP membrane.
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Regarding the virus breakthrough, several models have been proposed, including the flow
decline model and the virus internal polarization model. In the flow decline model, Bolton et al.
hypothesized that the LRV decline is due to the selective plugging of small pores, then viruses
are directed through the remaining larger pores. The following equation predicts LRV decline
caused by flux decay:
𝐿𝑅𝑉 = 𝐿𝑅𝑉0 − 𝑛𝑙𝑜𝑔

𝑄0
𝑄

(Eq. 1.6)

Where LRV0 is the initial virus retention, n is the number of membrane layers, Q0 is the initial
flow rate, and Q is the instantaneous flow rate. This model well predicted the LRV of X174
bacteriophage with Viresolve NFP filter with the presence of model protein or industrial
monoclonal antibodies under various solution conditions (Bolton, et al., 2005). Jackson et al.
have proposed an ‘internal polarization model’ to describe the virus retention behavior of the
UltiporeVF membrane (Jackson, et al., 2014). According to the model, phage passage through
the membrane arises from an accumulation of the phage in the reservoir (upper) layer within the
membrane, which increased the challenge to the retention (lower) layer. The support for the
model was provided by an imaging study, with confocal scanning microscopy of fluorescently
labeled bacteriophages within the membrane.
A pressure release is also related to the LRV decline. The pressure release or process
interruptions are very common in large scale manufacturing operations when bags or tanks are
used to transfer process intermediates between the steps (LaCasse, et al., 2016). When the
process intermediates are stored in multiple bags, then process interruptions could happen when
the bags are disconnected and reconnected. Besides, a buffer flush is always performed at the
end of the filtration to increase product recovery. Process interruptions also could happen when
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the buffer is transferred to the load tank. Several studies have shown that pressure release or
process interruption can significantly reduce virus retention (Dishari, Venkiteshwaran, &
Zydney, 2015) (Woods & Zydney, 2014). Dishari et al. attributed this effect to the diffusion of
the initially captured viruses out from the pores when the pressure is removed (Dishari, et al.,
2015). The effects of pressure release are discussed in this dissertation.
In batch mode, virus clearance is achieved by a combination of virus inactivation (e.g.,
low pH or solvent detergent) and virus removal, including chromatography and virus filtration.
The low pH inactivation step follows the Protein A chromatography, where the product is eluted
at a low pH. In batch mode, the duration for low pH hold is easy to control. In a continuous
process, Protein A-elute is continuously collected, thus resulting in longer or shorter hold times.
To resolve this issue, Pall Corporation launched a Cadence™ Virus Inactivation System, which
is programmed to automatically collect the elute from Protein A, titrate to the required low pH,
holding it at low pH for a predefined time, and titrate it to high pH then discharge (Levison,
Schofield, Gantier, & Gjoka, 2017). Virus filtration can be integrated into a continuous process
as well; however, other things need to be considered, such as when to change the filter and how
to conduct the virus clearance assessment studies.
In this dissertation, an FDA required model virus, Minute Virus of Mice (MVM), was
spiked into the feed solutions of different protein molecules to validate virus filters and
investigate the factors that influence the filtrate flux, membrane capacity, and virus clearance.
The filtration experiments were performed with four commercial virus filters of various material
and configurations, namely Viresolve Pro, Planova™ 20N, Planova™ BioEx, and Virosart®
HF. Combined pore blocking and cake filtration model was used to predict the protein fouling
mechanism.
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Chapter 2 The Effects of Buffer Condition on the Fouling Behavior of MVM Virus
Filtration of an Fc-fusion Protein
* This chapter is based on a published paper: Namila, F., Zhang, D., Traylor, S., Nguyen, T.,
Singh, N., Wickramasinghe, R., & Qian, X. (2019). The effects of buffer condition on the fouling
behavior of MVM virus filtration of an Fc‐fusion protein. Biotechnology and bioengineering,
116(10), 2621-2631.
Abstract
A combined pore blockage and cake filtration model was applied to the virus filtration of
an Fc-fusion protein using the three commercially available filters, F-1, F-2, and F-3, in a range of
buffer conditions, including sodium phosphate and tris-acetate buffers with and without 200 mM
NaCl at pH 7.5. The fouling behaviors of the three filters were described well by this combined
model for all the solution conditions. The fouling of the virus filters is dominated by the pore
blockage mechanism during the initial stage of the filtration and transformed to the cake filtration
mechanism during the later stage of the filtration. Both flux and transmembrane resistance can be
described well by this model. The pore blockage rate and the rate of increase of protein layer
resistance over blocked pores are found to be affected by membrane properties as well as the
solution conditions resulting from the modulation of interactions between virus, protein, and
membrane by the solution conditions.
2.1 Introduction

Viral safety is an important issue in the downstream processing of products such as
monoclonal antibodies (mAbs) or other protein therapeutics derived from mammalian cell lines
and plasmas. Employing viruses in genetic modification of cell lines and the usage of various
biological reagents such as animal serum in the production processes give rise to the risk of viral
contamination. Regulatory agencies such as the U.S. Food and Drug Administration (FDA)
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provides guidelines to ensure that the downstream manufacturing processes will accomplish
adequate clearance of virus (FDA, 1997) (ICH, 1998). Current viral clearance strategies applied
during the manufacturing process include viral removal as well as inactivation. Various viral
inactivation methods can be used, including low pH, heat/ radiation, and solvent-detergent (SD).
Viral filtration is a robust way of virus clearance by rejecting a virus from the process stream based
on a size-exclusion mechanism using a porous membrane operated in the dead-end mode. The
goal of virus clearance studies is to demonstrate that the process steps under evaluation are
effective in removing and inactivating an adequate amount of virus (ICH, 1998). This is achieved
by spiking a very small volume of concentrated virus stock into the product solution reaching
approximately 106 infective virus particles per milliliter (mL), and performing a size-exclusionbased virus filtration with a scale-down membrane model. The minute virus of mice (MVM), an
FDA recommended model parvovirus, has frequently been used to spike the protein feed solutions
and validate virus clearance. MVM is a non-enveloped single-stranded DNA virus with a diameter
of 18-24 nm, the smallest virus that can be easily titrated to high levels (Weaver, Husson, Murphy,
& Wickramasinghe, 2013).
An ideal virus filtration membrane can remove at least 4 logs of viruses in the feed stream
and recover over 95% of the mAb product of interest. Viral filtration is one of the most expensive
steps during the downstream processing of therapeutic proteins (Bolton et al. 2010). Therefore, a
high capacity or throughput and a high filtrate flux are desirable to reduce the filter area and
process time. Previous studies (Bakhshayeshi & Zydney, 2008) (Bolton, Spector, & LaCasse, 2006)
(Dishari, et al., 2015) (Hongo-Hirasaki, Komuro, & Ide, 2010) (Rayfield, et al., 2015)
(Wickramasinghe, Stump, Grzenia, Husson, & Pellegrino, 2010) show that buffer conditions
including pH, buffer type, and ionic strength could affect the filtration performance of the virus
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filters. In addition, earlier studies have shown that the performance of virus filters is also dependent
on the specific protein in the feed (Stuckey, et al., 2014).
Membrane fouling is an important issue that can greatly reduce filter throughput (Loh, et
al., 2009) (Palecek & Zydney, 1994) (Polyakov & Zydney, 2013) (Syedain, Bohonak, & Zydney,
2006) (Tracey & Davis, 1994) (Wickramasinghe S. R., 2008). Early studies (Bolton, Spector, &
LaCasse, 2006) (Bolton, Basha, & Lacasse, 2010) observed that a prefiltration membrane with
entrapped diatomaceous earth could greatly increase the capacity of parvovirus retentive filters
and concluded that the major fouling species are a subset of oxidized or degraded IgG molecules
with more hydrophobic surface properties. Many previous studies have investigated the effect of
pH and types of fouling species on the virus filter capacity and proposed various strategies such
as using adsorptive prefilters to achieve higher throughput (Bakhshayeshi & Zydney, 2008)
(Bolton, Spector, & LaCasse, 2006) (Dishari, et al., 2015) (Wickramasinghe, Stump, Grzenia,
Husson, & Pellegrino, 2010) (Hongo-Hirasaki, Komuro, & Ide, 2010). However, up to now, there
is still little understanding on the effects of ionic strength, pH and buffer type on the fouling
behavior of virus filters and subsequently their performances including both throughout and virus
retention. Previous work (Rayfield, et al., 2015) also examined the correlation between the
biophysical properties and the virus filtration performance and found that molecular size
determined by absolute size exclusion chromatography is an important factor. While solutes with
an average hydrodynamic diameter larger than 17 nm typically demonstrate poor filtration flux
and loading, filter performance for feed containing solutes with average hydrodynamic diameter
less than 13 nm is unlikely affected by the presence of aggregates.
Filtration flux is one of the key measures for evaluating the performance of virus filters for
the biopharmaceutical industry. Flux decay due to the deposition of protein and virus particles as
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well as their aggregates on the surface and inside the pores of the membrane, is of major concern.
A major cause of membrane fouling is protein (or protein aggregate) adsorption on the
membrane and pore surface. Numerous previous investigators have indicated that initial fouling
by proteins is due to interactions between the membrane and protein species (Belfort, Davis, &
Zydney, 1994) (Kelly & Zydney, 1994). Membrane fouling is very complex and is affected by
the operation condition, the solution condition and the hydrophobicity, charge and polarity of the
foulants and the properties of the membrane surface. Membrane fouling in a dead-end filtration
has been widely described (Hermia, 1982) by the four classical pore blocking models: standard
blocking, complete blocking, intermediate blocking and cake filtration. All four models (Hermia,
1982) can be expressed using the following formula:
𝑑2 𝑡
𝑑𝑉 2

𝑑𝑡

= 𝑘(𝑑𝑉)𝛽

(Eq. 2.1)

where t is the filtration time, V is the total filtered volume and k is constant. The exponent 
characterizes different fouling models with the  values of 0, 1, 3/2, and 2 representing cake
filtration, intermediate blocking, standard blocking and complete pore blocking, respectively. In
the standard blocking model, protein or foulant is typically smaller than the pores and deposits
uniformly inside the pore walls leading to a decrease in pore diameter. In the completely blocking
model, solute completely blocks a pore. When solute partially blocks a pore, an intermediate
blocking model can be used to describe the fouling behavior. Finally, cake filtration occurs when
the solute forms a cake layer on the surface of the filter. The basic assumption of these models is
that the pores are cylindrical, uniform and straight, which is different from the actual filters.
During protein filtration, the  values have often been found to be different from the four
numbers (0, 1, 3/2 and 2) associated with the four classical fouling models due to the complexity
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of the membrane pore structures as well as the feed conditions (Bowena, Calvob, & Hernández,
1995) (Tracey & Davis, 1994). Membrane pores are not uniform but interconnected and tortuous.
Moreover, in a single filtration experiment, more than one blocking model can be applied to
describe the flux decay depending on the progression of the filtration and the location of
protein/foulant deposits (Ho & Zydney, 2000). The exact mechanism for protein fouling remains
somewhat uncertain.
Earlier studies (Ho & Zydney, 2000) have developed a combined pore blockage and cake
filtration model to describe protein fouling. The model was able to capture the flux performance
and fouling behavior of bovine serum albumin (BSA) filtration using 0.2 𝜇m polycarbonate tracketched (PCTE) membranes with the initial pore blockage followed by cake formation mechanisms.
The model assumes that volumetric filtrate flow rate through a membrane can be expressed by
summing the flow rates through open and blocked pores:
𝑄 = 𝑄𝑜𝑝𝑒𝑛 + 𝑄𝑏𝑙𝑜𝑐𝑘𝑒𝑑

(Eq. 2.2)

𝑄𝑜𝑝𝑒𝑛 can be determined by the following equation:
∆𝑃

𝑄𝑜𝑝𝑒𝑛 = 𝜇𝑅 𝐴𝑜𝑝𝑒𝑛
𝑚

(Eq. 2.3)

where ∆𝑃 is the transmembrane pressure, 𝜇 is the viscosity of the feed solution, 𝑅𝑚 is the
resistance of the clean membrane, 𝐴𝑜𝑝𝑒𝑛 is the area of the membrane without any protein or foulant
deposition. The pore blockage as a function of time is assumed to be proportional to the flow rate
𝑄𝑜𝑝𝑒𝑛 and bulk protein concentration 𝐶𝑏 :
𝑑𝐴𝑜𝑝𝑒𝑛 (𝑡)
𝑑𝑡

= −𝛼𝑄𝑜𝑝𝑒𝑛 𝐶𝑏 (Eq. 2.4)
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where 𝛼 is a parameter measuring the membrane area blocked per unit mass of protein convected
to the membrane surface, i.e., the pore blockage rate. It is affected by the membrane characteristics,
the feed solution and the operation condition. Assuming a uniform resistance over the fouled
surface of the membrane, the final approximate solution to the volumetric flow rate becomes:

𝑄 = 𝑄𝑜 𝑒𝑥𝑝 {(−

𝛼Δ𝑃𝐶𝑏
𝜇𝑅𝑚

𝑡) + 𝑅

𝑅𝑚

𝑚 +𝑅𝑝 (𝑡)

(1 − 𝑒𝑥𝑝 (−

𝛼Δ𝑃𝐶𝑏
𝜇𝑅𝑚

𝑡))}

(Eq. 2.5)

where 𝑅𝑝 (𝑡) is the resistance of deposited protein or foulants layer over time. 𝑅𝑝 can be expressed
using the following expression:

𝑅𝑝 (𝑡) = (𝑅𝑚 + 𝑅𝑝𝑜 )√1 +

2𝑓 ′ 𝑅′ ∆𝑃𝐶𝑏
2

𝜇(𝑅𝑚 +𝑅𝑝𝑜 )

𝑡 − 𝑅𝑚

(Eq. 2.6)

here 𝑅𝑝𝑜 is the initial resistance of the protein or foulant deposit, 𝑓 ′ 𝑅 ′ is the rate of the increase of
the protein layer resistance per unit mass of proteins filtered, which depends strongly on the feed
solution condition such as pH and ionic strength (Palecek & Zydney, 1994). The values of 𝛼,
𝑅𝑝𝑜 and 𝑓 ′ 𝑅 ′ can be obtained by fitting the flux data over time using least square regression. From
these fitted parameters, good agreement between the measured resistance and calculated resistance
has been obtained to describe the fouling behavior of BSA filtration. Moreover, the fitting
parameters have been independently validated from direct or indirect experimental measurements
(Ho & Zydney, 2000).
Virus filtration for monoclonal antibodies and fusion proteins is more complex than protein
filtration only since the feed contains both the protein and the virus particles. Since the interactions
involving protein-protein, protein-virus, virus-virus particles are strongly solution pH and salt
concentration dependent, the aggregates thus formed will also be strongly solution condition
dependent. Moreover, the size and conformation of the protein will also vary based on the solution
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condition. So far, there is no one model that can capture the flux performance of virus filtration
well and is able to correlate the feed conditions with the fouling behavior of virus filters. Previously,
a standard blocking model was used to fit the flux data based on the linearized form of the model
using the following equation
𝑡
𝑉

= 𝐴𝑡 + 𝐵 (Eq. 2.7)

where t is the filtration time; V is the time-dependent volume of the filtrate; A and B are fitting
parameters when plotting t/ 𝑉 vs t. 𝑉𝑚𝑎𝑥 defined by equation (8) is a measure of the filtration
capacity of the filter when the pore plugging is gradual, and the plot is linear (Shaligram, et al.,
2013):
1

𝑉𝑚𝑎𝑥 = 𝐴

(Eq. 2.8)

Studies (Zydney & Ho, 2002) show that 𝑉𝑚𝑎𝑥 significantly overestimates the capacity for proteins
such as BSA with a pore blockage fouling mechanism. 𝑉𝑚𝑎𝑥 underestimate the capacity for
proteins like lysozyme, which fouls largely via cake formation mechanism. For virus filtration for
proteins with different pI values and hydrophobicity as well as for membranes with different pore
structures and properties, 𝑉𝑚𝑎𝑥 is not the most reliable measure of the capacity of the filtration
since the fouling mechanism depends on the properties of the protein in the feed. However, Vmax
remains to be a quick and useful measure of the performance of the virus filters for the
biopharmaceutical industry.
Our previous work focuses on the fouling behavior of the three virus filters for the filtration
of an Fc-fusion protein spiked with MVM virus particles. In particular, the combined pore
blockage and cake formation model was applied to fit the flux data of the three filters under
different buffer conditions: citrate-phosphate with 23 mM NaCl, sodium phosphate and tris-acetate
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with and without 200 mM NaCl. The pH values of the feed solutions were kept in the range
between 7.5 and 7.6. The Fc-fusion protein concentration was kept between 5-8 g/L for all the
filtration experiments. The feed solutions were spiked with 7.4 logs/mL MVM virus particles for
a total viral load of 9-10 logs (see supplementary document Table S2.1). Here the virus titers were
determined using qPCR, which includes all infectious and non-infectious virus particles. Total
virus particle numbers determined by qPCR were used here as the fouling behavior of virus filters
is affected by the virus particles loaded onto the filter irrespective of their infectivity. From the
model flux data fitting, the 𝛼 parameter which describes the pore blockage rate, and 𝑓 ′ 𝑅 ′ the value
which corresponds to the rate of increase of the protein layer resistance were determined and
discussed with regard to the filter type and buffer conditions.
2.2 Materials and Methods
2.2.1 Virus Filters
Filter 1 (F-1), Filter 2 (F-2), Filter 3 (F-3) and the Prefilter 1 (Pre-1) for F-1 were provided by the
manufacturers. Table 2.1 list the properties of the three viral filters used in this study.
Table 2.1 List of the three viral filters and their properties
Membrane material
Membrane structure
Membrane area

F-1
PES†
flat sheet; asymmetric;
2 layers
3.1 cm2

F-2
CRC†
hollow fiber;
asymmetric
10 cm2

F-3
PVDF†
hollow fiber;
asymmetric
10 cm2

†PES: polyethersulfone; CRC: cuprammonium regenerated cellulose; PVDF: polyvinylidene
fluoride.
2.2.2 Protein Feed Solution Preparation and Characterization
The Fc-fusion protein, with a molecular weight of 94 kDa and an isoelectric point (pI) of
5.9, was provided by Bristol-Myers Squibb (Devens, MA) in a citrate-phosphate buffer solution
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containing 23 mM NaCl at pH 7.6. The protein was also buffer-exchanged into either 20 mM
sodium phosphate buffer or ~20 mM Tris-acetate buffer at pH 7.5, with and without 200 mM NaCl.
The buffer conditions for the virus filtration experiments based on the design of experiment (DOE)
are listed in Table 2.2. Buffer-exchange was performed by diafiltration of 1-1.5 L of protein stock
at approximately 5-7 g/L protein for 5 diavolumes using a Novasep Sius-LSn HyStream 30 KD
TFF cassette (Shrewsbury, MA). Reagents used for buffer preparation were sodium phosphate
monobasic monohydrate (ACS reagent, ≥98%) and anhydrous sodium phosphate dibasic from
MilliporeSigma (ReagentPlus, ≥99.0%) (St. Louis, MO), sodium chloride (biotechnology grade)
from VWR Life science (Radnor, PA), OmniPur sodium acetate trihydrate (molecular biology
grade), Omnipur sodium citrate dehydrate (molecular biology grade) and citric acid anhydrous
(molecular biology grade) from EMD Millipore (Billerica, MA), Sucrose (biology grade) from
Alfa Aesar (Ward Hill, MA), and Tris base (biotechnology grade) from G-BioSciences (St. Louis,
MO). The pH was measured using pH 500 Economy Benchtop Meter from Oakton Instruments
(Vernon Hills, IL), and the conductivity was measured using symphony SP70C (Radnor, PA).
Following the buffer exchange, protein stocks were used immediately for virus filtration or stored
at 4oC for up to one week.
Protein concentration and turbidity were determined by measuring the absorption at 280
nm and 340 nm, respectively, using Genesys 10 UV scanning system (Waltham, MA) with VWR
quartz spectrophotometer cell (path length 1 cm) (West Chester, PA). Dynamic light scattering
(DLS) was performed using Delsa™ Nano particle size analyzer (Beckman Coulter, Brea, CA) to
determine the hydrodynamic diameter of the Fc-fusion protein under different buffer conditions.
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Table 2.2 Buffer conditions, protein concentrations, and hydrodynamic diameters measured by
DLS for the filtration experiments
Buffer Type

pH
NaCl (mM)
Protein
F-1 filter
Concentration F-2 filter
(g/L)
F-3 filter
Hydrodynamic diameter
(Å)

Citratephosphate
Buffer
7.6
23
5.79±0.04
6.34±0.04
6.34±0.04
12.98±0.52

Sodium Phosphate
Buffer

Tris-acetate Buffer

7.5
0
200
0
200
7.90±0.17 7.70±0.23 5.03±0.07 5.57±0.11
8.32±0.11 7.97±0.11 5.14±0.01 6.10±0.20
8.32±0.11 7.99±0.15 5.14±0.01 6.10±0.20
10.60±0.58 11.88±0.50 10.92±0.50 11.94±0.08

2.2.3 Virus Production, Purification, and Titer Determination
The minute virus of mice (MVM) is a representative parvovirus that can infect the Chinese Hamster
Ovary (CHO) cell culture. The initial stock of the MVM (ATCC® VR1346™) was purchased from
American Type Culture Collection (Manassas, VA). Further production of MVM was performed based on
an adapted protocol from literature (U.S.A. Patent No. EP2377927A1, 2011). Briefly, A9 cells (ATCC®
CCL-1.4™) were grown to confluence in a T175 CELLSTAR® cell culture flask using DMEM
(MilliporeSigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (MilliporeSigma, St.
Louis, MO) and 4% Hyclone L-Glutamine (Waltham, MA). Upon confluence, the cell culture medium
was removed, and the cells were inoculated with MVM stock. MVM production medium was composed of
Gibco advanced DMEM (Carlsbad, CA) containing 1% FBS, 4% L-glutamine, and 1% Hyclone NEAA
(Waltham, MA). On the third day after inoculation, the medium was replaced by a serum-free production
medium, which is MVM production medium without FBS.

Harvesting was done on the 18th-21st day after inoculation when all the cells were lysed
and detached from the bottom of the flasks. Harvests were centrifuged with clarified supernatant
filtered through 0.22 µm bottle-top vacuum filter with PES membrane (Waltham, MA) and further
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concentrated with an Amicon® Ultra-15 centrifuge filter device 100K (Billerica, MA).
Subsequently, they were buffer exchanged into the TNE buffer (10 mM Tris, 150 mM NaCl, 1
mM EDTA) with the same device. MVM virus stock was then concentrated using a Beckman
Coulter Optima XPN-100 Ultracentrifuge. After centrifugation, the pellets were soaked at 2-8 °C
for two days in TNE buffer. The virus titers were determined using qPCR, usually in the range of
10.5-11.5 logs/mL. Re-suspended virus stocks were stored at -80 °C until thawed at room
temperature for virus spiking. The overall host cell protein (HCP) concentration was determined
to be less than 0.4 g/L. During MVM spiking studies, the targeted virus titer is 7.4 logs/mL using
only 100-200 𝜇 L of the virus stock for a 200-300 mL feed solution. As a result, the HCP
concentration from the virus stock in the feed is low in the order of 10-5 g/L.
A Bio-Rad CFX Connect Real Time System (Hercules, CA) with Bio-Rad CFX Manager
software were used for qPCR method to quantify the number of copies of viral genomes in virus
stocks and feed solution. Before the qPCR, 5 µL of the sample was treated with DNase (Promega,
Madison, WI) containing solution (5 µL of DNase, 5 µL of reaction buffer, and 35 µL of water) at
37 °C for 40 min, which was then inactivated with 5 µL of DNase stop solution at 65 °C for 20
min. The total volume after these two steps was 55 µL, from which 1 µL of the sample was taken
and mixed with 9 µL of a mixture containing iTaq universal SYBR green supermix (Bio-Rad,
Hercules, CA), water and primers. The primers and qPCR conditions have been reported
previously (Weaver J. , Husson, Murphy, & Wickramasinghe, 2013). The forward primer was 5’GAC GCA CAG AAA GAG AGT AAC CAA -3’ and the reverse primer was 5’- CCA ACC ATC
TGC TCC AGT AAA CAT -3’. The qPCR reaction conditions were as follow: 1) 95 °C for 10
min; 2) 95 °C for 15 seconds; 3) 57 °C for 10 seconds; 4) 72 °C for 45 seconds; 5) 72 °C for 10
seconds. Steps 2 to 4 were repeated for 45 cycles. The viral titer was then calculated by plotting
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on a standard curve. The standard curve was made by the following method: an MVM specific
genomic fragment was amplified with PCR then purified with QIAquick PCR purification kit
(Qiagen, Germantown, MD) after confirmation with gel electrophoresis. TOPO® TA Cloning® Kit
for Sequencing (Life Technologies, Carlsbad, CA) was used for plasmid construction and
purification. The recombinant plasmid was transformed into One Shot™ TOP10 Chemically
Competent E. coli (Thermo Scientific, Waltham, MA) and the blue-white screening method was
used for positive selection. The recombinant plasmid was amplified and purified. The standard
curve was made by qPCR amplification of serial diluted recombinant plasmid ranging from 101109 copies/mL. Three technical repeats were done to plot the standard curve with that the 95%
confidence limit is mean  0.5 log considered as an acceptable criterion.
2.2.4 Virus Filtration
2.2.4.1 Virus Filtration with Filter F-1
Prior to filtration with filter F-1, the non-spiked protein solution was prefiltered with Pre1. Deionized water filtered with 0.22 µm bottle-top filter was added into the Planova™ pressure
reservoir (Asahi Kasei, Japan), and the Pre-1 was wetted by closing the outlet and opening the vent
under 1-3 psi with the pressure controlled by Ashcroft pressure gauge (Part number: EW-6833415; 0-100 psi, resolution 0.1, accuracy  0.5 full-scale). The Pre-1 was then flushed with 100 L/m2
of DI water, then with 100 L/m2 of equilibration buffer. The feed reservoir was air-pressurized
using industrial grade nitrogen at 10.0 psi. The 0.22 µm filtered protein solution was gently poured
down the wall of the vessel and filtered at 13-14 psi to achieve filtrate flux of 2-3 mL/min.
Wetting, water and buffer flushing processes were the same for F-1 as for the Pre-1 with
the exception that the filtration pressure was at kept at 30.0 psi. The protein solution after
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prefiltration was spiked with our purified MVM stock at a target titer of 7.4 logs/mL (titer
determined with qPCR) then filtered with 0.22 µm filter and gently poured into the pressure vessel
along the wall. The feed reservoir was air-pressurized using industrial grade nitrogen at 30.0 psi.
A total of three fractions (Fraction 1: 0-110 mL, Fraction 2: 110-220 mL, Fraction 3: 220-330 mL)
were collected. The cumulative weight of the filtrate was recorded every minute using a
BalanceLink software connected to a Mettler Toledo scale (Columbus, OH). Average flux of every
ten minutes was used to plot the figures in the results section.
2.2.4.2 Virus Filtration with Filters F-2 and F-3
Prior to the F-2 filtration, the non-spiked protein solution was filtered with 0.1 a µm
Corning® PES bottle-top vacuum filter (Tewksbury, MA). Pre-use integrity testing, visual leakage
testing (VLT), was performed by air-pressurizing the system with industrial-grade nitrogen at 14
psi, placing the filter horizontally, and observing the filter for at least 20 seconds. If the filter is
free of continuous bubbling during VLT, then priming, water flush (at 14.2 psi), and buffer flush
(at 12 psi) steps were performed. The virus spiking step, followed by 0.22 µm filtration of the
spiked feed, was performed following the same procedure as for F-1. The feed reservoir was
pressurized at 12.0 psi, a total of three fractions (Fraction 1: 0-80 mL, Fraction 2: 80-160 mL and
Fraction 3: 160-250 mL) were collected and the cumulative weight was recorded every minute.
Virus filtration with F-3 is the same as F-2 except that the feed reservoir was pressurized at 49.7
psi for the visual leak test (VLT), water flush and buffer flush, and at 45 psi for the product
filtration.
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2.3 Results and Discussion
2.3.1 The Effects of Solution Condition on Flux and Resistance

F-1

Condition
NaCl (mM)
pH
R2

Citratephosphate
26
7.6
0.95

Sodium
Phosphate
200

Sodium
Phosphate
0

Tris-acetate

Tris-acetate

200

0

0.98

0.95

7.5
0.98

0.95

Figure 2.1 Relative flux as a function of filtration throughput for virus filters F-1 (top), F-2
(middle) and F-3 (bottom) at different buffer conditions. Symbols represent experimental
measurements of averaged fluxes during a 10 min period. Lines represent fits using combined
pore blocking and cake formation model to the flux data. The tables contain the R2 for each
fitting.

64

F-2

Condition
NaCl (mM)
pH
R2

Citratephosphate
26
7.6
0.96

Sodium
Phosphate
200

Sodium
Phosphate
0

Tris-acetate

Tris-acetate

200

0

0.99

0.87

7.5
0.85

0.92

Figure 2.1 (Cont.) Relative flux as a function of filtration throughput for virus filters F-1 (top),
F-2 (middle) and F-3 (bottom) at different buffer conditions. Symbols represent experimental
measurements of averaged fluxes during a 10 min period. Lines represent fits using combined
pore blocking and cake formation model to the flux data. The tables contain the R2 for each
fitting.
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F-3

Condition
NaCl (mM)
pH
R2

Citratephosphate
26
7.6
0.95

Sodium
Phosphate
200

Sodium
Phosphate
0

Tris-acetate

Tris-acetate

200

0

0.93

0.98

7.5
0.99

0.95

Figure 2.1 (Cont.) Relative flux as a function of filtration throughput for virus filters F-1 (top),
F-2 (middle) and F-3 (bottom) at different buffer conditions. Symbols represent experimental
measurements of averaged fluxes during a 10 min period. Lines represent fits using combined
pore blocking and cake formation model to the flux data. The tables contain the R2 for each
fitting.
A throughput of 750 L/m2 was targeted for F-1 for filtration of the Fc-fusion protein as
recommended by our industrial partner. A throughput of 250 L/m2 was targeted for both F-2 and
F-3. In order to minimize the effect of filter variability and the buffer condition itself on the
performance of the virus filters, relative fluxes normalized over their respective buffer fluxes (J/J0)
were used for the investigation of the filter fouling behaviors at different solution conditions.
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The filtrate relative fluxes of the three virus retentive membranes as a function of
throughout in L/m2 during the filtration of Fc-fusion protein in citrate-phosphate buffer spiked at
7.4 logs/mL (qPCR titer) are shown in Figure 2.1. The filtrations were performed under the
recommended pressure for each filter (30, 12 and 45 psi for F-1, F-2 and F-3 respectively). Each
data point was an average of the flux measurement over a 10 min interval. The best fittings using
the combined pore blocking and cake formation fouling model were also shown. The fitting
parameters including the rate of pore blockage 𝛼 and the rate of increase of protein/foulant layer
resistance 𝑓 ′ 𝑅 ′ over blocked pores are shown in Table 2.3. Earlier studies (Ho & Zydney, 2000)
demonstrated that the fitting parameters obtained have actual physical meaning and can be
validated by experimental measurements directly or indirectly. The initial membrane resistance
Rm for three different filters under citrate-phosphate, sodium phosphate and tri-acetate buffer
conditions are also shown.
Table 2.3 Fitting parameters to the virus filtration fluxes using the combined pore blocking and
cake formation model for the three filters in citrate-phosphate, phosphate and tris-acetate buffers.
The membrane resistance Rm in different buffers are also shown. The product filtrations was
performed under 30, 12 and 45 psi respectively for F-1, F-2 and F-3 filters.
Fitting
Parameters

𝑹𝒎
x 1012 (m-1)
𝜶
m2 kg-1
𝒇′𝑹′
x 1012
(m kg-1)

Buffer
Condition
F-1
F-2
F-3
F-1
F-2
F-3
F-1
F-2
F-3

CitratePhosphate
1.72
5.40
9.51
3.88
26.3
6.21
8.14
1.45
4.82

Sodium Phosphate
0
1.69
6.20
9.88
2.65
6.78
25.4
3.46
1.32
17.9

200 mM
NaCl
1.60
5.58
9.30
1.79
39.3
6.49
7.09
1.79
17.1

Tris-Acetate
0
1.76
5.87
8.60
7.84
4.68
28.42
4.47
1.00
18.4

200 mM
NaCl
1.48
5.87
9.51
2.15
60.0
1.53
14.0
6.28
22.4
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Our earlier efforts to fit the flux data with the classical blocking model did not yield
conclusive results. The obtained 𝛽 values are quite different from 0, 1, 3/2 and 2 predicted from
the classical pore blocking models. As a result, the fouling mechanism(s) of the virus filters for
the filtration of the Fc-fusion protein remain unresolved. It can be seen that the combined pore
blockage and cake filtration model fits very well to the flux data for all three filters. The combined
model was able to describe surprisingly well the flux decay and fouling behavior of virus filtrations
under citrate phosphate, sodium phosphate, and Tris-acetate buffer conditions for all three filters.
Pore blockage leads to the relatively faster flux decay at the beginning of the filtration. As pores
are being filled by protein molecules, virus particles as well as their aggregates, additional layers
of protein/virus particles will deposit on top of the fouled pores leading to the relatively slower
decay of the flux. This model demonstrates that fouling generally occurs via more than one
mechanism during virus filtration. Flux decay is caused by the pore blockage at the beginning due
to the deposition of protein molecules or virus particles and their aggregates inside the pores.
However, as more proteins are filtered through the membranes, cake filtration becomes more
dominant during the subsequent filtration process. The transition of pore blockage to cake filtration
is strongly dependent on the filter properties as well as on the feed buffer conditions, which will
be discussed in more detail below.
From Table 2.3, it can be seen that the membrane resistance of the three filters are very
different. Filter F-1 has resistances in the range of 1.5-1.7 x1012 𝑚−1 under the five different
buffer conditions. Filter F-2 has resistances in the range of 5.4-6.2 x1012 𝑚−1 under the same
buffer conditions. Filter F-3 has the highest resistances in the range of 8.6-9.9 x1012 𝑚−1 . Even
though the mechanism for virus retention for these three filters is size-exclusion, membrane
properties can also be affected by the buffer conditions used for virus filtration as exhibited by the
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different membrane resistances measured in three buffers and at lower or higher ionic strengths.
Filter and batch-to-batch variations can also contribute to the variations of membrane resistances
since up to about 10% variations in the water permeability values for each filter type under the
same operation condition have been observed, which is about a similar range of variation for the
membrane resistances measured. However, higher water permeability did not always correspond
with a higher buffer permeability. The rate of pore blockage 𝛼, however, exhibits very interesting
trend. The values of 𝛼 for F-1 under different buffer conditions are in the range of 1.8-7.8 𝑚2 𝑘𝑔−1,
whereas the corresponding values for F-2 and F-3 are in the ranges of 4.7-60.8 𝑚2 𝑘𝑔−1 and 2.431.7 𝑚2 𝑘𝑔−1 respectively. Moreover, both F-1 and F-3 show that the rates of pore blockage are
higher at higher ionic strength than the corresponding rates at lower ionic strength under both
sodium phosphate and tris-acetate buffers. However, F-2 exhibits opposite trends with the pore
blockage rate smaller at higher ionic strength and larger at lower ionic strength conditions. This is
not surprising as membrane material is different for different filters. F-1 and F-3 membranes are
made of PES and PVDF materials, respectively, and are likely more hydrophobic compared to that
of regenerated cellulose of the F-2 membrane material. Higher ionic strength promotes stronger
hydrophobic interaction leading to higher pore blockage rates for F-1 and F-3. The rate of increase
of protein layer resistance 𝑓 ′ 𝑅 ′ has been shown previously to be strongly solution condition such
as pH and ionic strength dependent (Palecek & Zydney, 1994). From Table 2.2, it can be seen that
values of 𝑓 ′ 𝑅 ′ are higher at higher ionic strength than the corresponding values at lower ionic
strength. As mentioned before, higher ionic strength promotes stronger hydrophobic interaction;
this leads to stronger interactions between the more hydrophobic protein molecules so that a higher
rate of increase of protein layer resistance was observed. For F-1, the rates of increase of protein
layer resistance over blocked pores are in the range of 3.5-4.5 𝑚 ∙ 𝑘𝑔−1 at lower ionic strength and
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7.1-14.0 𝑚 ∙ 𝑘𝑔−1 at higher ionic strength. For F-2, the resistance increase rates over blocked pores
are in the ranges of 1.0-1.3 𝑚 ∙ 𝑘𝑔−1 and 1.8-6.3 𝑚 ∙ 𝑘𝑔−1 at lower and higher ionic strength
respectively. The rate of increase of protein layer resistance is expected to depend on membrane
properties as well such as porosity, membrane morphology, pore size and pore size distribution.
For F-3, the rates of increase of protein layer resistance are much higher in the range of 18-23 𝑚 ∙
𝑘𝑔−1 in both phosphate and Tris-acetate buffers at both lower and higher ionic strength conditions.
However, F-3 has much smaller 𝑓 ′ 𝑅 ′ value of about 4.9 𝑚 ∙ 𝑘𝑔−1 in citrate-phosphate buffer. One
possible reason for this relatively smaller 𝑓 ′ 𝑅 ′ value in citrate phosphate buffer is that citratephosphate was the original buffer before the protein was being exchanged to tris-acetate and
sodium phosphate buffers thereby, a relatively low amount of lower molecular weight aggregates
were present.
The parameters obtained from the combined pore blockage and cake filtration model
provide valuable insights into the fouling behaviors of the three virus filters. F-1 has the lowest
membrane resistance and pore blockage rate among the three filters. However, once the pores are
blocked, the rate of increase of protein layer resistance over blocked pores is much larger compared
to F-2, but somewhat smaller than F-3. On the other hand, F-2 has an intermediate membrane
resistance among the three filters. However, the rate of pore blockage could be very high and is
strongly solution condition dependent. For the Fc-fusion protein filtration, the higher ionic strength
leads to much larger pore blockage rates of 39 and 60 𝑚2 𝑘𝑔−1 in the phosphate and tris-acetate
buffers respectively compared to the corresponding values of 6.7 and 4.8 𝑚2 𝑘𝑔−1 at the lower
ionic strength condition. Interestingly, the rate of increase of protein layer resistance over blocked
pores is the lowest for F-2 among the three filters. F-3 has the highest membrane resistance as well
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as comparatively high rate of pore blockage and a high rate of increase of protein layer resistance
over blocked pores.
Figure 2.2 exhibits the total resistance as a function of time during the course of filtration
for the three filters measured experimentally as well as calculated using the parameters obtained
from the previous fitting of the flux data. The experimental total resistance was determined using
∆𝑃⁄ where ∆𝑃 is the pressure applied, 𝜇 is the solution viscosity and J is the filtration flux. Here
𝜇𝐽
the effect of viscosity is not investigated and assuming that it is the same as that of water. It can
be seen that the calculated total resistance agrees well with the experimental measurements for all
three filters at different buffer conditions. This indicates that the parameters (𝛼, 𝑓 ′ 𝑅 ′ ) obtained are
physically reasonable. The flux data show that highest and lowest flux decay are for filtrations
performed in tris-acetate buffer at higher ionic strength and lower ionic strength respectively for
both F-1 and F-2 filters. Flux decay under sodium phosphate and citrate-phosphate buffers lies
somewhere in between. This can be reflected from the total resistance measured as it is inversely
correlated with the flux decay. For F-3 filter, citrate-phosphate buffer has the lowest decay and
total resistance whereas the fluxes and resistances are very similar to one another under sodium
phosphate and tris-acetate buffer conditions. The combined pore blockage and cake filtration
model was able to predict both the flux and resistance trend over time very well. It is worthwhile
to point out that the rate of pore blockage and the rate of increase of protein layer resistance are
described with respect to unit mass of protein passed through membranes whereas the flux and
resistance are plotted over time. The three filters were investigated with the same protein
throughput of about 250 L/m2. Due to their different fluxes, the resistance increase over time is
different from the rates of pore blockage and increase of protein layer resistance described per unit
mass of protein filtered. F-1 has the highest resistance increase over time due to its high flux.
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Protein recovery for the filtration of the Fc-fusion protein under all the buffer conditions
for the three filters are between 95-100%. Variation in the range of 5% is considered normal. No
systematic trend was observed for protein recovery with regard to feed conditions including buffer
type and ionic strength.

F-1

Figure 2.2 Total resistance as a function of filtration time for virus filters F-1 (top), F-2
(middle) and F-3 (bottom) at citrate-phosphate, sodium phosphate and tris-acetate buffer
conditions during the filtration of Fc-fusion protein. Symbols represent the measured total
resistances. Lines represent the calculated resistance from the fitting of the flux data.
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F-2

F-3

Figure 2.2 (Cont.) Total resistance as a function of filtration time for virus filters F-1 (top), F-2
(middle) and F-3 (bottom) at citrate-phosphate, sodium phosphate and tris-acetate buffer
conditions during the filtration of Fc-fusion protein. Symbols represent the measured total
resistances. Lines represent the calculated resistance from the fitting of the flux data.
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In order to demonstrate that protein fouling of the virus filters via both pore blocking and
cake filtration mechanisms is possible, the coverage of the lost protein on the filters during
filtration was estimated. Assuming protein loss in the membrane is 1% of the total protein in the
feed solution, the weight of the protein lost due to membrane fouling is about 0.0125 g for F-2 and
F-3 filters with the feed volume of 250 mL and protein concentration of 5 g/L. The area that can
be covered by a monolayer of lost protein is about 590 m2 assuming the protein size is about 5 nm
in radius for the Fc-fusion protein based on the DLS measurement. Since the filter area is only
10.0 cm2 for F-2 and F-3 filters, multilayers of protein plugging the pores and forming a cake layer
over the barrier layer is very likely. Similar argument can be made for the F-1 filter.
The observed fact that buffer conditions have strong influence on filtration performance is
not difficult to understand. Protein conformation, stability and size as well as their interactions are
influenced by buffer conditions. Different ions have different ability to change protein
conformation or even denature protein following the so-called Hofmeister series (Collins, 2004)
(Du, Wickramasinghe, & Qian, 2010). In particular, cations and anions follow different series
(Schwierz, Horinek, & Netz, 2010). Previous literature shows that the higher the charge on the
cation, the more destabilizing it is to a protein whereas the opposite is true for the anions (Du,
Wickramasinghe, & Qian, 2013). Generally, ions that have strong degree of hydration and no
direct interaction with the protein will stabilize the protein. Ions that exhibit weak hydration but
with stronger tendency to directly interact with the protein will destabilize the protein. However,
the order will also depend on the properties of the proteins. In some cases, a reverse Hofmeister
series has been observed. It is no surprise that acetate, phosphate and citrate anions have different
effects on the stability of the Fc-fusion protein thereby its tendency for aggregation and its
interaction with the virus and the membrane. In addition, since the pH of the feed solution is around
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7.5, the Fc-fusion protein and the MVM virus particles will be negatively charged leading to an
overall repulsive electrostatic interaction among them. On the other hand, the presence of salt ions
will tend to screen the electrostatic repulsion and enhance the hydrophobic interaction leading to
stronger protein-protein associations. This is consistent with our observation here that the presence
of 200 mM reduces filtration flux for the moderately hydrophobic Fc-fusion protein investigated.
2.3.2 The Effects of Virus Spiking on Flux and Fouling
It is known that spiking virus particles to the feed solution could potentially affect the
performance of the virus filters, particularly for filter F-1. Moreover, impurities in virus stocks
such as host cell proteins and DNAs could affect the performance of virus filters. Previous studies
(Khan, Parrella, Genest, & Colman, 2009) showed virus spiking could accelerate membrane
fouling thus result in more flux decay even in the absence of protein product. As a result, high
purity and high titer virus stock is critical for this study. In this study, precautions were taken to
ensure minimal fouling of the filters by the virus stock. As mentioned before, the titer of our MVM
virus stock is around 11 logs/mL based on qPCR. For the filtration studies, less than 50 l of the
virus stock was used for each filtration experiment with HCP concentration at around 10 𝜇g/L only
in the feed solutions. Nevertheless, it is still important to investigate the effects of virus particles
and associated impurities on filter performance. In the previous Fc-fusion protein virus filtration
experiments, the total number of MVM particles loaded onto the filters were between 9-10 logs
(qPCR) for all the feed samples. Here MVM virus stock was spiked into the four buffer solutions
(20 mM sodium phosphate and tris- acetate buffers with and without 200 mM NaCl at pH 7.5) to
reach the same range of MVM loading to the filters at 9-10 logs (qPCR feed titer of 7.4 logs/mL)
as the filtration conditions in the presence of the protein. Virus filtrations were carried out
following the same procedure as before for all the three filters. As is seen from the Figure 2.3,
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spiking of MVM at 9-10 logs has only a slight effect on the fluxes for all three virus filters under
all the four buffer conditions. Filter F-1 has a higher flux decay compared to the other filters. About
20% flux decline was observed at the end of 1000 L/m2 throughput for all the four feed conditions.
Only very slight flux changes were observed for filter F-2 and F-3 during the filtration of the four
feed buffers spiked with 9-10 logs of MVM up to 250 L/m2 throughput. More interestingly, for all
the filters and the two buffer types, it appears that filtration flux is higher in the presence of 200
mM NaCl compared to the same buffer without the salt, opposite to what was observed for the
virus filtration of Fc-fusion protein.
There could be several reasons for this enhanced filtration flux in the presence of salt.
Firstly, it is known that low concentrations of salt can enhance the solubility of the mAbs and other
proteins. Since the MVM capsid is made of proteins, the solubility of the virus can be increased to
some degree in 200 mM NaCl solutions. This increased solubility is due to the direct interaction
between the Na+ ions and the negatively charged groups on the virus capsid proteins as Na+ ions
are generally strongly hydrated. Secondly, the physiological salt concentration at which most
biomolecules are most stable is around 154 mM, close to the salt concentration in the buffers with
salt. It can be inferred that from the flux data that the flux difference for the same buffer at different
salt concentration is not a result of electrostatic interaction since both the virus particles and at
least one of the membrane filters are known to be negatively charged at pH 7.5 (Hongo-Hirasaki,
Komuro, & Ide, 2010). Increasing salt concentration will reduce virus-membrane or virus-virus
repulsive interaction thereby potentially a reduction in the flux. Clearly, electrostatic interaction is
not dominating the flux behavior here. However, an opposite flux behavior in the presence of Fcfusion protein where a reduction of the flux in the presence of 200 mM NaCl was observed. This
is likely due to the more hydrophobic nature of the Fc-fusion protein. It is known that higher ionic
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strength will induce stronger hydrophobic interaction due to increased surface tension of the feed
solutions with salt.
The effects of virus spiking on membrane fouling in the presence of protein molecules have
not been discussed so far. Virus particles with diameters of 18-24 nm are expected to be rejected
by the membranes based on the size-exclusion mechanism. The effects of feed conditions on virus
breakthrough will be discussed in the Part II of this study. However, virus particles will block the
membrane pores contributing to the rate of pore blockage 𝛼 during the initial stage of virus
filtration. As the filtration progresses, virus particles will also contribute to the rate of increase of
the protein/foulant layer resistance 𝑓 ′ 𝑅 ′ over blocked pores. Since the number of protein
molecules deposited on the membrane surface or inside the pores is estimated to be about one
million times more than that of the virus particles, the contribution of virus particles to the cake
layer formation or the rate of increase of the protein/foulant layer resistance 𝑓 ′ 𝑅 ′ over blocked
pores is probably small. Instead, the virus particles may have more impact on the pore blockage
rate per unit mass of protein filtered due to its relatively large size.
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F-1: Spiked Buffer Filtration
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F-2: Spiked Buffer Filtration
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Figure 2.3 Flux as the function of throughput for F-1 (top), F-2 (middle) and F-3 (bottom) for
virus spiked buffer filtrations. Filtration experiments were performed in both 20 mM phosphate
and 20 mM Tris-acetate buffers at pH 7.5 with and without 200 mM NaCl.
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F-3: Buffer spiked filtration
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Figure 2.3 (Cont.) Flux as the function of throughput for F-1 (top), F-2 (middle) and F-3
(bottom) for virus spiked buffer filtrations. Filtration experiments were performed in both 20
mM phosphate and 20 mM Tris-acetate buffers at pH 7.5 with and without 200 mM NaCl.

2.4 Conclusions and Discussion

A combined pore blockage and cake filtration model was applied to the virus filtration of
an Fc-fusion protein using the three commercially available filters, F-1, F-2 and F-3. The fouling
behaviors of the three filters were described well by this combined model. The fouling of the virus
filters is dominated by the pore blockage mechanism during the initial stage of the filtration and
transformed to the cake filtration mechanism during the later stage of the filtration. Besides flux
data, the increase of the transmembrane resistance can also be described well by this model. The
pore blockage rate 𝛼 per unit mass of protein filtered, the rate of increase of protein layer resistance
𝑓 ′ 𝑅 ′ over blocked pores are found to be affected by membrane properties as well as the solution
conditions. It can be inferred from this study that solution conditions modulate the interactions
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between protein, virus and membranes. At higher ionic strength, higher flux and lower fouling
were observed for virus filtration of Fc-fusion protein in sodium phosphate and tris-acetate buffers
respectively with both F-1 and F-2 filters, whereas no significant differences were observed under
these two buffers for F-3 filter. Buffer type also plays a role in the fouling behavior of the filters.
Even though this combined model provided very good fits for all the data sets, it does not
mean the actual fouling of the membrane occurs by the same effect of pore blockage and cake
filtration. There are a few limitations in using this model to describe the fouling behavior of a virus
filter. Firstly, this model was originally developed for a microporous (Ho & Zydney, 2000) tracketched membrane, whose foulants are much smaller than the membrane pores in size. In MVM
spiked virus filtrations, the foulants are viruses, protein aggregates, and loosely self-associating
single protein molecules; thus, the foulants sizes are equal to or greater than the pores, meaning
that the actual fouling process could also be very different. In addition, this model was developed
on the basis of the four classical membrane fouling models, for which the membrane pores are
assumed to be uniform, cylindrical, and straight. However, virus filtration membranes have unique
structures with sharp pore size distributions and interconnected torturous pores. Lastly, virus
filtration membranes, like Viresolve® Pro and Planova™ 20N, are composed of a macroporous
structure providing mechanistic stability and a thin skin layer providing selectivity and virus
retention. With this unique composite structure, it is unlikely that a structured cake layer would
form. Thus, both the ‘pore blockage’ and ‘cake filtration’ would not be the most accurate wording
to describe the fouling behavior. Even with the limitations, the model fits well for all the data sets,
providing us with information about the effect of solution conditions on the fouling of virus filters.
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Chapter 3 The Effects of Solution Condition on The Performance of Commercial Virus
Filters During Filtration of Monoclonal Antibodies and an Fc-fusion Protein
Abstract
Viral safety is one of the major concerns in the production of mammalian cell and
plasma-derived biotherapeutic products. A demonstration of virus clearance is required by the
regulatory agencies. Virus filtration unit operation has been integrated into many downstream
purification processes because it can provide a robust virus removal. In this chapter, the effects
of process interruption, cumulative viral load, and fouling behaviors of the filter as well as
solution condition on virus retention during virus filtration are systematically investigated for the
filtration of two monoclonal antibodies, and an Fc-fusion protein spiked with the minute virus of
mice (MVM) using three commercial parvovirus filters. Our results demonstrate that process
interruption leads to more severe virus breakthrough due to the back diffusion and redistribution
of the virus particles in the membrane pores, and the longer the duration, the more the virus
breakthrough. Virus breakthrough occurs more frequently at a later stage of filtration due to the
increased virus loading resulting in the virus particles’ repartitioning at the solid-liquid interface.
Interactions between protein molecules and the viruses could affect viral removal as well. Our
study shows that the virus breakthrough is complex but strongly filter and solution condition
dependent. Surprisingly, the virus breakthrough appears to be most severe under the relatively
low membrane fouling condition for one of the commercial filters investigated.
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3.1 Introduction
Viral safety is an important issue in the downstream processing of products such as
monoclonal antibodies (mAbs) or other protein therapeutics derived from mammalian cell lines
and plasmas. Employing viruses in genetic modification of cell lines and using various biological
reagents such as animal serum in the production processes give rise to the risk of contamination
by endogenous retrovirus or adventitious parvoviruses (Miesegaes, Lute, & Brorson, 2010).
Regulatory agencies such as the U.S. Food and Drug Administration (FDA) provides guidelines
to ensure that the downstream manufacturing processes can accomplish adequate clearance of the
virus (FDA, 1996) (ICH, 1999). Current viral clearance strategies applied during the
manufacturing process include viral removal as well as inactivation. Biopharmaceutical
manufacturers use various viral inactivation strategies, such as low pH, solution-detergent (S.D.),
heat, and radiation. These methods inactivate enveloped viruses by destroying their core proteins,
nucleocapsid, and genome or dissolution of their envelopes (FDA, 1996). However, the commonly
used inactivation methods are generally harsh and could potentially harm the protein products of
interest. Also, the inactivated virus particles remain in the product stream. More importantly, some
non-enveloped small parvovirus viruses such as minute virus of mice (MVM) are resistant to
inactivation; thus, the physical removal of virus particles is also needed. During the downstream
purification process, viruses can be removed by chromatography-based unit operations and virus
filtration. Viruses are generally negatively charged at neutral pH and can be removed by the
anionic exchange chromatographic step (Weaver, Husson, Murphy, & Wickramasinghe, 2013).
Viral filtration is a dedicated and robust way of virus clearance by rejecting a virus from the
process stream using a porous membrane operated in dead-end mode (Wickramasinghe, Stump,
Grzenia, Husson, & Pellegrino, 2010). Commercial virus filtration membranes are designed to
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remove 99.99% of viruses (18-26 nm) in the feed stream while allowing more than 95% of the
product of interest (8-10 nm) to pass through the filter (Ray & Dolan, 2010).
The high retention of small viruses is achieved with a narrow pore size distribution (PSD)
of the separation active layer of virus filters (Charcosset, 2012). Even though size exclusion is
considered the primary working mechanism of a virus filter, multiple previous studies show the
factors that could influence the virus retention capacity are not limited to the particle sizes. The
cut-off pore diameters of a filter, determined either with Gold nanoparticles (GNPs) or liquidliquid displacement porosimetry (LLDP), could predict the size of viruses the filter can retain
(René Israel Peinador, 2011) (Sal Giglia, 2015) (Kosiola, Hansmann, & Mathias Ulbricht, 2017).
The filter structure, such as the distribution and the location of the smallest pores, is also related
to the robustness of a filter (Nazem-Bokaee, et al., 2018) (Nazem‐Bokaee, Chen, O'Donnell, &
Zydney, 2019). Besides, lower operating pressure or process interruption can lead to an increased
viral passage through virus filters (Woods & Zydney, 2014) (Dishari, Venkiteshwaran, & Zydney,
2015) (Hannelore Willkommen, 2013), as the previously captured viruses could migrate by
Brownian motion to larger pores or towards the filter outlet when the flow velocity (or pressure)
is lower (Dishari, Venkiteshwaran, & Zydney, 2015). However, those diffusive movements can be
constrained when there are adsorptive interactions between the membrane and viruses or with the
presence of proteins (Kosiol, Kahrs, Thom, Ulbricht, & Hansmann, 2018).
Even though multiple studies with microscopy and nanoparticles provided insights on the
retention mechanism of virus filters, the complex biochemical nature of virus particles and the
proteins need to be considered as well. The solution conditions, including the buffer species, pH,
and ionic strength, can modulate the intermolecular forces, such as the protein-protein, proteinvirus, protein-membrane, and virus-membrane interactions, and further influence virus filtration
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performance (Wickramasinghe S. R., Stump, Grzenia, M.Husson, & Pellegrino, 2010). The
attractive interactions between virus particles and the membrane or the specific virus-protein
interactions could both enhance virus retention by a filter (Dishari S. K., Micklin, Sung, & Zydney,
2015)(Kreil, et al., 2006). Besides, solution conditions affect the fouling behavior of a filter and
could further affect virus retention of a filter. For example, it was observed that a greater degree
of membrane fouling is associated with an increased amount of virus passage through a virus filter
(Bolton, et al., 2005). The authors attributed this phenomenon to a preferential blockage of the
smaller pores by proteins/impurities, which led the virus to pass through the remaining larger pores.
The effects of ionic strength, pH, and buffer type on the retention of viruses are still needed
to be systematically investigated in conditions with the presence of proteins and viruses. In this
work, an FDA-recommended non-specific model parvovirus, minute virus of mice (MVM), was
used. MVM is a non-enveloped single-strand DNA virus and is one of the smallest viruses with
18-24 nm in diameter. The virus titers in the feed and the permeate solutions were determined
separately with tissue culture infectious dose 50 assays (TCID50) or large volume plating (LVP) to
calculate the log reduction value (LRV), which determines the effectiveness of the virus clearance
step. The objective of this study is to assess the effects of pH, salt, and buffer species on virus
retention of three commercial virus filters of various membrane configurations and materials in
the presence of two monoclonal antibodies and one Fc-fusion protein or absence of any protein. In
our earlier study (Namila, et al., 2019), we have demonstrated that a combined pore blockage and
cake filtration model can be used to describe the flux decay and fouling behavior of all three virus
filters for Fc-fusion protein filtration. The same model was successfully applied to the filtration of
the other two proteins. The effect of membrane fouling on virus retention has also been studied
here.
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3.2 Materials and Methods
3.2.1 Virus Filters
Virus filter 1 (F-1), filter 2 (F-2), filter 3 (F-3) and the prefilter for F-1 (Pre-1, 5 cm2)
were obtained from the filter manufacturers. Prefilters for F-2 and F-3 (Pre-2 and Pre-3) are 0.1
µm polyethersulfone (PES) bottle-top vacuum filter from Corning (Corning, NY). Pre-1 capsule
filter is an absorption-based prefilter with an effective membrane area of 5 cm2. It removes
process impurities with entrapped diatomaceous earth, while the Pre-2 and Pre-3 remove
impurities with a size-exclusion mechanism. F-1 capsule filter is a flat sheet surface-modified
PES membrane consisting of two identical asymmetric layers, with an effective membrane area
of 3.1 cm2. F-2 is an asymmetric hollow fiber membrane made from cuprammonium regenerated
cellulose (CRC), with a membrane area of 10 cm2. F-3 is an asymmetric hollow fiber membrane
made from surface-modified polyvinylidene fluoride (PVDF), with a membrane area of 10 cm2
(or 3 cm2).
3.2.2 Protein Feed Solution Preparation
Three biopharmaceutical products, provided by Bristol-Myers Squibb (Devens, MA)
were used in this study, they are a monoclonal antibody mAb A with a molecular weight around
155 kDa and an isoelectric point (pI) around 7.2 to 7.5; a second monoclonal antibody mAb B
with a molecular weight of kDa and an isoelectric point (pI) around 8.0; an Fc-fusion protein
with a molecular weight of 94 kDa and an isoelectric point (pI) of 5.9. The Fc-fusion protein was
shipped in a citrate-phosphate buffer solution containing 23 mM NaCl with pH titrated to 7.6
using 0.5 M Tris. All three protein solutions were shipped to the site in a frozen state and stored
at -80 C until used.
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Table 3.1 Buffer conditions and the protein concentrations of the feed in the virus filtration
experiments. (a) Sodium phosphate buffer. (b) Tris-acetate buffer. (c) Citrate-phosphate buffer.
Buffer Species

(a) 20 mM Sodium Phosphate buffer

pH

7.5

Salt (mM)

Fc-fusion
(g/L)

mAb A (g/L)

6.0

0

200

0

200

F-1

7.90±0.17

7.70±0.23

-

-

F-2

8.32±0.11

7.97±0.11

-

-

F-3

8.32±0.11

7.99±0.15

-

-

F-1

5.14±0.01

4.94±0.01

5.15±0.01

5.10±0.08

F-2

5.01±0.01

5.01±0.03

5.23±0.01

5.07±0.01

F-3

3.62±0.01

5.15±0.00

3.76±0.01

5.12±0.00

F-1

3.18±0.02

4.76±0.02

3.57±0.02

4.86±0.01

F-2

5.24±0.01

4.99±0.03

5.14±0.02

5.05±0.02

mAb B (g/L)

Buffer Species
pH

7.5

Salt (mM)

Fc-fusion
(g/L)

mAb A
(g/L)

mAb B
(g/L)

© CitratePhosphate buffer

(b) Tris-20mM Acetate buffer
5.0

7.6

0

200

0

200

23

F-1

5.03±0.07

5.57±0.11

-

-

5.79±0.04

F-2

5.14±0.01

6.10±0.20

-

-

6.34±0.04

F-3

5.14±0.01

6.10±0.20

-

-

6.34±0.04

F-1

2.48±0.01

4.54±0.02

4.46±0.01

4.66±0.01

-

F-2

1.88±0.01

4.73±0.01

4.58±0.01

4.74±0.01

-

F-3

2.08±0.00

5.17±0.01

4.99±0.00

5.28±0.01

-

F-1

4.93±0.03

4.71±0.01

5.01±0.02

4.72±0.01

-

F-2

4.80±0.02

4.72±0.01

4.62±0.02

4.78±0.01

-

Buffer conditions and the protein concentrations of the feed in the virus filtration
experiments are listed in Table 3.1. Chemicals with molecular biology or biotechnology grade
were chosen for buffer preparation whenever possible: sodium chloride (biotechnology grade)
from VWR Life science (Radnor, PA), sodium phosphate monobasic monohydrate (ACS
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reagent, ≥98%), and sodium phosphate dibasic from MilliporeSigma (ReagentPlus, ≥99.0%) (St.
Louis, MO), Tris base (biotechnology grade) from G-BioSciences (St. Louis, MO), OmniPur
sodium acetate trihydrate (molecular biology grade), OmniPur sodium citrate dehydrate
(molecular biology grade) and citric acid anhydrous (molecular biology grade) from EMD
Millipore (Billerica, MA), Sucrose (biology grade) from Alfa Aesar (Ward Hill, MA). pH 500
Economy Benchtop Meter from Oakton Instruments (Vernon Hills, IL) and symphony SP70C
(Radnor, PA) was used to determine the pH and the conductivity of respectively.
Prior to each set of experiment, proteins were thawed in a room-temperature water bath and
buffer exchanged into one of the desired buffers listed above by diafiltration with the following
set-ups: SARTOFLOW® Slice 200 Benchtop Crossflow System (Sartorius AG, Göttingen,
Germany) with Millipore Pellicon® Mini Cassette Holder were used with a Novasep Sius-LSn
HyStream 30 kD TFF cassette (Shrewsbury, MA). The proteins at a concentration of 5-7 g/L
were buffer exchanged with 7 diavolume of the formulation buffer, with the feed flow rate kept
at 400 ml/min and the transmembrane pressure (TMP) kept at 15 psi. Protein concentration and
turbidity were determined by measuring the absorption at 280 nm and 340 nm, respectively,
using Genesys 10 U.V. scanning system (Waltham, MA) with VWR quartz spectrophotometer
cell (path length 1 cm) (West Chester, PA). All the virus filtrations were done immediately or at
most within one week after buffer exchange. Protein solutions after buffer exchange were stored
at 2-8 ℃ until use.
3.2.3 Virus Stock Preparation
The minute virus of mice (MVM) is a representative parvovirus that can infect the Chinese
Hamster Ovary (CHO) cell culture. The minute virus of mice (MVM) (ATCC® VR1346™)
stock was purchased from American Type Culture Collection (Manassas, VA). Further
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productions and purifications of high titer high purity MVM stock were performed according to a
protocol adapted from literature/ patent. Briefly, A9 cells (ATCC® CCL-1.4™) were grown to
full confluency then inoculated with the MVM stock at a target multiplicity of infection (MOI) ~
2.5. The inoculated cells were then grown in MVM production medium, which is Gibco
advanced DMEM (Carlsbad, CA) containing 1% FBS, 4% L-glutamine, and 1% Hyclone
NEAA (Waltham, MA) for three days. Then the medium was replaced by a serum-free MVM
production medium. The harvesting and purification were done on the 18th-21st day after
inoculation when all the cells were lysed and detached from the bottom of the cell culture flasks.
The harvested virus was then buffer exchanged into the 10 ml of TNE buffer (10 mM Tris, 150
mM NaCl, 1 mM EDTA) using an Amicon® Ultra-15 centrifuge filter device 100K (Billerica,
MA) and then concentrated with ultracentrifugation. Purified virus stocks were stored at -80 °C
until use.
3.2.4 Virus Filtration
Virus filtrations were performed with the virus filters connected to a Planova™ reservoir
(Asahi Kasei, Japan) using plastic tubing. The reservoir was pressurized with industrial-grade
nitrogen, and the pressure was controlled at the manufacturer’s recommended values using an
Ashcroft pressure gauge. Prefiltration visual leak tests (VLT) were performed for F-2 and F-3.
Before each virus filtration run, virus filters and Pre-1 were flushed with the manufactures
recommended amount of 0.22 µm filtered deionized water and equilibration buffer. Prefiltered
protein solutions were spiked with purified minute virus of mice (MVM) stock at a targeted load
of 7-8 logs infective particles and filtered with Thermo Scientific™ Nalgene™ Rapid-Flow™
0.22 µm bottle-top vacuum filter (Waltham, MA). During the virus filtration, the cumulative
weight of the filtrate was recorded every minute using BalanceLink software connected to a
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Mettler Toledo scale (Columbus, OH). A total of three fractions were collected for each filter
unless there is any unexpected flux decay. The volume of each fraction is 1/3 of the target
throughput of the filters (990 L/m2 for F-1, 250 L/m2 for F-2 and F-3). After collecting three
fractions or the flux declined to ≤10% of the buffer flux, the valves upstream of the filter were
closed, the pressure vessel was completely depressurized for 90 min or 15 min, and the solution
in the reservoir was replaced with the equilibration buffer (during the interval). After the pause,
virus filters were flushed with 5 L/m2 of buffer at virus filtration pressure. The buffer chase was
collected separately.
3.2.5 Determination of Virus Titer: TCID50 Assay and Large Volume Plating
The viral titer of the feed was determined by tissue culture infectious dose 50 (TCID50)
assay. The revised version of the assay with an improved detection limit, large volume plating
(LVP), was used to determine the titer of the filtrate and buffer chase samples. The indicator
cells, NB324K (gifted from Peter Tattersall at Yale University), were grown in a T-75
CELLSTAR® cell culture flask using DMEM supplemented with 10% FBS, 1% L-Glutamine,
1% Non-essential amino acid, and 0.1 U/mL Penicillin/streptomycin. Once the confluency was
reached, the cells were washed with DPBS (St. Louis, MO) then trypsinized off the flask using
0.25% Trypsin-EDTA (T.E.). T.E. was removed by adding 5 ml of medium, transferring to a
centrifuge tube, centrifugation at 130 g for 5 min, and discarding the supernatant. The cells were
resuspended, counted with a standard hemocytometer, and seeded into a 96-well Nunclon
Delta Surface plate (ThermoScientific, Denmark) at a density of 3,000 cells/well with 100
µl/well. The seeding medium was composed of DMEM, 2% FBS, 1% L-Glutamine, 1% NEAA,
and 0.1 U/ml penicillin/ streptomycin. For the TCID50 assay, only the 60 wells in the middle
were seeded with cells, and the surrounding wells were filled with sterile deionized water to
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avoid evaporation of the medium. For LVP assay, all the 96 wells were seeded with cells. The
cells were returned to a 37 °C, 5% CO2 cell culture incubator overnight then inspected under a
microscope for the desired confluency of 20-50%. For TCID50 assay, a virus-containing sample
was subjected to five serial 10-fold dilutions using seeding media as the diluent. Each dilution
was inoculated onto 6 wells of the 96-well plate at 100 μl/well. The negative control wells were
inoculated with the same seeding medium. Two replicates were done for each sample. For LVP,
virus-containing samples were diluted for 3x (fractions) or 15 x (buffer chase samples). The
diluted sample was inoculated onto all the 96 wells at 200 μl/well. Plates were returned to the
incubator for ten days before virus-induced CPE observation. On day 10, the inoculated wells
were inspected under a microscope for CPE.
To calculate the TCID50 titer, the Spearman-Kärber method (see the formula below) was
used.
𝑑

𝑙𝑜𝑔10 𝑇𝐶𝐼𝐷50 /𝑚𝑙 = − (−𝑌0 + 2 − 𝑑𝑃𝑖 − 𝑣)

(Eq. 3.1)

where Y0 is the decadic logarithm of the highest dilution factor of the sample that causes the
infection of all parallel cultures; d is the decadic logarithm of dilution factor; Pi is the observed
reaction rate starting at Y0; v is the decadic logarithm of the volume conversion factor.
Standard error Se and the confidence limit C (C=  2 Se) were calculated for each assay.

𝑆𝑒 = 𝑑√∑

𝑃𝑖 (1−𝑃𝑖 )
(𝑛𝑖 −1)

(Eq. 3.2)

where Se is the standard error; Pi is the reaction rate; ni is the number of determination; d is the
decadic logarithm of the dilution factor.
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In the large volume plating assay, depending on the reaction rate (the number of positive
wells divided by the number of wells tested), different formulas were chosen as described below:
1. When the reaction rate is between 15-50%:
the Spearman-Kärber method was used with an assumption that a 1:3 higher concentrated
dose compared to the highest dose tested leads to CPE in all parallel cultures.
2. the reaction rate is < 15%, virus titer was calculated with the following equation:
𝐷

𝑛−𝑛𝑝

𝑤

𝑛

𝑇𝑖𝑡𝑒𝑟/𝑚𝑙 = 𝑉 (−𝑙𝑛

)

(Eq. 3.3)

where D is the pre-dilution factor of the sample; np is the number of CPE positive wells; n is the
total number of wells tested; Vw is the sample volume per well.
3. When no CPE was observed, the following equation was applied:
𝑇𝑖𝑡𝑒𝑟/𝑚𝑙 =

𝑙𝑛𝑝
𝑣
𝑉

𝑉𝑙𝑛(1− )

(Eq.3.4)

where p equals 0.05; v is the tested sample volume, and V is the processed fraction volume.
3.3 Results and Discussion
3.3.1 Filtration of MVM Spiked Buffer
Virus spiking can impact virus filters’ behavior, as the virus stock contains some impurities,
such as host cell protein (HCP) and DNA (Cabatingan M. , 2005) (Lutz, et al., 2011). Thus,
having a virus stock with high purity and high titer is crucial for virus filtration assessment
studies. In our work, the titer of the virus stock produced in-house is around 11 logs/ml (qPCR);
so, only less than 50 µL of the stock is needed for each run to reach the target feed titer of 7.4
logs/ml, containing less than 10 µg/L of HCP. The impact of spiking on flux is discussed in
Chapter 2. Sodium phosphate buffer and tris-acetate buffer at pH 7.5 with 0 mM or 200 mM
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sodium chloride were spiked with MVM and filtered through the three virus filters. Without
showing significant flux decays, all three filters were able to reach the target filtration throughput
endpoint, which is 990 L/m2 for F-1, 250 L/m2 for F-2 and F-3. The total viral loads all landed
between 7-8 logs TCID50 (9-10 logs with qPCR). During the filtration with F-1, in phosphate
buffer without NaCl, the flux decay was 28%, and with 200 mM NaCl the flux decay was 21%
of the J0 (the initial fluxes); while in acetate buffer without NaCl, the flux decay was 33%, and
with NaCl, the flux decay is 22% of the J0. For F-3, these numbers are 16%, 8%, 14% and 3%
respectively. However, in all conditions, the flux decay of F-2 was less than 5% of the J0. As is
discussed in Chapter 2, higher relative fluxes of F-1 and F-3 were observed with the presence of
NaCl, which can be attributed to the increased solubility of MVM capsid protein in the presence
of low concentration salt. Also, an increase in pore diameter caused by electrostatic charge
shielding can increase the flux of a filter as well (Kosiol, Kahrs, Thom, Ulbricht, & Hansmann,
2018). Even with a potential increase of pore size with the salt present, indicated by the higher
fluxes, there was no virus detected in the fractions of F-1 and F-3 in all the solution conditions
(Figure 3.1 and Table 3.2). While without significant flux decays, viruses were detected in the
fractions of F-2 after a 90 min process interruption (the buffer chase). But these virus
breakthroughs only occurred during the filtrations for phosphate buffer, with 0 mM and 200 mM
NaCl, and the overall LRVs are all higher than 5 logs (Figure 3.1, Table 3.2, and Table 3.3).
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MVM Log Reduction Value (LRV)

8
7
6

Virus Clearance for Spiked Buffer Filtration
Sodium Phosphate buffer - 200 mM NaCl
Sodium Phosphate buffer - 0 mM NaCl
Tris-acetate buffer - 200 mM NaCl
Tris-actate buffer - 0 mM NaCl
≥
5.56
≥
5.56
5.42
≥5.35 ≥5.35 ≥5.43 ≥5.52
≥5.43 ≥5.18≥5.35 ≥5.35
5.19

5
4
3
2
1
0

F-1

F-2

F-3

Figure 3.1 The overall LRV for virus filtration of MVM spiked buffer at different solution
conditions for F-1, F-2, and F-3 filters.
Table 3.2 The virus titer in each fraction point during the filtration of MVM spiked buffer with
the three-virus filter in different solution conditions. the pH of all the solutions is 7.50.
Virus
Filter

Buffer
type

NaCl
(mM)

Total
Viral
Load
(Logs)

Sodium
Phosphate
buffer

200

Virus titer in each fraction
Total
LRV

Fraction 1

Fraction 2

Fraction 3

Buffer
Chase

7.60±0.43

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤-0.08±0.00

≥5.43
±0.43

0

7.35±0.49

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤-0.08±0.00

≥5.18
±0.49

TrisAcetate
buffer

200

7.52±0.49

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤-0.08±0.00

≥5.35
±0.49

0

7.52±0.43

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤-0.08±0.00

≥5.35
±0.43

Sodium
Phosphate
buffer

200

7.57±0.57

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

0.75±0.03

5.42±
0.57

0

7.40±0.49

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

1.00±0.04

5.19±
0.50

TrisAcetate
buffer

200

7.65±0.45

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤0.26±0.00

≥5.56
±0.45

0

7.65±0.37

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00

≤0.26±0.00

≥5.56
±0.37

Sodium
Phosphate
buffer

200

7.40±0.51

≤-0.39±0.00

≤-0.39±0.00

≤-0.39±0.00

≤0.26±0.00

≥5.35
±0.51

0

7.40±0.43

≤-0.39±0.00

≤-0.39±0.00

≤-0.39±0.00

≤0.26±0.00

≥5.35
±0.43

TrisAcetate
buffer

200

7.48±0.47

≤-0.39±0.00

≤-0.39±0.00

≤-0.39±0.00

≤0.26±0.00

≥5.43
±0.47

0

7.56±0.39

≤-0.39±0.00

≤-0.39±0.00

≤-0.39±0.00

≤0.26±0.00

≥5.52
±0.39

F-1

F-2

F-3
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Table 3.3 Virus breakthrough status indicated by the number of wells shown cytopathic effect
(CPE) during the filtration of MVM spiked buffer with F-2.
Buffer

NaCl
(mM)

pH

Total viral
load (logs)

Breakthrough status

LVP # of positive wells
out of 96 wells

LRV

(F1; F2; F3; BC)
Sodium
Phosphate buffer
Tris- Acetate
buffer

200

7.50

7.57±0.57

YES

0; 0; 0; 7

5.42±0.57

0

7.50

7.40±0.49

YES

0; 0; 0; 12

5.19±0.50

200

7.50

7.65±0.45

NO

0; 0; 0; 0

≥5.56±0.45

0

7.50

7.65±0.37

NO

0; 0; 0; 0

≥5.56±0.37

A diffusion-based virus transmission mechanism was proposed to explain the reduction
of virus retention after process interruption (P.I.) (Yamamoto, Hongo‐Hirasaki, Uchi, Hayashida,
& Nagoya, 2014) so that an adsorptive interaction between the filter and the virus or an increased
solution viscosity could reduce the LRV decay after P.I. (Kosiol, Kahrs, Thom, Ulbricht, &
Hansmann, 2018). The regenerated cellulose membranes as F-2 are negatively charged at pH 7.5
(Hongo‐Hirasaki, Komuro, & Ide, 2010), and MVM, whose isoelectric point is 5.2, is also
negatively charged at pH 7.5; repulsive forces exist between F-2 and MVM. Since virus
breakthrough was detected in both with salt and without salt conditions, indicating that it was the
buffer species (Phosphate vs Tris-acetate) and the counter ions play a role in virus passage
occurred during the spiked buffer filtration with F-2.
3.3.2 Filtration of Three Different Product Proteins
The three biopharmaceutical product proteins, including two monoclonal antibodies and an
Fc-fusion protein, were filtered with the three virus filters under various solution conditions. It is
shown in Chapter 2 that a combined pore blockage and cake filtration model can describe the
fouling behavior of the virus filters for the filtration of Fc-fusion protein under different buffer
conditions (Namila, et al., 2019). The same model was successfully applied to describe the
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fouling behavior of virus filtrations for the two monoclonal antibodies, mAb A and mAb B, with
the three filters. The relative fluxes plotted as a function of throughput during the virus filtration
of mAb A and mAb B with filter F-1 are shown in Figure 3.2, with filter F-2 are shown in Figure
3.3. The filtrations of mAb B with F-3 are shown in Figure 3.4. As is shown in the figures, filter
types, protein molecules, and solution conditions have effects on the performance of the virus
filters, indicating the complex interactions between all the parameters involved.

Condition
NaCl
(mM)
pH
R2

Tris-acetate Buffer

Sodium Phosphate Buffer
200

200

0

0

200

200

0

6
0.70

7.5
0.89

6
0.96

7.5
0.96

5
0.97

7.5
0.95

5
0.89

a.
Figure 3.2 Relative flux as a function of filtration throughput/time for virus filters F-1 and F-3 in
different buffer conditions. Panel (a)(b) is filtration with F-1 for mAb A and mAb B, respectively.
Symbols represent experimental measurements of averaged fluxes during a 10 min period. Lines
represent fits using combined pore blocking and cake formation model to the throughput data.

98

b.

Condition
NaCl
(mM)
pH
R2

Sodium Phosphate Buffer

Tris-acetate Buffer

200

200

0

0

200

200

0

0

6
0.94

7.5
0.98

6
0.98

7.5
0.99

5
1.00

7.5
0.99

5
0.99

7.5
0.99

Figure 3.2 (Cont.) Relative flux as a function of filtration throughput/time for virus filters F-1 and
F-3 in different buffer conditions. Panel (a)(b) is filtration with F-1 for mAb A and mAb B,
respectively.

99

a.
Condition
NaCl
(mM)
pH
R2

Sodium Phosphate Buffer

Tris-acetate Buffer

200

200

0

0

200

200

0

6
0.55

7.5
0.40

6
0.80

7.5
0.87

5
0.81

7.5
0.53

5
0.70

Figure 3.3 Relative flux as a function of filtration throughput for virus filters F-2 in different
buffer conditions. Panel (a) is for mAb A and (b) is for mAb B.
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b.
Condition
NaCl
(mM)
pH
R2

Sodium Phosphate Buffer

Tris-acetate Buffer

200

200

0

0

200

200

0

0

6
0.96

7.5
0.95

6
0.75

7.5
0.993

5
0.94

7.5
0.93

5
0.97

7.5
0.94

Figure 3.3(Cont.) Relative flux as a function of filtration throughput for virus filters F-2 in
different buffer conditions. Panel (a) is for mAb A and (b) is for mAb B. Symbols represent
experimental measurements of averaged fluxes during a 10 min period. Lines represent fits using
combined pore blocking and cake formation model to the throughput data.
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Condition
NaCl
(mM)
pH
R2

Sodium Phosphate Buffer

Tris-acetate Buffer

200

200

0

0

200

200

0

6
0.90

7.5
0.86

6
0.94

7.5
0.97

5
0.97

7.5
0.82

5
0.98

Figure 3.4 Relative flux as a function of filtration throughput for virus filters F-3 in different buffer
conditions for mAb B filtration.
The overall log reduction values (LRV) for the filtrations of the Fc-fusion protein, mAb A
and mAb B, with virus filters F-1, F-2, and F-3 are shown in Figure 3.5, with the detailed numbers
are shown in the tables (Table 3.4, Table 3.5, Table 3.6). Virus titers of both the feed and the
filtrates were determined using TCID50 or LVP assay, respectively. As mentioned, the LVP assay
was used to increase the sensitivity of the assay. The filtrate of all three filters was collected in
three fractions, with each fraction approximately a third of the initial target throughput. However,
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in some cases, only one or two fractions were collected due to the premature membrane fouling.
For example, due to the flux decay by more than 90%, during the filtrations with F-1, the
throughput reached ~200 L/m2 in two cases with mAb A and reached less than 100 L/m2 in all the
cases with mAb B. Similarly, filtration for mAb A with F-3 in one solution condition had a
premature membrane fouling so that the filtration stopped before reaching the throughput endpoint.

LRV for Fc-fusion Protein Filtration in Different Buffer Conditions

MVM Log Reduction Value (LRV)

8

Citrate-phosphate buffer
Sodium Phosphate buffer - 0 mM NaCl
Tris-acetate buffer - 0 mM NaCl
≥5.77

6

≥5.29≥5.42

≥4.92

Sodium Phosphate buffer - 200 mM NaCl
Tris-acetate buffer - 200 mM NaCl

≥5.26 5.30 5.38

≥5.44
4.63

≥5.30 ≥5.30

5.38

5.80

≥4.88

4.39

4

2

0
F-1

F-2

F-3

a.
Figure 3.5 The overall log reduction value (LRV) of MVM during the filtration of Fc-fusion
protein (a), mAb A(b) and mAb B(c) with virus filter F-1, F-2 and F-3 in different solution
conditions. All the Fc-fusion protein filtrations were conducted at pH 7.5.
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LRV for mAb A Filtration in Different Buffer Conditions

MVM Log Reduction Value (LRV)

8

6

Sodium Phosphate buffer - 200 mM NaCl-pH 6.0
Sodium Phosphate buffer - 200 mM NaCl-pH 7.5
Sodium Phosphate buffer - 0 mM NaCl-pH 6.0
Sodium Phosphate buffer - 0 mM NaCl-pH 7.5
Tris-acetate buffer - 200 mM NaCl-pH 5.0
Tris-acetate buffer - 200 mM NaCl-pH 7.5
Tris-actate buffer - 0 mM NaCl-pH 5.0
Tris-actate buffer - 0 mM NaCl-pH 7.5
≥5.96
≥5.38
5.22
≥5.17 ≥5.25
5.08 ≥5.10 4.99
≥5.05
≥4.75
4.77
≥4.79
≥4.75
≥4.55
4.46

4

≥3.68

≥3.29

≥2.35

≥2.20

≥2.05
≥1.51

2

≥2.08

≥1.55
≥1.18

0
F-1

F-2

F-3

b.

LRV for mAb B Filtration in Different Buffer Conditions
8

MVM Log Reduction Value (LRV)

6

Sodium Phosphate buffer - 200 mM NaCl-pH 6.0
Sodium Phosphate buffer - 0 mM NaCl-pH 6.0
Tris-acetate buffer - 200 mM NaCl-pH 5.0
Tris-actate buffer - 0 mM NaCl-pH 5.0
≥5.39
≥4.93
≥4.82
≥4.69
≥4.60 ≥4.38
≥4.52≥4.43

Sodium Phosphate buffer - 200 mM NaCl-pH 7.5
Sodium Phosphate buffer - 0 mM NaCl-pH 7.5
Tris-acetate buffer - 200 mM NaCl-pH 7.5
Tris-actate buffer - 0 mM NaCl-pH 7.5
≥5.22

≥5.22 5.00

4.81
4.09
3.94 3.68

4
2.52

2

0
F-1

F-2

c.
Figure 3.5 (Cont.) The overall log reduction value (LRV) of MVM during the filtration of Fcfusion protein (a), mAb A(b) and mAb B(c) with virus filter F-1, F-2 and F-3 in different solution
conditions. All the Fc-fusion protein filtrations were conducted at pH 7.5.
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Table 3.4 The virus titer in each fraction is shown during the filtration of Fc-fusion protein with
the three filters in different solution conditions. pH 7.50.
Virus
Filter

Total Viral
Load (Logs)

Fraction 1

Fraction 2

Fraction 3

23

6.85±0.49

≤-0.35±0.00

N/A

N/A

≥5.2±0.49

Sodium Phosphate
buffer

200

7.04±0.33

≤-0.35±0.00

N/A

N/A

≥5.42±0.33

0

6.63±0.41

≤-0.35±0.00

N/A

N/A

≥4.92±0.41

Tris- Acetate
buffer

200

7.25±0.33

≤-0.35±0.00

N/A

N/A

≥5.77±0.33

0

7.27±0.45

≤-0.35±0.00

≤-0.37±0.00

N/A

≥5.44±0.45

23

6.92±0.41

-0.35±0.01

0.06±0.01

0.12±0.01

4.63±0.41

Sodium Phosphate
buffer

200

7.31±0.41

≤-0.35±0.00

≤-0.35±0.00

0

7.35±0.49

≤-0.35±0.00

≤-0.35±0.00

-0.35±0.01

5.30±0.49

Tris- Acetate
buffer

200

7.65±0.49

≤-0.35±0.00

≤-0.35±0.00

0.12±0.01

5.38±0.49

0

7.52±0.39

-0.35±0.00

0.37±0.02

1.10 ±0.02

4.39±0.39

23

7.35±0.37

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00 ≥5.30±0.37

Sodium Phosphate
buffer

200

7.35±0.51

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00 ≥5.30±0.51

0

6.93±0.41

≤-0.35±0.00

≤-0.35±0.00

≤-0.35±0.00 ≥4.88±0.41

Tris- Acetate
buffer

200

7.43±0.41

≤-0.35±0.00

≤-0.35±0.00

-0.35±0.01

5.38±0.41

0

7.85±0.31

≤-0.35±0.00

-0.35±0.01

-0.35±0.0

5.80±0.31

Citrate-Phosphate
buffer

F-1

Citrate-Phosphate
buffer

F-2

Citrate-Phosphate
buffer

F-3

Virus titer in each fraction

NaCl
(mM)

Buffer type

Total LRV

≤-0.35±0.00 ≥5.26±0.41
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Table 3.5 The virus titer in each fraction shown during the filtration of mAb A with the three
filters in different solution conditions.
Virus
filter

Buffer
Species

NaCl
pH
(mM)

200
Sodium
Phosphate
Buffer
0
F-1
200
Trisacetate
buffer

Total
virus
(logs)

0
F-2
200
Trisacetate
buffer
0

200
Sodium
Phosphate
Buffer
0
F-3
200
Trisacetate
buffer

F2

F3

Chase

≤-0.38±0.00 ≤-0.40±0.00 ≤-0.08±0.00 ≥5.04±0.34

7.5 7.35±0.42 ≤-0.38±0.00

≤-0.38±0.00 ≤-0.40±0.00 ≤-0.08±0.00 ≥5.22±0.42

6.0 4.72±0.44 ≤-0.39±0.00

N/A

≤-0.08±0.00 ≥3.29±0.44

7.5 7.31±0.38 ≤-0.40±0.00

N/A

≤-0.08±0.00 ≥5.96±0.38

5.0 6.66±0.44 ≤-0.38±0.00

≤-0.38±0.00 ≤-0.39±0.00 ≤-0.08±0.00 ≥4.55±0.44

7.5 7.50±0.44 ≤-0.38±0.00

≤-0.38±0.00 ≤-0.40±0.00 ≤-0.08±0.00 ≥5.38±0.44

5.0 4.17±0.30 ≤-0.38±0.00

≤-0.38±0.00 ≤-0.38±0.00 ≤-0.08±0.00 ≥2.05±0.30

7.5 2.67±0.30

Sodium
Phosphate
Buffer

LRV
F1

6.0 7.09±0.34 ≤-0.38±0.00

0

200

Virus titer in each fraction

≤0.28±0.00

≤-0.08±0.00 ≥1.51±0.30

N/A

6.0 7.39±0.50 ≤-0.39±0.00

-0.80±0.00

-0.80±0.00

1.86±0.06

4.77±0.50

7.5 7.65±0.46 ≤-0.39±0.00

≤-0.39±0.00

-0.80±0.00

1.76±0.06

5.08±0.46

6.0 5.73±0.30 ≤-0.39±0.00

≤-0.39±0.00 ≤-0.39±0.00 ≤-0.26±0.00 ≥3.68±0.30

7.5 7.15±0.40 ≤-0.39±0.00

≤-0.39±0.00 ≤-0.39±0.00 ≤-0.26±0.00 ≥5.10±0.40

5.0 6.81±0.40 ≤-0.39±0.00

≤-0.39±0.00 ≤-0.39±0.00 ≤-0.26±0.00 ≥4.79±0.40

7.5 7.48±0.48 ≤-0.39±0.00

≤-0.39±0.00 ≤-0.39±0.00

5.0 4.40±0.44 ≤-0.39±0.00

≤-0.39±0.00 ≤-0.39±0.00 ≤-0.26±0.00 ≥2.35±0.44

7.5 2.70±0.00 ≤-0.39±0.00

1.62±0.05

4.99±0.48

≤-0.26±0.00 ≥1.55±0.00

N/A

6.0 6.21±0.54 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00 ≤-0.08±0.00 ≤-0.44±0.00

7.5 6.29±0.40 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00

6.0 3.26±0.38 ≤-0.44±0.00

≤-0.72±0.00

7.5 6.62±0.46 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00 ≤-0.08±0.00 ≥5.17±0.46

5.0 6.21±0.34 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00 ≤-0.08±0.00 ≥4.75±0.34

7.5 6.71±0.42 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00 ≤-0.08±0.00 ≥5.25±0.42

5.0 3.54±0.30 ≤-0.44±0.00

≤-0.44±0.00 ≤-0.43±0.00 ≤-0.08±0.00 ≥2.08±0.30

0
7.5 2.22±0.00

≤0.27±0.00

N/A

N/A

1.41±0.00

4.46±0.40

≤-0.08±0.00 ≤-0.44±0.00

≤-0.08±0.00 ≥1.18±0.00
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Table 3.6 The virus titer in each fraction shown during the filtration of mAb B with the three
filters in different solution conditions.
Virus
Filter

Buffer
Species

NaCl
pH
(mM)

Sodium
Phosphate
Buffer

200

Trisacetate
buffer

200

Sodium
Phosphate
Buffer

200

0

F-1

F-2
Trisacetate
buffer

0

0
200

6.0
7.5
6.0
7.5
5.0
7.5
5.0
7.5
6.0
7.5
6.0
7.5

Total
virus
(logs)
5.39±0.42
5.48±0.38
6.31±0.42
6.06±0.38
5.53±0.40
6.26±0.52
6.01±0.44
6.28±0.44
7.32±0.44
7.15±0.50
7.40±0.44
8.07±0.44

5.0 7.31±0.44
7.5 7.56±0.56

0

5.0 7.29±0.38
7.5 7.32±0.44

Virus titer in each fraction
F1

F2

F3

≤0.23±0.00
N/A
≤0.27±0.00
N/A
≤-0.46±0.00
N/A
≤0.28±0.00
N/A
≤0.26±0.00
N/A
≤-0.50±0.00
N/A
≤0.29±0.00
N/A
≤-0.46±0.00
N/A
≤-0.39±0.00 -0.80±0.00 -0.80±0.00
0.22±0.01
1.58±0.12
2.25±0.28
≤-0.39±0.00 ≤-0.39±0.00 -0.39±0.01
-0.19±0.01
0.73±0.02
0.99±0.02
≤≤-0.39±0.00 ≤-0.39±0.00
0.39±0.00
-0.44±0.00 -0.44±0.01 0.57±0.02
≤≤-0.39±0.00 ≤-0.39±0.00
0.39±0.00
≤-0.39±0.00 ≤-0.39±0.00 -0.19±0.01

Chase
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
≤-0.08±0.00
1.41±0.05
3.67±0.22
2.75±0.19
3.83±0.25

LRV
≥4.52±0.42
≥4.43±0.38
≥5.39±0.42
≥4.93±0.38
≥4.51±0.40
≥5.48±0.52
≥4.76±0.44
≥5.38±0.44
5.05±0.44
2.52±0.45
3.94±0.41
3.52±0.47

≤-0.26±0.00 ≥5.27±0.44
2.58±0.12

4.21±0.43

≤0.26±0.00

≥5.27±0.38

1.29±0.05

4.97±0.44

As is shown in Figure 3.5 (b), during the filtrations for mAb A, LRVs with all three filters
are especially low in three solution conditions even without any virus breakthrough observed.
These conditions are sodium phosphate buffer without salt at pH 6.0, Tris-acetate buffer without
salt at pH 5.0, and Tris-acetate buffer without salt at pH 7.5. In the first two conditions (pH 5.0
and pH 6.0, without salt), the low LRVs are due to the low virus titer of the feed. This is because,
during the post-spiking pre-filtration step with 0.22-micron filter, some viruses were removed due
to aggregating at those pHs close to the isoelectric point of MVM. However, the interaction
between mAb A and MVM also have played certain roles in the aggregation and removal of the
virus with 0.22-micron filter since we did not see a similar phenomenon during mAb B filtrations,
even in those solution conditions that are prone to form MVM aggregates. This difference can be
attributed to the different stability of the proteins in those solution conditions. Interactions between
product protein and the virus play roles in virus retention, and it has been attributed to the
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nonspecific electrostatic interactions (Strauss, et al., 2017) (Dishari, et al., 2015). The low LRV in
Tris-acetate buffer without salt at pH 7.5 was caused by an extra low throughput of all the filters
caused by an aggregation of the product protein at a pH close to mAb A's isoelectric point (pI: 7.27.5).

Except for the cases mentioned above, F-1 provided robust virus clearance with LRV>4
during the filtrations of all three proteins in all the solution conditions. During the filtration of Fcfusion protein with F-3, the virus was detected in the filtrate in Tris-acetate buffer, with and without
salt. However, in both cases, only 1 well out of 96 wells has shown CPE in LVP assay, so that the
result is not considered significant. Except for these, F-3 also have shown a robust clearance for
MVM with LRV>4 during the filtrations of Fc-fusion protein and mAb A in all the solution
conditions. F-2 is prone to have more virus breakthrough in some cases, and the factors that could
have caused those breakthroughs are discussed in the following session.

3.4 Discussion About the Factors that Could Cause Virus Breakthrough
The degree of viral breakthrough can be indicated by the number of wells shown CPE in
LVP assay (Table 3.7). During the filtration of Fc-fusion protein, virus breakthrough was
observed in four out of five solution conditions, with the filtration in tris-acetate buffer without
salt shown the greatest virus passage. In the filtration of mAb A, virus breakthrough occurred in
only three out of eight filtrations, with the greater virus passage happened only after the process
interruption. However, during the filtration for mAb B, six out of eight conditions have shown
virus breakthrough, with three of them showing severe viral passage, presenting virus in the very
first fraction. Even with the same virus filter, in the same solution conditions, the presence of
different protein molecules resulted in different degrees of virus retention, indicating a complex
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interplay between the filter, protein, and the virus. The effect of total viral load, solution
conditions, and process interruption are discussed below.
Table 3.7 The degree of viral breakthrough occurred during filtrations with F-2 indicated by the
number of wells shown CPE in LVP assay. (a) Fc-fusion protein (b) mAb A (c) mAb B. The
fractions collected before process interruption (F1, F2, F3) were diluted 3X for the assay, while
fractions collected after process interruption (B.C.) were diluted for 15X for the assay.
a. Fc-fusion protein

Buffer

pH

NaCl
(mM)

Total viral
load (logs)

Breakthrough
status

LVP # of
positive wells
out of 96
wells

LRV

(F1; F2; F3)
Citrate-phosphate
buffer

7.6

Sodium
Phosphate buffer

23

6.92±0.41

YES

1; 7; 8

4.63±0.41

200

7.31±0.41

NO

0; 0; 0

≥5.26±0.41

0

7.35±0.49

YES

0; 0; 1

5.30±0.49

200

7.65±0.49

YES

0; 0; 8

5.38±0.49

0

7.52±0.39

YES

2; 14; 33

4.39±0.39

7.5
Tris-acetate
buffer

b. mAb A
Buffer

NaCl
(mM)

pH

Total viral
load (logs)

Breakthrough
status

LVP # of positive wells
out of 96 wells

LRV

(F1; F2; F3; BC)
6.0

7.39±0.50

YES

0; 1; 1; 46

4.77±0.50

7.5

7.65±0.46

YES

0; 0; 1; 38

5.08±0.46

6.0

5.73±0.30

NO

0; 0; 0; 0

≥3.68±0.30

7.5

7.15±0.40

NO

0; 0; 0; 0

≥5.10±0.40

5.0

6.81±0.40

NO

0; 0; 0; 0

≥4.79±0.40

7.5

7.48±0.48

YES

0; 0; 0; 27

4.99±0.48

5.0

4.40±0.44

NO

0; 0; 0; 0

≥2.35±0.44

7.5

2.70±0.00

NO

0; 0

≥1.55±0.00

200
Sodium
Phosphate
buffer
0

200
Tris- Acetate
buffer
0
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Table 3.7 (Cont.) The degree of viral breakthrough occurred during filtrations with F-2
indicated by the number of wells shown CPE in LVP assay. (a) Fc-fusion protein (b) mAb A
(c) mAb B. The fractions collected before process interruption (F1, F2, F3) were diluted 3X for
the assay, while fractions collected after process interruption (B.C.) were diluted for 15X for the
assay.
c. mAb B
Buffer

NaCl
(mM)

pH

Total viral
load (logs)

Breakthrough
status

LVP # of positive wells
out of 96 wells

LRV

(F1; F2; F3; BC)
6.0

7.32 ± 0.44

YES

0; 1; 1; 28

5.05 ± 0.44

7.5

7.15 ± 0.50

YES

10; 53; 87; 96

2.52 ± 0.45

6.0

7.40 ± 0.44

YES

0; 0; 2; 71

3.94 ± 0.41

7.5

8.07 ± 0.44

YES

4; 29; 46; 96

3.52 ± 0.47

5.0

7.31 ± 0.44

NO

0; 0; 0; 0

≥5.27±0.44

7.5

7.56 ± 0.56

YES

1; 2; 21; 91

4.21 ± 0.43

5.0

7.29± 0.38

NO

0; 0; 0; 0

≥5.27±0.38

7.5

7.32 ± 0.44

YES

0; 0; 4; 22

4.97 ± 0.44

200
Sodium
Phosphate
buffer
0

200
Tris- Acetate
buffer
0

3.4.1 The Effect of the Total Viral Load
Compared to the fractions collected earlier, later fractions tend to present higher viral
titers. Increased virus loading onto the filters leads to the repartitioning of the virus particles at
the membrane/permeate solid-liquid interface and the virus breakthrough in the permeate (Figure
3.6). Also, longer processing time at the later fractions means that virus particles have a higher
probability of transmission through the membranes. The fraction number, the range of
throughput, and the range of cumulative viral load when virus breakthrough first occurred during
the filtrations of Fc-fusion protein, mAb A, mAb B with virus filter F-2 in different solution
conditions are shown in Table 3.8. 95% confidence limits of the virus assay are < 0.5 logs in
most cases. During the filtration of Fc-fusion protein in the citrate-phosphate buffer, a presence
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of virus was detected in the first fraction, when the cumulative virus load was less than 6.52 logs.
However, in phosphate buffer with salt, there was no virus breakthrough observed even when the
viral load reached 7.30 logs. During the filtration of mAb A, in phosphate buffer with salt at both
pH 6.0 and pH 7.5, the earliest fractions with the virus are Fraction 2 (F2) and the range of
cumulative virus loads are 6.90-7.21 logs and 7.16-7.46 logs, respectively. While in all the other
conditions, no virus breakthrough observed before process interruption, even when virus load
reached 7.48 logs in Tris-acetate buffer with salt at pH 7.50. Similarly, during the filtration of
mAb B, in phosphate buffer with salt at pH 7.50, virus breakthrough occurred during the
collection of the first fraction, when the cumulative viral load was less than 6.66 logs. However,
in Tris-acetate buffer with salt at pH 5.0, when the viral load reached 7.32 logs, there was still no
virus breakthrough observed. All these results indicate that cumulative viral load is not directly
correlated with the degree of virus breakthrough.

Cumulative Viral Load (logs)

10

a.

Fc-fusion protein
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Figure 3.6 Cumulative viral load (logs) in the function of throughput during the virus filtration
with F-2 for Fc-fusion protein(a), mAb A(b) and mAb B(c).
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Figure 3.6 (Cont.) Cumulative viral load (logs) in the function of throughput during the virus
filtration with F-2 for Fc-fusion protein(a), mAb A(b) and mAb B(c).
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Table 3.8 The fraction number, the range of throughput and the range of cumulative viral load
when virus breakthrough first occurred during the filtrations of Fc-fusion protein, mAb A, mAb
B with virus filter F-2 in different solution conditions.
Buffer

Sodium Phosphate Buffer

NaCl (mM)

200 mM NaCl

pH

6.0
Fraction

Fc-fusion
protein

Throughput
2

(L/m )
7.30

Fraction

F2

F2

Throughput

160250

160-250

2

(L/m )
Viral Load
(logs)
Fraction
Throughput
2

mAb B

6.0

NB

Viral Load
(logs)

mAb A

7.5

0 mM NaCl

(L/m )
Viral Load
(logs)

6.907.16-7.46
7.21

NB

7.5

Tris- Acetate Buffer
200 mM NaCl
5.0

7.5

0 mM NaCl
5.0

CitratePhosphate buffer
23 mM NaCl

7.5

7.6

F3

F3

F1

F1

160-250

160-250

0-80

0-80

7.15-7.35

7.45-7.62

No virus7.03

No virus-6.52

NB

NB

BC

NB

NB

250

5.73

7.15

6.82

7.48

4.4

2.95

NB

F1

NB

F3

F2

F1

F3

F1

80-160

0-80

160250

0-80

6.827.12

NO
VIRUS6.66

6.917.40

0-80

160-250

NO
NO
VIRUS- 7.32 VIRUS- 7.30 6.82-7.32
7.58
7.08

3.4.2 The Effect of Solution Conditions
Contradictory views had been held over the effect of fouling on virus retention (Bolton,
et al., 2005) (Ruppach, 2018). Our previous study has shown that a combined pore blockage and
cake filtration model can be used to describe the fouling behavior of the virus filters for the
filtration of Fc-fusion protein under different buffer conditions. The same model was
successfully used for describing the fouling behavior of the three filters for the filtration of mAb
A and mAb B, and the parameters are shown in Table 3.12. It has been found that fouling is
much more severe for the filtration of Fc-fusion protein in both sodium phosphate and tris113

acetate buffers at higher ionic strength conditions compared to that at lower ionic strength
condition. The pore blockage rates 𝛼 per unit mass of protein processed are 60 and 39 m2kg-1 for
the filtration of Fc-fusion protein under tris-acetate and sodium phosphate buffer conditions
higher ionic strength condition. The corresponding pore blockage rates 𝛼 under lower ionic
strength condition are only 4.7 and 6.8 m2kg-1, respectively, in tris-acetate and sodium phosphate
buffers. Moreover, the lower ionic strength conditions have more virus breakthrough, especially
in tris-acetate buffer conditions. It seems that a correlation between low pore blockage rate and
high virus breakthrough exists. The reason is likely that more open pores lead to more virus
breakthrough. When fouling is severe, more pores are blocked by protein aggregates leading to
the rejection of the virus particles. Moreover, the pore blockage rate can be effectively correlated
with the solution condition. At higher ionic strength, electrostatic repulsion between the proteinprotein, protein-virus particles are screened and reduced, whereas hydrophobic interaction is
enhanced, leading to a stronger association of the particles at the higher salt condition. This, in
turn, leads to more pore blockage and higher rejection of the virus particles. It seems that virus
breakthrough under citrate phosphate for Fc-fusion protein filtration with F-2 can neither be
correlated with higher viral loading nor with lower fouling conditions. In fact, its viral loading is
the lowest among all the conditions investigated. Moreover, there is more flux decay compared
to most of the other solution conditions indicating a higher fouling rate. However, upon closer
examination, the hydrodynamic diameter of the Fc-fusion protein measured by DLS in the
citrate-phosphate buffer is about 13 nm, larger than those under other buffer conditions, as can
be seen in Table 3.11. The increased size of the Fc-fusion protein likely leads to more exposure
of the hydrophobic core of the protein, thereby stronger aggregation as indicated by removal of
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virus particles during the prefiltration step. This stronger association between the virus and
protein may lead to a breakthrough under citrate-phosphate buffer conditions, as observed.
Table 3.9 The isoelectric points of each species and their charges at each pH tested.
Species

Isoelectric Point

The net charge of the proteins at different pH

5

6

7.5

MVM

5.2

Neutral to positive

Negative

Negative

Fc-fusion protein

5.9

\

\

Negative

mAb A

7.2-7.5

Positive

Positive

Negative to neutral

mAb B

8

Positive

Positive

Positive

Table 3.10 Membrane fouling related parameters obtained by fitting flux data into the combined
pore blocking and cake filtration model. (a) Parameters for filtration of mAb A with F-2. (b)
Parameters for the filtration of mAb B with F-2.
a. mAb A

Sodium Phosphate Buffer

NaCl (mM)

0

Tris- Acetate Buffer

200

0

200

pH

6.0

7.5

6.0

7.5

5.0

5.0

7.5

q0

50.94

57.38

53.25

54.23

50.12

59.35

60.28

protein

5.15

5.01

5.08

5.01

4.58

4.74

4.73

0

11

Rp :1e
11

F'R':1e
a

88.53

45.90

41.84

46.69

68.26

18.82

17.21

Rp0

19.51

11.41

10.33

10.61

24.24

7.86

7.74

F’R’

8.08

6.86

0.53

0.66

3.07

7.33

1.55

0.80

0.87

0.55

0.40

0.70

0.81

0.53

2

R
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Table 3.10 (Cont.) Membrane fouling related parameters obtained by fitting flux data into the
combined pore blocking and cake filtration model. (a) Parameters for filtration of mAb A with F2. (b) Parameters for filtration of mAb B with F-2.
b. mAb B

Sodium Phosphate Buffer

NaCl
(mM)

0

Tris- Acetate Buffer

200

0

200

pH

6.0

7.5

6.0

7.5

5.0

7.5

5.0

7.5

q0

63.03

68.20

59.60

63.04

66.14

65.62

68.22

71.00

protein

5.14

5.24

5.05

4.99

4.62

4.8

4.78

4.72

Rp0:1e
F'R':1e

11

11

a

125.08

111.40

140.48

128.27

87.57

96.22

91.49

103.88

Rp0

22.34

18.91

14.67

12.43

26.26

18.12

22.02

16.35

F’R’

5.34

12.04

24.34

32.37

24.42

8.09

28.70

30.51

0.75

0.93

0.96

0.95

0.973

0.94

0.944

0.93

R

2

Table 3.11 The hydrodynamic diameter of Fc-fusion protein is measured by Dynamic Light
Scattering (DLS) in different solution conditions.
Buffer Type

Citratephosphate
Buffer

pH

7.6

NaCl (mM)

23

0

200

0

200

Hydrodynamic
diameter (𝒏𝒎)

12.98±0.52

10.60±0.58

11.88±0.50

10.92±0.50

11.94±0.08

Sodium Phosphate Buffer

Tris-acetate Buffer

7.5

In mAb A filtration, the highest fluxes were observed in phosphate buffer with salt pH
6.0 and pH 7.5, and in Tris-acetate buffer with salt at pH 7.5, associated with higher ionic
strength. From Table 3.7 (b), we can also see that the highest amount of virus breakthrough
occurred in phosphate buffer with salt at pH 6.0 and pH 7.5 and in Tris-acetate buffer with salt at
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pH 7.5. Thus, higher fluxes are associated with a greater degree of virus breakthrough. In
phosphate buffer no salt at pH 7.50, there was no virus breakthrough even when the total viral
load reached 7.15 logs. However, the solution conditions with virus breakthrough have the
lowest 𝑓 ′ 𝑅 ′ , which is the rate of the increase of the protein layer resistance per unit mass of
proteins filtered, which depends strongly on the feed solution condition such as pH and ionic
strength (Palecek & Zydney, 1994)
During the filtration of mAb B, as is shown in Figure 3.3 (b), the filtrate flux was the
lowest in Tris-acetate buffer at pH 5.0, with or without salt conditions (showing in light blue and
dark green lines). Regarding virus retention, the performance of F-2 was the worst in phosphate
buffer at pH 7.5 with or without salt, while no virus breakthrough was observed in Tris-acetate
buffer at pH 5.0 both with salt and without salt conditions. Similar to the previously shown
results for mAb A and Fc-fusion protein, higher filtrate fluxes are associated with greater virus
breakthrough. Comparing between the conditions in which F-2 had the most and the least
amount of virus breakthrough, we can see that the conditions showed higher pore blockage rate α
and lower initial resistance of the protein/foulant deposit 𝑅𝑝𝑜 had more virus breakthrough. In
addition, an obvious trend in mAb B filtration is that virus breakthrough occurs more easily at
pH 7.5 and less at pH 5.0.
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3.4.3 The Effect of Process Interruption
Since 2011, it has been repeatedly reported that flow resumption after a pressure release
could lead to severe decay in virus retention of virus filters (Hannelore Willkommen, 2013)
(Shudipto K. Dishari, 2015) (Kosiol, Kahrs, Thom, Ulbricht, & Hansmann, 2018) (Strauss, et al.,
2017). This reduction in LRV has been attributed to an increased diffusive movement at lower
pressure, which allows the viruses to get into non-retentive pores, thus even result in
transmission through the membranes. During the filtration of Fc-fusion protein in Tris-acetate
buffer no salt at pH 7.5 with filters F-1 and F-2, the inlet pressure was released (0 psi) for 15 min
and 90 min, then resumed to chase with 5 L/m2 equilibration buffer. The virus titer in the chase
buffer was measured with LVP assay as well. The fractions collected before pressure release
were diluted 3X for LVP assay while the fractions with chase buffer were diluted 15X for the
assay, considering expected higher viral titers (Table 3.12 and Table 3.13). Results showed no
increase in virus breakthrough occurred after pressure release for F-1. While virus retention with
F-2 has drastically decreased after the pressure release, and the longer the interruption, the more
the LRV decay. This confirms the diffusion lead virus breakthrough theory. Yamamoto et al.
hypothesized that the virus entrapment within a hollow fiber membrane with a void-and-capillary
structure depends on a balance between convective flow and the Brownian motion of the viruses
within the void (Yamamoto, Hongo‐Hirasaki, Uchi, Hayashida, & Nagoya, 2014). That is, with
higher flow velocity, movements of viruses are constrained so that they are trapped at the
entrance of capillaries whose diameter is smaller than the virus; while at a lower flow velocity,
Brownian motion widens the movement of viruses and bring them to a capillary with larger
entrance, which could lead them to move to the next void, enhancing the possibility of a viral
breakthrough. They also have confirmed the hypothesis with simulation and experiments.
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Table 3.12 Effect of the duration of process interruption: 15 min VS 90 min. (a) The virus titer
in each fraction during the filtration of Fc-fusion protein in Tris-acetate buffer pH 7.50 no salt,
with F-1 and F-2. (b) The degree of virus breakthrough is indicated by the number of wells
shown CPE.
Virus
Filter

Pressure
release
(min)

Total
Viral
Load
(Logs)

15

(a) Virus titer in each fraction
Total LRV
Fraction 1

Fraction 2

Fraction 3

Buffer Chase

7.84±0.39

≤-0.35±0.00

≤-0.35±0.00

-0.35±0.00

≤-0.08±0.00

5.72±0.39

90

7.52±0.24

≤-0.35±0.00

≤-0.35±0.00

N/A

≤ -0.08±0.00

≥5.62±0.24

15

7.77±0.33

0.17±0.01

1.16±0.02

1.37±0.17

1.82±0.06

4.20±0.39

90

7.68±0.24

-0.19±0.24

1.17±0.02

1.53±0.24

2.61±0.22

3.88±0.54

F-1

F-2

Virus
Filter

Pressure release
(min)

(b) LVP: number of wells shown
breakthrough / 96 wells

Total Viral Load
(logs)

F1 (3x)

F2 (3x)

F3 (3x)

BC (15 x)

LRV

15 min

7.84± 0.39

0

0

1

0

5.72 ± 0.39

90 min

7.52± 0.24

0

0

N/A

0

≥5.62±0.24

15 min

7.77± 0.33

9

44

68

43

4.20 ± 0.39

90 min

7.68± 0.24

4

47

74

78

3.88 ± 0.54

F-1

F-2

3.5 Conclusions
A systematic study using three commercial virus filters was performed to understand the
factors influencing virus retention during the filtration of three biopharmaceutical protein
products as a function of membrane properties and solution conditions. Size exclusion is the
primaryα mechanism of virus filtration membranes. In addition to membrane pore size, other
factors such as process interruption, viral load, and filter fouling are proved to be important to
virus retention as well. In this study, an increased virus breakthrough was observed after process
interruptions, and the longer the duration, the more the virus breakthrough. This result is
consistent with the previously reported hypothesis that virus transmission under low/no pressure
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is due to a diffusive reorganization of previously trapped viruses. The long processing time leads
to higher virus loading, thus increases the chance of virus breakthrough as well. However, this
study also has shown that viral load is not directly related to virus transmission when other
factors such as solution condition and properties of protein molecules are involved. Interactions
between protein molecules and the virus could cause aggregation in some conditions (pH close to
pI of the virus) and affect the feed solution's virus titer. The fouling behavior of all the three
membranes can be predicted by a combined pore blocking and cake filtration model during the
filtration of all the three proteins. The data indicate that a worse virus retention behavior of a
virus filter F-2 is correlated with less fouling/higher fluxes of the filter. These less fouling/higher
fluxes are reflected by smaller pore blockage rate α in Fc-fusion protein filtration, smaller f’R’
(the rate of the increase of the protein layer resistance per unit mass of proteins filtered) in mAb
A filtration, or smaller 𝑅𝑝𝑜 (initial resistance of the protein/foulant deposit) in mAb B filtration.
All three factors are greatly influenced by the solution conditions. Filtration performance of filter
F-2 for mAb A is influenced by the ionic strength of the solution, while the performance for
mAb B filtration is affected by the solution pH. Even with virus breakthrough, all the three filters
provided robust retention of virus, reaching an LRV over 4 in most conditions.
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Chapter 4 The Role of Protein-Protein Interactions on Virus Filtration Performance
Abstract
Optimization of the unit operation in the downstream process development of a
monoclonal antibody (mAb) is essential. Flux decay of a virus filter can be caused by various
fouling species, such as antibody fragments, the oxidized forms of mAb, and oligomers.
Oligomers form because of complex intermolecular forces and the self-association of protein
molecules, which could be affected by multiple factors, such as solution pH and ionic strength.
In this study, we measured the mean hydrodynamic diameter and the diffusion coefficient of a
mAb at five different concentrations (1, 5, 10, 15, and 20 g/L) using dynamic light scattering
(DLS), then calculated the diffusion interaction parameter, kD. To better understand the effect of
solution conditions on mAb self-association, those measurements were done in eight different
conditions, including two buffer species, two salt concentrations, and three pH. Virus filtrations
were conducted with a commercial virus filter, Planova 20N, for the mAb in the same eight
solution conditions, and the filtrate fluxes were recorded. In the same buffer type (phosphate or
acetate), when the kD value is negative, a more negative kD value responds to a relatively lower
filtrate flux. These results showed that kD value can be applied to predict the relative filtrate flux
of a virus filter in some conditions.
4.1 Introduction
There is a potential risk of viral contamination in the pharmaceutical products generated with
mammalian cell culture. In order to ensure patients’ safety, regulatory agencies require
biopharmaceutical manufacturers to have their purification process to be able to remove an
adequate amount of viruses (Log reduction value>4) (EMEA, 2008) (FDA, 1997) (ICH.Q5A(R1),
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1999). Viral inactivation with low pH or solvent detergent and virus removal with chromatography
or virus filtration is the most commonly used virus clearance methods in the downstream process
(Aranha & Forbes, 2001). Virus filtration is a widely applied unit operation. Virus filters are
ultrafiltration membranes with 19±2 nm pore size and able to remove both the enveloped and nonenveloped viruses (Sofer, et al., 2005). Even with the advantages such as easy of implementation,
virus filters tend to foul easily, which results in flux decline and reduced capacity, further increases
the required membrane area and processing time. Thus, understanding the fouling mechanism of
a virus filter to mitigate fouling is essential.
Multiple factors involving membrane chemistry and structure influence the degree of membrane
fouling in various ways. Membranes made of more hydrophobic materials, such as polyvinylidene
fluoride (PVDF), have a higher tendency towards fouling compared to membranes made with
hydrophilic materials (e.g., regenerated cellulose) due to the adsorption of proteins onto the
membrane. Besides, electrostatic interactions between the membrane and the protein also
contribute to fouling when they carry opposite charges (Hongo-Hirasaki, Komuro, & Ide, 2010).
An analysis of Immunoglobulin G (IgG) adsorption on cellulose filter using a quartz crystal
microbalance energy dissipation (QCM-D) revealed that post-adsorption conformational changes
of the protein also have a negative impact on the filtrate flux (Hamamoto, et al., 2017). For
membranes with an asymmetric structure, like Viresolve 180 and Viresolve Pro, filters have higher
capacity when the skin-side facing away from the feed, as the more porous structure can serve as
an internal prefilter and protect the selective layer with smaller pore sizes (Bohonak & Zydney,
2005) (Syedain, Bohonak, & Zydney, 2006). Membranes having steeper pore size gradient (PSG)
are also more susceptible to fouling, different from the ones with shallow PSGs whose big portion
of the structure acts as an internal depth filter (Kosiol, et al., 2018). Additionally, a systematic
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study should be carried out for finding the better operation mode (constant flux or constant pressure)
and the optimal processing values, as those factors have great effects on filter capacity as well
(Syedain, Bohonak, & Zydney, 2006).
During the manufacturing of recombinant DNA technology products using mammalian cell
culture, impurities that are immunogenic or potent to the patients are also generated along with the
target proteins. Those impurities can be classified as product-related or process-related impurities.
Process-related impurities include viruses, host-cell proteins (HCP) and DNAs, and leachable (e.g.,
Protein A), while product-related impurities are molecular variants, including aggregates,
fragments, charge variants, or incorrectly glycosylated proteins (ICH, 1999). According to the
regulations, a final product with <5% aggregates, <100 ppm HCPs, and < 10 ng/dose DNAs is
considered acceptable (Chon & Zarbis-Papastoitsis, 2011). Virus filtration is a unit operation
typically placed at the end of the purification train so that we can expect minimal amounts of those
impurities (Wickramasinghe, Stump, Grzenia, M.Husson, & Pellegrino, 2010). However, due to
their special structure and narrow pore size gradients, virus filters are susceptible to trace amounts
of impurities. Selecting an appropriate prefilter for the virus filter can significantly increase the
capacity of parvovirus filters (Souza, Scott, & Genest, 2016) (Bolton, Spector, & LaCasse, 2010)
(Ireland, Bolton, & Noguchi, 2006). The impurities eluted from those prefilters are oxidized or
degraded IgG, subclasses of the IgG with more hydrophobic antigen-binding sites; thus, an
application of hydrophobic interacting prefilter (e.g., containing diatomaceous earth) or ion
exchange prefilter (e.g., ion exchange membrane adsorbers) would remove most of the impurities
that cause fouling on virus filters (Brown, et al., 2010). Low interacting size exclusion-based
microfiltration membranes with pore size 0.1 to 0.2 microns are also used as VF prefilters.
However, studies have shown that foulants on virus filtration membranes are mostly in the size
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range of 16 to 40 nm (Barnard, Kahn, Cetlin, Randolph, & Carpenter, 2014) (Rayfield, et al., 2015).
Thus, microfiltration prefilters cannot entirely remove the foulants.
In a study using a high-throughput filtration screening device, Bieberbach et al. recognized two
types of aggregates, reversible (or self-assembly) and irreversible, can affect virus filtration
behavior differently (Bieberbach, et al., Investigation of Fouling Mechanisms of Virus Filters
during the Filtration of Protein Solutions Using a High Throughput Filtration Screening Device,
2019). They found that the irreversible foulants can be detected using size exclusion
chromatography (SEC) and removed using hydrophobic interaction prefilter. Meanwhile,
reversible foulants can be evaluated from the diffusion interaction parameter, 𝑘𝑆 , of the feed
solution. 𝑘𝐷 is directly related to the second virial coefficient, 𝐵2, a commonly used parameter to
predict weak interactions between two particles (Saito, et al., 2012) (A George, 1994). The
determination of 𝐵2 is relatively time-consuming since it needs both the 𝑘𝐷 and the sedimentation
interaction parameter, 𝑘𝑆 , to be measured separately. Besides, the partial specific volume and the
molecular mass are required (Eq. 1).
𝐵2 =

𝑘𝑠 +𝑘𝐷 +𝑣̅
2𝑀

(Eq. 4.1)

However, multiples studies have shown that kD can be used as a predictor for particle interactions
as B2 (Connolly, et al., 2012) (Tomar, Singh, Li, Broulidakis, & Kumar, 2018).
Using the acquired diffusion coefficient, a diffusion interaction parameter, 𝑘𝐷 , was then calculated
with the following formula:
𝐷𝑡 = 𝐷0 (1 + 𝑘𝐷 𝑐)

(Eq. 4.2)
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Where 𝐷𝑡 is the observed diffusion coefficient, 𝐷0 is the self-diffusion coefficient at infinite
dilution, 𝑘𝐷 is the diffusion interaction parameter, and c is the antibody concentration. 𝐷𝑡 is a
function of the concentration since non-specific interactions between protein molecules have
mostly resulted from charged and hydrophobic residues (Kenrick & Some, 2014). Thus, a negative
𝑘𝐷 value indicates there is an attractive intermolecular interaction, while a positive value
represents repulsion.
Solution pH and ionic strength play critical roles in the downstream purification of mAbs because
they affect the electrostatic and hydrophobic interactions between protein-protein and proteinsubstrate (Hongo‐Hirasaki, Komuro, & Ide, 2010) (Bolton, Basha, & LaCasse, 2010) (Sahin,
Grillo, Perkins, & Roberts, 2010). As is studied by Hofmeriter a century ago, specific ions and
buffer types can affect the solubility of protein molecules (salting-in or salting-out) (Kunz, Henle,
& Ninham, 2004). In high concentration therapeutic protein solution, these effects are reflected as
the changes in viscosity and protein aggregation behaviors, which affect the filtrate flux and filter
capacity of virus filtration membranes. In this study, we systematically evaluated the effect of
solution conditions, including pH, buffer species and salt concentration, on the intermolecular
interactions of a monoclonal antibody and their further impacts on the filtrate flux of a virus filter.
The intermolecular interactions, either repulsion or attraction, of the mAb was evaluated by
measuring the hydrodynamic diameter and 𝑘𝐷 using dynamic light scattering (DLS). The prefilter
used in this study is a low interacting 0.1-micron size-exclusion based membrane. As a result, the
negative kD values can qualitatively predict the relative trend of virus filtration fluxes.
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4.2 Materials and Methods
4.2.1 Protein and Feed Solution Preparation
One monoclonal antibody with a molecular weight of 155 kDa, exhibiting isoelectric point (pI) of
7.2-7.5, was provided by Bristol-Myers Squibb (Devens, MA). The protein was shipped to the site
in a frozen state and stored at -80 ℃ until used. The concentration of the mAb was determined
photometrically using a Genesys 10 UV scanning system (Waltham, MA), with a VWR quartz
spectrophotometer cell (path length 1 cm) (West Chester, PA). The turbidity of the protein solution
was evaluated by measuring the absorbance at 340 nm using the same device. For doing the
dynamic light scattering, the protein was concentrated with a UF/DF system consists of a Novasep
Sius-LSn HyStream 30 KD TFF cassette (Shrewsbury, MA) in a Millipore Pellicon® Mini
Cassette Holder with a SARTOFLOW® Slice 200 Benchtop Crossflow System (Sartorius AG,
Göttingen, Germany) to reach a concentration of 20 g/L (or slightly above 20 g/L). Then buffer
exchanged into a desired buffer solution. The concentrations of the mAb were then adjusted to the
target concentrations (1, 5, 10, 15, and 20 g/L) by diluting with respective buffers (Table 5.1). For
performing virus filtration, protein concentration was adjusted to approximately around 5 g/L and
then buffer exchanged into the desired buffer with UF/DF, then diluted to 5 g/L before virus
filtration. Each buffer exchanging was done with 7 diavolumes of formulation buffer, with the
transmembrane pressure (TMP) kept at 15 psi, and the feed flow rate kept at 400 ml/min. Then the
protein solutions were stored at 2-8 ℃ until use (within one week).
The solution conditions studied in this study are sodium phosphate buffer at pH 6.0 and 7.5, made
with sodium phosphate monobasic monohydrate (ACS reagent, ≥98%) and sodium phosphate
dibasic (MilliporeSigma ReagentPlus, ≥99.0%, St. Louis, MO), and Tris-acetate buffer at pH 5.0
and 7.5, made with biotechnology grade Tris base (G-BioSciences, St. Louis, MO), OmniPur
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sodium acetate trihydrate (EMD Millipore, Billerica, MA) and glacial acetic acid (Sigma-Aldrich,
St. Louis, MO). pH 500 Economy Benchtop Meter from Oakton Instruments (Vernon Hills, IL)
was used to determine solution pH. The salt concentration of the solutions was either 0 mM or 200
mM NaCl, adjusted with biotechnology grade sodium chloride (VWR Life science, Radnor, PA).
The solution conductivity was measured with a Symphony SP70C (Radnor, PA).
Table 4.1 The exact concentration of the protein used for measuring the diffusion coefficient with
DLS. Each sample was measure for three times.
NaCl
(mM)

pH

Con. 1
(g/L)

Con.
2,(g/L)

Con. 3
(g/L)

Con. 4
(g/L)

Con. 5
(g/L)

6.0

19.06±0.01 13.75±0.01 9.08±0.01 4.63±0.00 1.03±0.01

7.5

18.39±0.04 13.37±0.03 8.94±0.01 4.45±0.00 0.88±0.01

6.0

19.38±0.00 14.6±0.01 9.60±0.03 4.86±0.00 0.95±0.01

7.5

17.80±0.05 13.22±0.01 8.82±0.01 4.42±0.02 0.77±0.01

5.0

21.75±0.05 16.37±0.01 11.09±0.01 5.57±0.02 1.12±0.00

7.5

22.52±0.00 16.29±0.06 11.19±0.00 5.53±0.02 1.08±0.00

5.0

17.01±0.03 12.67±0.02 8.59±0.01 4.29±0.01 0.83±0.01

7.5

9.22±0.01 7.80±0.01 6.21±0.02 3.01±0.00 0.53±0.01

200 mM
Phosphate
buffer
0 mM

200 mM
Tris-acetate
buffer
0 mM

4.2.2 Dynamic Light Scattering and Diffusion Interaction Parameter
Dynamic light scattering (DLS) was used for measuring the hydrodynamic radius and the diffusion
coefficient of the mAb at different concentrations. Protein solutions were first filtered with a 0.2micron polyethersulfone (PES) syringe filter, and a 1 mL-aliquot was then transferred into a
disposable polystyrene cuvette with 1 cm pathlength (BrandTech, Essex, CT). DLS was conducted
with a Delsa™ Nano particle size analyzer (Beckman Coulter, Brea, CA), with data recording that
was performed by 150 acquisitions in each repeat and three repeats with different aliquotes were
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done for each sample. The acquired data were analyzed with the software, resulting in a mean
hydrodynamic dynamic diameter and a diffusion coefficient for the mAb at each concentration in
each solution condition.
In DLS, a fast photon counter captures the time-dependent fluctuations in the intensity of scattered
light that is caused by random Brownian motions of macromolecules in solution. The diffusion
coefficient as well as hydrodynamic radius of a molecule can be derived from the captured DLS
intensity data. The hydrodynamic radius refers to the radius of an equivalent hard sphere diffusing
at the same rate as the molecule under observation. The hydrodynamic radius, 𝑟ℎ , reported by a
DLS software is the average hydrodynamic radius (ravg) of macromolecules, as below:
∑𝑖 𝑀𝑖2 𝑐𝑖

𝑟𝑎𝑣𝑔 = ∑

2
𝑖 𝑀𝑖 𝑐𝑖 /𝑟𝑖

(Eq. 4.3)

where 𝑀𝑖 , 𝑐𝑖 and 𝑟𝑖 are the molar fraction, concentration, and the hydrodynamic radii of the
individual species. When there is no self-association of proteins in a solution, the 𝑟𝑎𝑣𝑔 would
remain constant; in contrast, the 𝑟𝑎𝑣𝑔 increases along with the increase of protein concentration in
a self-associating system, due to the appearance of oligomers. For a globular protein, the
theoretical hydrodynamic radius of a monomer can be predicted by its’ molecular weight using the
equation below:
1

𝑟ℎ = 𝑎0 𝑀𝑎

(Eq. 4.4)

for which, the literature reported value of 𝑎0 for globular protein is between 2-3. Using a model
presented by Hanlon et al. (D.Hanlon, I.Larkin, & M.Reddick, 2009), the theoretical diameter of
mAb A (155 KDa) is expected to be 9.2 nm. Thus, when the measured diameter is higher than 9.2
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nm, it is indicating that oligomers with greater diameter are present in the solution. The greater the
diameter, the higher the molar fraction of the oligomers.
4.2.3 Virus Filter and Virus Filtration
Commercial virus filter F-N was in this study. Filter-N is an asymmetric hollow fiber membrane
made from cuprammonium regenerated cellulose (CRC). Before filtrations, a mAb solution with
a concentration of 5 g/L was prefiltered with a 0.1 µm polyethersulfone (PES) bottle-top vacuum
filter (Corning, NY). Virus filtrations were conducted in constant pressure mode at manufacturer
recommended values, with the virus filters connected to a pressure vessel, Planova™ reservoir
(Asahi Kasei, Japan) using plastic tubing. Appropriate priming and visual leak tests (VLT) were
done for the filters before starting the filtrations. Filters were then wetted with manufacturer
recommended amount of DI water and equilibration buffers. The cumulative weight of the filtrate
was measured and recorded every minute with a Mettler Toledo scale (Columbus, OH) for
determining the fluxes. The protein concentration of the filtrates was measured for calculating
protein recovery.
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4.3 Results and Discussion
4.3.1 Influence of Solution Conditions on the Self-association of Proteins

Hydrodynamic Diameter (nm)

a.
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Figure 4.1 Characterization of mAb A oligomerization as a function of solution conditions by
measuring the average hydrodynamic diameter. (a) 20 mM phosphate buffer. (b) Tris-acetate
buffer.
Table 4.2 The Hydrodynamic diameter (nm) of the mAb in different buffer solutions at various
concentrations. The Dh were measured with DLS.
(a) Tris-acetate buffer
0 mM, pH 5

0 mM, pH 7.5

200 mM, pH 5

200 mM, pH 7.5

Conc. 1

10.9±0.1

19.1±0.2

13.1±0.1

14.2±0.4

Conc. 2

10.8±0.1

18.3±0.2

12.7±0.1

13.4±0.1
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Table 4.2 (Cont.) The Hydrodynamic diameter (nm) of the mAb in different buffer solutions at
various concentrations. The Dh were measured with DLS.
(a) Tris-acetate buffer
0 mM, pH 5

0 mM, pH 7.5

200 mM, pH 5

200 mM, pH 7.5

Conc. 3

11.1±0.1

17.0±0.2

12.1±0.2

12.6±0.1

Conc. 4

11.1±0.1

14.9±0.2

11.4±0.3

11.9±0.0

Conc. 5

11.0±0.1

12.2±0.2

11.1±0.1

11.3±0.1

(b) Phosphate buffer
0 mM, pH 6

0 mM, pH 7.5

200 mM, pH 6

200 mM, pH 7.5

Conc. 1

18.9±0.3

16.0±0.3

13.4±0.1

13.8±0.1

Conc. 2

17.0±0.1

14.8±0.1

12.9±0.2

13.3±0.2

Conc. 3

15.0±0.2

13.6±0.6

12.2±0.1

12.6±0.0

Conc. 4

13.2±0.1

12.6±0.2

11.7±0.1

11.9±0.1

Conc. 5

11.4±0.1

12.6±0.1

11.3±0.1

11.3±0.1

The hydrodynamic diameter of mAb A was measure using DLS, in sodium phosphate buffer and
Tris-acetate buffer with a concentration-gradient manner. Five concentration points were selected
in each solution condition and three replicates were done for each data point (Figure 4.1). In 20
mM sodium phosphate buffer, mAb A was found to form oligomers (Fig. 4.1, a). The degree of
self-association was assessed in four different solution conditions, including two sodium chloride
concentrations, 0 and 200 mM, at two pH, pH 6 and 7.5. The increase of the average hydrodynamic
diameter along with the concentration was faster without the presence of NaCl and was the fastest
at pH 6.0. This is indicating that there is an attractive force exists between the protein molecules
in phosphate buffer system, and this force is dominated by electrostatic interactions. However,
hydrophobic interaction is also playing a role. In Tris-acetate buffer (Fig. 4.1, b), a dramatic
increase of hydrodynamic diameter was observed at pH 7.5, without NaCl. In contrast, at pH 5.0,
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a slight decrease of diameter was shown, indicating the attractive electrostatic force has turned to
a repulsive intermolecular electrostatic force. However, presence of NaCl can attenuate both the
attractive and repulsive electrostatic interactions and induce hydrophobic interaction.
The diffusion coefficient was the other output from DLS measurements. The measured diffusion
coefficients were plotted against the protein concentration, then the diffusion interaction
parameters (kD), which characterizes protein-protein interactions, were calculated using the
equation listed in the Methods section. In recent years, kD has been widely accepted as a predictor
parameter for characteristics such as solution viscosity, colloidal stability and protein aggregation
(Yadav, J.Shire, & S.Kalonia, 2010) (He, Woods, Becker, Narhi, & Razinkov, 2011) (Atul Saluja,
Diffusion and Sedimentation Interaction Parameters for Measuring the Second Virial Coefficient
and Their Utility as Predictors of Protein Aggregation, 2010). Like the second virial coefficient,
B22, the more negative kD value represents the higher attractive forces between protein molecules,
while a positive kD value corresponds to a repulsive intermolecular force. In agreement with the
previous results obtained using hydrodynamic diameter data, kD values reveal that different
degrees of intermolecular forces exist between mAb molecules in both sodium phosphate buffer
and Tris-acetate buffer (Figure 4.2, Figure 4.3).
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kD of mAb in Sodium phosphate buffer
200 mM NaCl, pH 6.0 200 mM NaCl, pH 7.5
- 8.82 mL/g
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0 mM NaCl, pH 6.0

0 mM NaCl, pH 7.5

-19.08 mL/g

- 15.11 mL/g

Figure 4.2 (a) The diffusion coefficient of the mAb measured by DLS at various concentrations
in sodium phosphate buffer, at pH 6.0 or pH 7.5, with the presence or absence of 200 mM NaCl.
(b) The calculated diffusion interaction parameter, kD, in the four solution conditions.
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Figure 4.3 (a) The diffusion coefficient of the mAb measured by DLS at varius concentrations in
Tris-acetate buffer, at pH 5.0 or pH 7.5, with the presence or absence of 200 mM NaCl. (b) The
calculated diffusion interaction parameter, kD, in the four solution conditions.
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We also have determined the solution turbidity by measuring the optical density of the solution at
340 nm wavelength. The turbidity data shows the propensity of particulation or the colloidal
stability of the molecules (Atul Saluja, 2010). As is seen from in Figure 4.4, the higher turbidity is
associated with an increased percentage of protein aggregates in the solution, thus, it has the similar
trend was observed as the hydrodynamic diameter and the kD.
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Phosphate Buffer
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0.25
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A340
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0.2
0

0
200 Mm pH 5.0

200 Mm pH 7.5

200 Mm pH 6.0

200 Mm pH 7.5

0 mM pH 5.0

0 mM pH 7.5

0 mM pH 6.0

0 mM pH 7.5

Figure 4.4 Absorbance of the mAb solution measured at 340 nm wavelength, representing the
turbidity of the protein solution at different concentrations in eight solution conditions.
Concentrations of the mAb was ≈20 g/L. Three measurements were done for each sample. Upper
panel: mAb in Tris-20 mM acetate buffer. Lower panel: mAb in 20 mM sodium phosphate buffer.
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Table 4.3 Absorbance of the mAb solution measured at 340 nm wavelength, representing the
turbidity of the protein solution at different concentrations in eight solution conditions.
Concentrations of the mAb are as follows: Conc. 1≈20 g/L, Conc. 2≈ 15 g/L, Conc. 3 ≈ 10 g/L,
Conc. 4≈5 g/L, Conc. 5≈1 g/L. Three measurements were done for each sample.
With 0.22

NaCl
(mM)

pH

Con. 1

Con. 2

Con. 3

Con. 4

Con. 5

6.0

0.078±0.02 0.059±0.001 0.038±0.001 0.018±0.001 0.003±0.001

7.5

0.081±0.000 0.076±0.004 0.041±0.000 0.019±0.001 0.004±0.000

6.0

0.137±0.001 0.097±0.001 0.063±0.001 0.021±0.000 0.005±0.001

7.5

0.119±0.001 0.082±0.002 0.056±0.001 0.025±0.001 0.008±0.002

5.0

0.115±0.002 0.067±0.001 0.052±0.002 0.027±0.001 0.005±0.002

7.5

0.117±0.001 0.072±0.001 0.049±0.001 0.024±0.001 0.009±0.001

5.0

0.062±0.002 0.046±0.001 0.033±0.001 0.017±0.001 0.003±0.000

7.5

0.041±0.001 0.031±0.000 0.023±0.001 0.013±0.002 0.005±0.001

200 mM
Phosphate
buffer
0 mM

Trisacetate
buffer

200 mM

0 mM

4.3.2 Influence of Solution Conditions on the Filtrate Flux of a Virus Filter and Its Relation
to 𝒌𝑫
The Planova 20N was used for evaluating the filtration behavior of the mAb in eight
different solution conditions with a 5 g/L concentration. The obtained results are plotted as relative
fluxes, normalized over the buffer fluxes in the respective conditions, in relation to the volumetric
throughput, for eliminating the variability from filter and buffers (Figure 4.5). The filtration was
performed at 12 psi, as recommended by the filter manufacture. Each data point represents the
average of the flux measured within 10 minutes interval. In our previous work, we have described
the filtration behavior with a combined pore blockage and cake filtration model, which attributed
the initial drop of flux to a deposition of protein molecules inside the pores and accumulation of
aggregates on the membrane surfaces (Namila, et al., 2019). Similarly, we observed a drop of flux
at the beginning in all buffer conditions. In phosphate buffer, the biggest degree of flux drop (20%)
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was at pH 6.0 without the presence of NaCl, while in acetate buffer, the biggest flux drop (60%)
occurred at pH 7.5, also without NaCl. In all cases, very small gradual decrease of fluxes followed
during the subsequent filtration process. According to a theory proposed by Bieberbach et al.,
virus filter flux decay can be caused by two types of fouling species, irreversible aggregates and
reversible aggregates (Bieberbach, et al., 2019). Irreversible aggregates can lead to a continuous
decay of flux with the increased protein throughput. By contrast, reversible aggregates, which are
in a rapid equilibration with the protein monomer, mostly affects the initial flux and does not cause
throughput-dependent flux decays. However, in our work, the protein concentration of the feed is
low at 5 g/L, as aggregates level at lower concentration does not have a significant effect on filtrate
flux of Planova™ 20N, the viscosity changes of the protein solution, reflected by 𝑘𝐷 , due to the
solution condition is most likely contribute to the variations in the flux. The initial flux decay in
the virus filtrations with Planova™ 20N is mostly due to the concentration polarization on the
upstream side of the membrane. Based on the laminar parabolic flux distribution within a pore, the
degree of decay of the initial flux as well as the transport velocity in the subsequent filtration
process depends on the size of the particles relative to the pore size of the filter. This is indicating
that lower fluxes could be related to the presence of oligomers with larger size, or a greater portion
of oligomers in the solution. According to Darcy’s law, the lower flux also can be due to the
increased solution viscosity. Both the formation of reversible oligomer and the increase of solution
viscosity is caused by greater protein self-association tendency, which can be reflected by the
diffusion interaction parameter, 𝑘𝐷 .
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Normalized Flux: Planova 20N
Filtrations without virus spiking
mAb A in 20 mM Sodium Phosphate Buffer
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a.
Figure 4.5 Virus filtration experiments with Planova 20N virus filter were performed for a mAb
at 5 g/L in sodium phosphate buffer (a) and Tris-acetate buffer (b) at a higher or a lower pH, with
the presence or absence of 200 mM sodium chloride. The relative fluxes (corrected with the buffer
flux) are given in relation to the volumetric throughput.
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Normalized Flux: Planova 20N
Filtrations without virus spiking
mAb A in Tris-acetate buffer
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Figure 4.5 (Cont.) Virus filtration experiments with Planova 20N virus filter were performed for
a mAb at 5 g/L in sodium phosphate buffer (a) and Tris-acetate buffer (b) at a higher or a lower
pH, with the presence or absence of 200 mM sodium chloride. The relative fluxes (corrected with
the buffer flux) are given in relation to the volumetric throughput.

Seeing the correlation between the flux decay of Planova 20N and the degree of protein
self-association, which can be represented by dissociation interaction parameter, kD, we looked at
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the correlation between the kD and the average filtrate flux to see if we can use kD to predict the
filtrate flux of a virus filter. As is shown in Fig 4.6, in phosphate buffer, a lower negative kD is
associated with a lower average flux. Similarly, in acetate buffer, the lowest filtrate flux was
observed at pH 7.5, without the presence of NaCl, when the kD was also the lowest of - 32.76 ml/g;
while when the fluxes are higher at pH 7.5 and pH 5.0, with 200 mM NaCl, the kD were higher as
of -8.0± 1.0 ml/g. In acetate buffer, no salt, at pH 5.0, we measured a positive kD value, indicating
repulsive intermolecular forces. When kD turned positive, the flux does not follow the same trend
as the others. This could be caused by the interaction between the protein molecules and the filter
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Figure 4.6 Average flux of Planova 20N in sodium phosphate buffer or Tris-acetate buffer at a
lower or a higher pH, with the presence or absence of 200 mM sodium chloride. The diffusion
interaction in the corresponding conditions are plotted as well.
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Figure 4.6 (Cont.) Average flux of Planova 20N in sodium phosphate buffer or Tris-acetate buffer
at a lower or a higher pH, with the presence or absence of 200 mM sodium chloride. The diffusion
interaction in the corresponding conditions are plotted as well.

Table 4.4 The average flux and the diffusion interaction parameter, kD, of the protein in different
buffer solutions.

mAb conc. 5 g/L

NaCl (mM)

pH

Average Relative
Flux (%)

KD

(±SD)
6.0

87.48±2.06

- 8.82 ml/g

7.5

88.07±2.18

-9.42 ml/g

6.0

75.78±4.19

-19.08 ml/g

7.5

80.12±3.27

- 15.11 ml/g

5.0

81.61±1.75

- 7.64 ml/g

7.5

83.19±1.33

- 8.99 ml/g

5.0

69.65±2.07

2.19 ml/g

7.5

4.27±6.12

- 32.76 ml/g

200 mM
Phosphate buffer
0 mM

200 mM
Tris-acetate
buffer
0 mM
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4.4 Conclusion
The diffusion interaction parameter, kD, a parameter derived from the second virial coefficient B22,
can be used to describe protein self-association properties. In this study, we measured the
hydrodynamic diameter and the diffusion coefficient of a monoclonal antibody, mAb A, in eight
different solution conditions using dynamic light scattering (DLS) at five different concentrations.
The eight conditions cover different buffer species, pH and salt concentrations. kD values were
calculated by plotting the diffusion coefficient against the protein concentration. Virus filtration
of the mAb A with a virus filter, Planova™ 20N were also performed in the same solution
conditions. In all cases, there was a significant flux decay at the beginning, followed by a minor
change of flux in the subsequent filtration process. The initial flux decay is likely due to the
concentration polarization formed on the feed side of the membrane, with protein present in the
solution. However, in the following course of the filtration, the difference of fluxes was observed
in different solution conditions. This is likely due to the changes of solution viscosity, which can
be reflected by the variation in 𝑘𝐷 . Thus, we looked for the association between the kD values of
the protein and the average relative flux of the virus filter. Results shown that when there is an
attractive intermolecular force (negative kD), within the same buffer species (phosphate or acetate)
lower kD value is correlated with a lower filtrate flux. However, it is non-comparable in different
buffer, due to the different interaction between the buffer ions and the protein molecule. Also,
when the kD turns to a positive value, which indicating an existence of a repulsive intermolecular
forces, kD also cannot be used to predict the flux anymore.
Diffusion interaction parameter can be easily determined using a DLS device, in a freesolution, label-free manner. It can be used to predict the filtration behavior and the relative flux
decay of a virus filter. However, this application is only limited to the flux decays caused by
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reversible aggregates formed due to attractive intermolecular forces. Further studies are needed to
determine how the buffer species, properties of the protein molecules and the protein-membrane
interactions affects the kD-flux correlations.
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Chapter 5 Filtration with Single-layer Virus Filter and Imaging of the Filter after
Filtration of Fluorescently Labeled Protein and Virus
Abstract
Virus filtration is an integral step of the manufacturing of biopharmaceuticals to assure
the viral safety of mammalian cell-derived biotherapeutics. Compared to other ultrafiltration
membranes, virus filters possess unique structures without significant defects, through which
viruses could pass. Both the filtrate flux and virus retention capability are influenced by the
membrane properties, such as the porosity, pore size distribution, thickness, and membrane
chemistry. Multiple recent studies have shown that usage of fluorescently-labeled bacteriophage
or nanoparticles together with confocal scanning electron microscopy allowed us to visualize the
internal structure and particle capture behavior of virus filters. However, the surface
characteristics of bacteriophage and nanoparticles are very different from commonly used model
viruses. The objective of this work is to demonstrate direct visualization of fluorescently labeled
minute virus of mice (MVM) and a monoclonal antibody within a commercial virus filter. A
comparison of a commercial virus filter's single-layer module and double-layer modules were
also made regarding their filtrate flux and virus removal. Results obtained from these studies
demonstrated the correlation between the particles' location and the virus filtration behavior of a
virus filter.
5.1 Introduction
Virus filtration membranes remove virus from the protein product stream based on a sizeexclusion based mechanism. Commercial parvovirus filters have a pore size around 20 nm (filter
specific), and they are designed to remove viruses with 18-24 nm in size, while retrovirus filters
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typically have a pore size around 50-70 nm to remove viruses as large as 100 nm. In a typical
downstream purification process, a virus filter is expected to provide an over 4 log reduction in
virus titer. The first-generation commercial virus filters operate in a tangential-flow filtration
(TFF) mode, where the flow direction is parallel to the membrane and constantly sweep the
membrane to reduce the formation of foulants (Reis & Zydney, 2001). However, since
implementing normal-flow filtration (NFF) is simpler than TFF and presented the advantage of
reduced capital cost and labor, current commercial virus filters mostly operate in a normal-flow
mode. Virus filters are designed to single-use to reduce the cost and labor for regeneration and
validation (Korneyeva & Rosenthal, 1998).
The most commonly used virus filters and their properties are shown in Table 1.5 in
Chapter 1. Those commercial virus filters have unique structures. For example, Viresolve® Pro is
a highly asymmetric membrane (thickness: 140 microns) made from hydrophilized
polyethersulfone (PES). It has a thin skin layer with a small pore size, providing virus retention
and a thick macroporous support layer, providing mechanistic integrity and serving as an internal
depth filter to remove large aggregates. Each membrane device is composed of two layers of
such membranes. The pore size of Viresolve® Pro varies between 20-300 nm, and the layer
responsible for parvovirus capture is located at 500-1000 nm upstream of the filter outlet
(Nazem-Bokaee, Fallahianbijan, Chen, & O'Donnell, 2018). Planova™ 20N is made from
cuprammonium-regenerated cellulose (CRC) and has a hollow fiber structure. It has a network
of interconnected voids and capillaries, making a multilayered membrane with a threedimensional (3D) microporous structure in which virus particles are effectively captured while
protein molecules pass through (Harada, et al., 1989). An observation with transmission electron
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microscopy (TEM) revealed that Planova™ 20N is about 40 μm thick and comprises a rough
inner, a dense middle, and a rough outer layer (Adan-Kubo, Tsujikawa, & Takahashi, 2019).
Microscopy, including scanning electron microscopy (SEM), TEM, and confocal
scanning electron microscopy, had been widely used to visualize the membrane structure and
pore size distribution of virus filters (Bakhshayeshi, Jackson, Kuriyel, Mehtac, & Zydneya,
2011) (Fallahianbijan, Giglia, Carbrello, & Zydney, 2017) (Adan-Kubo, Tsujikawa, &
Takahashi, 2019). However, most of the work focused on using non-biological particles (gold
nanoparticles, fluorescent nanoparticles, etc.) or fluorescently labeled bacteriophage. Their
surface properties are different from viruses or proteins; thus, they can not describe the behavior
of viruses and proteins accurately. In this work, an FDA recommended model virus, minute virus
of mice (MVM), and a monoclonal antibody is labeled with a fluorescent dye and filtered
through a commercial virus filter, Filter V. Then imaging was done with confocal microscopy to
visualize the location of the virus and protein particles. Besides, a comparison between single
and double layer filtrations was also made to correlate the particle location to the filtration
behavior.
5.2 Materials and Methods
5.2.1 Virus Filter and Virus Filtration
The properties and the operating condition of the evaluated filter, Filter V, are listed in
the following table (Table 5.1). The commercial Filter V has two lays of flat sheet membranes;
however, to better understand the filter behavior, in this set of experiments, a single layer module
of the Filter V is used for the virus clearance experiments. The filtrations were done in a constant
pressure mode, with the transmembrane pressure value was determined based on the filter
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manufacturer's recommendation. The target throughput of the membrane was determined based
on their dollar/gram values. Prefiltration can remove large aggregates as well as some oxidized
or denatured protein foulants. A hydrophobically interacting prefilter containing entrapped
diatomaceous earth and functions by adsorptive mechanism was used as a prefilter for Filter V.
Table 5.1 The filter properties and the operating conditions of the Filter V and its prefilter.
Membrane material
Membrane structure
Membrane area
Inlet Pressure
Target Throughput
Name
Pore size
Prefiltration method

Material
Structure
Area
Mechanism

Filter V
Polyethersulfone (PES)
Flat sheet;
Asymmetric;
Single-layer or 2 layers.
3.1 cm2
30 psi
990 L/m2
Hydrophobic interacting depth filter
N/A
Diatomaceous earth (major
effective component)
Capsule filter
5 cm2
Adsorption

The monoclonal antibody, mAb A, used for this work has a molecular weight around 155
kDa and an isoelectric point (pI) around 7.2 to 7.5. Eight solution conditions, with varying buffer
pH, ionic strengths, and buffer species, were studied in this work. The proteins were first buffer
exchanged into the desired solution with the tangential flow filtration method (Ultrafiltration and
Diafiltration/ UFDF) before each set of virus filtration experiments. In two experiments, the
protein was the first buffer exchanged into sodium phosphate buffer, without salt condition,
using UF/DF, while the 200 mM salt was added using a titration method to see the effect of
UF/DF itself (Table 5.1, b). The solution conditions and protein concentration in the
corresponding conditions are listed in the table below:
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Table 5.2 Solution conditions for the filtration with a single layer Filter V and the protein
concentration in the corresponding solution conditions. (a) Buffer exchange was done with
UF/DF. (b) Salt was added with the titration method.
a.
Buffer Type
NaCl (mM)
pH
Protein
Concentration
(g/L)

6.0

Sodium Phosphate Buffer
200
0
7.5
6.0

5.01±0.02

4.92±0.01

4.67±0.07

Tris-acetate Buffer
200

0

7.5

5.0

7.5

5.0

7.5

4.69±0.05

5.09±0.01

5.20±0.00

4.97±0.01

2.33±0.00

b.
Buffer Type
NaCl (mM)
pH
Protein Concentration (g/L)

Sodium Phosphate Buffer
200- salt added with titration methods
6.0
7.5
4.79±0.01
4.90±0.01

A typical virus filtration experimental flow with Filter V is as follows: the deionized (DI)
water and the equilibration buffer are filtered with a 0.22 µm filter to remove large particles and
other contaminants such as bacteria. Prefiltration was done for the protein solutions to remove
any large aggregates or hydrophobic foulants. The prefilter was first flushed with DI water and
equilibration buffer. Then the 0.22 µm filtered protein solution was filtered at 13-14 psi to
achieve filtrate flux of 2-3 mL/min. Tubing that can reach the bottom of the filtrate container was
connected to the prefilter outlet to avoid aggregation caused by dripping. Then an MVM stock
was spiked into the prefiltered protein solution at a target titer of 7.4 logs/mL (titer determined
with qPCR). The virus spiked protein solutions were then treated with a 0.22 µm filter to remove
any contaminants from the virus stock. Planova™ pressure reservoir (Asahi Kasei, Japan) was
used for all the filtrations with the pressure controlled by the Ashcroft pressure gauge. Water
flush, buffer flush, and product filtration were done at 30.0 psi. A total of three fractions
(Fraction 1: 0-110 mL, Fraction 2: 110-220 mL, Fraction 3: 220-330 mL) were collected from
each run to determine if there is any change in the protein recovery and log reduction value
(LRV) with the filtration proceeds. The cumulative weight of the filtrate was recorded every
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minute using a Balance-Link software connected to a Mettler Toledo scale (Columbus, OH). The
recorded data was used for calculating the filtrate flux. The protein concentration of the feed and
each filtrate fraction was determined by measuring the absorbance at 280 nm with a
spectrophotometer to determine protein recovery. The virus titer of the spiked feed and each
filtrate fractions was determined for calculating the LRV.
5.2.2 Virus Production and Virus Titer determination
The minute virus of mice (MVM) is a representative parvovirus that can infect CHO cell
culture. We produce MVM in the house using an ultracentrifugation method. The detailed
production and purification methods, and the virus titer determination methods, including qPCR
and infectivity assays, are included in Chapter 3.
5.2.3 Fluorescent Labeling and Confocal Imaging
DyLight 488 NHS Ester and DyLight 633 NHS Ester fluorescent dye were used for
labeling the feed protein and the MVM virus, respectively. The 1 mg dye was dissolved in 1 ml
of DMF solution before use and stored at -20 oC. The protein and the MVM were buffers
exchanged into the labeling buffer (0.1 M sodium phosphate, 0.15 M sodium chloride, pH 7.5)
with dialysis or 100 kDa Amicon Ultra centrifuge filter. Then the labeling reaction was done at
room temperature for an hour with gently agitating every 10 min. The excess dye was then
removed by performing dialysis for 4 hours with 100 DV buffer. Then the fluorescently labeled
protein or MVM virus was spiked into the bulk protein solution or buffer. The filtration
experiments were performed in the same way as previously described, using the double-layer
module Filter V. The images were taken with a Leica SP5 confocal optical microscopy. The
optical resolution (400 nm) of the microscopy is 0,14 μm, 0,16 μm and 0,5 μm at 63x, 40x and
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10x magnification, respectively. The digital revolution of the setup ranges from 512x512 pixels
to 8196x8196 pixels.
5.3 Results
5.3.1 Filtration Flux and Virus Retention with Single-layer Membrane
A throughput of 990 L/m2 was targeted for Filter V, as recommended by the industrial
sponsor. The permeability of Filter V as a function of throughput in L/m2 over the course of the
filtration of mAb A in 20 mM sodium phosphate buffer (Figure 5.1) and 20 mM Tris-acetate
buffer (Figure 5.2) are presented below. The target MVM spiking level was 7.4 logs/ml
(determined with qPCR). However, due to the experimental errors, there are slight differences in
the viral load in different runs (Figure 5.1,b and Figure 5.2, b). The filtrations were performed
under the recommended pressure of 30 psi. Each data point was an average of the flux
measurement over a 10 min interval.
As is seen from Figure 5.1, except in phosphate buffer 0 mM NaCl condition at pH 7.5,
Filter V performed well in all the other conditions, with the throughput reached over 800 L/m2.
In the presence of 200 mM salt, at both pH 6.0 and pH 7.5, the runs with the salt added using a
titration method performed much better than the runs with the salt added using UF/DF; this is
indicating that pumping during UF/DF did generates aggregates/impurities that cannot be
removed with the hydrophobic interacting prefilter. Without the presence of salt, at pH 7.5, the
flux dropped significantly starting from the beginning of the filtration, and the overall throughput
was less than 250 L/m2, which is only about ¼ of the target volumetric throughput. On
the opposite side of the spectrum, at pH 6.0, 0 mM NaCl condition, the filter performed very
well, with the throughput reached over 1000 L/m2, presenting a flux stayed stable throughout the
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filtration. This is indicating that without the presence of salt, electrostatic interactions play a
major role, and when the solution pH is close to the protein pI, molecules with neutral surface
charge tend to aggregate and cause membrane fouling. In contrast, when the pH is around 6.0,
molecules all possess negative charges; thus, repulsive forces between the molecules prevent

Permeability (LMH/Bar )

them from forming aggregates, then protect the membrane from fouling and flux decay.
phosphate buffer 200 mM NaCl pH 7.5
phosphate buffer 200 mM NaCl pH 6.0
phosphate buffer 0 mM NaCl pH 7.5
phosphate buffer 0 mM NaCl pH 6.0
phosphate buffer 200 mM NaCl pH 7.5- repeat
phosphate buffer 200 mM NaCl pH 6.0- repeat

450
400
350
300
250
200
150
100
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0
0
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Throughput (L/m2)
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a.
Water Flush
Permeability
Flux
(LMH/Bar)
(LMH)

Buffer Flush
Permeability
Flux
(LMH/Bar)
(LMH)

Feed titer
(qPCR)logs/ml

Phosphate buffer, no salt,
pH 6.0

422.61

847.14

443.53

917.42

7.06 ± 0.73

Phosphate buffer, no salt,
pH 7.5

427.37

883.99

446.21

922.96

7.39 ± 0.10

Phosphate buffer, with salt,
pH 6.0

471.54

975.35

497.72

1029.50

7.17 ± 0.11

Phosphate buffer, with salt,
pH 7.5

498.61

1031.34

513.46

1062.06

7.13 ± 0.06

Phosphate buffer, with salt,
pH 6.0-repeat

448.88

928.47

493.43

1020.63

6.83 ± 0.01

Phosphate buffer, with salt,
pH 7.5-repeat

447.47

925.57

484.08

1001.28

6.94 ±0.09

b.
Figure 5.1 Filtration of mAb in 20 mM sodium phosphate buffer with Filter V. (a) The filter
permeability over the course of filtration, plotted against the volumetric throughput. (b) The
water and buffer flush permeability/flux and the feed titer determined with qPCR.
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As is shown in Figure 5.2, in the tris-acetate buffer, except at pH 7.5 without salt
condition, Filter V also performed well, with the throughput reached over 800 L/m2. Without
salt, at pH 7.5, the filter crashed immediately after the filtration started. Only one data point was
collected from this run, as the throughput reached less than 10 L/m2. At pH 7.5, with the
presence of 200 mM NaCl, the throughput reached over 800 L/m2. However, the flux dropped to
<20% of the initial value. In contrast, at pH 5.0, with or without salt, the filter performed very
well, presented a stable high flux, and throughput of >1000 L/m2. These results also can be
attributed to electrostatic interactions between protein molecules.
The different behavior of the Filter V in phosphate buffer and Tris-acetate buffer can be
explained by the different protein destabilizing behavior of the phosphate and acetate ions,
following the Hofmeister series (Du, Wickramasinghe, & Qian, 2010). The cations with higher
charges have more destabilizing effects on proteins, while the opposite is true for the anions (Du,
Wickramasinghe, & Qian, 2010) (Du, Wickramasinghe, & Qian, 2013). Ions that do not directly
interact with proteins, presenting stronger hydration degrees, can stabilize the protein. In
contrast, ions that exhibit weak hydration but with a stronger tendency to directly interact with
the protein would destabilize the protein. This could be one of the reasons why at pH 7.5 without
salt, the filter performance was worse in the Tris-acetate buffer than in phosphate buffer.
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No Signal

b.
Figure 5.2 Filtration of mAb A in 20 mM Tris-acetate buffer with Filter V. (a) The filter
permeability over the course of filtration, plotted against the volumetric throughput. (b) The
water and buffer flush permeability/flux and the feed titer determined with qPCR.

Filtration of the mAb A with a double layer Filter V was shown in Figure 5.3. Compared
to double-layer filters, the single-layer filter presented similar flux declining patterns during the
mAb A filtrations, except the overall filtrate flux, including the water and buffer flux, doubled
the previous values.
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Figure 5.3 The filtration of mAb A with double-layer Filter V in different solution conditions.
(a) Sodium phosphate buffer. (b) Tris-acetate buffer.

The titers of the virus detected in each fraction are shown in Table 5.3. For the filtrations
with the protein in phosphate buffer with salt, only the results for the runs with the salt added
with titration methods are shown. In the sodium phosphate buffer, virus breakthroughs occurred
in all the four tested solution conditions. It was the most severe at pH 7.5 without salt, as the
virus titer was the highest in the first fraction (F1). In the tris-acetate buffer, virus clearance
results obtained from the condition without salt pH 7.5 is excluded as almost no filtrate was
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collected from this run. Virus breakthrough occurred in all the other three conditions, and it was
the most severe at pH 7.5 with 200 mM NaCl present. The corresponding throughput was also
the lowest in this solution condition
Table 5.3 Solution conditions, corresponding total viral loads in logs TCID50, virus titer in each
fraction (logs TCID50/ml), and the total LRV for the mAb A filtrations with Filter V.
NaCl
(mM)
Sodium
Phosphate
Buffer

200

Trisacetate
buffer

200

0

0

pH
7.5
6
7.5
6
7.5
5
7.5
5

Total
virus
(logs)
7.18 ± 0.30
7.50 ±0.44
6.96 ±0.54
7.17 ±0.52
7.53 ±0.44
7.44 ±0.44
1.88 ±0.00
6.72 ±0.38

Virus Titer in Each Fraction (logs/ml)
F1
1.58 ± 0.12
1.67 ± 0.17
2.33 ± 0.20
1.75 ± 0.19
1.92 ± 0.19
1.58 ± 0.12
≤1.50±0.00
≤1.50±0.00

F2

F3

2.33 ± 0.20 2.08 ± 0.2
1.75 ± 0.19 2.17 ± 0.20
N/A
2.00 ± 0.25 2.00 ± 0.25
2.42 ± 0.24 2.10 ± 0.20
1.92 ± 0.19 2.42 ± 0.25
N/A
≤1.50±0.00 ≤1.50±0.00

Chase
3.75±0.32
3.08±0.22
2.67±0.22
2.08±0.24
3.08±0.22
3.58±0.19
1.58±0.12

LRV
2.49 ± 0.32
3.06 ± 0.40
2.75 ± 0.36
2.74 ± 0.48
2.84 ± 0.43
2.76 ± 0.40
≥0.00±0.00
2.75 ± 0.20

The double-layer Filter V provides excellent retention for MVM in the filtration of mAb
A in the eight solution conditions, with no virus breakthrough observed (Table 5.4). The overall
LRV was high. Only when the solution pH is close to the pI of MVM, aggregation of viruses
could happen, and some viruses got removed from the feed by the 0.22-micron prefilter, leading
to a reduced total viral load and lower LRV. In addition, the decreased stability of the protein in
those solution condition could also have caused the reduction of the feed virus titer as well.
However, during the filtration with single-layer Filter V, the total viral load was high in all the
conditions (7.00 ±0.50 logs TCID50), but the total LRV was low (2.5-3.0) due to the virus
breakthrough. This can be attributed to the reduced membrane resistance and the transport
pathway in the single-layer module. These results are in line with the conclusion obtained in
Chapter 4.
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Table 5.4 Solution conditions, corresponding total viral loads in logs TCID50, virus breakthrough
status expressed with the positive-well numbers in LVP, and the total LRV for the mAb A
filtrations with Filter V.
pH

NaCl
concentration
(mM)

Total viral
load (logs)

Breakthrough
status

Sodium
Phosphate
buffer

6.0

Tris-acetate
buffer

5.0

200
0
200
0
200
0
200
0

7.09
4.72
7.35
7.31
6.66
4.17
7.50
2.67

NO
NO
YES
NO
NO
NO
NO
NO

7.5

7.5

LVP # of
positive
wells/ 96
wells (F1;
F2; F3; BC)
0; 0; 0; 0
0; 0; 0; 0
0; 0; 0; 1
0; 0; 0; 0
0; 0; 0; 0
0; 0; 0; 0
0; 0; 0; 0
0; 0

LRV

≥5.05
≥3.29
5.21
≥5.96
≥4.55
≥2.05
≥5.38
≥ 1.51

5.3.2 Confocal Imaging of the Filter After the Filtration of Fluorescently Stained Virus and
Proteins
A combination of confocal scanning microscopy and the fluorescently labeled
viruses/proteins could be a powerful technique to visualize the location where the virus is
captured within the membrane and where the protein fouling occurred. MVM virus was
fluorescently labeled with DyLight 633 NHS Ester fluorescent dye and spiked into 20 mM
sodium phosphate buffer at pH 6.0. Filtration was performed with Filter V and the membrane
was observed under a confocal electron microscopy. As is shown in Figure 5.3 Panel a, the larger
aggregates of the virus were captured within the porous section of the membrane and most of the
virus are captured within the dense retentive layer of the filer.
DyLight 488 NHS Ester dye was used to label mAb A, and a filtration was performed
with Filter V (Figure 5.3, Panel b). The fluorescent signal from the protein could be seen all over
the membrane, indicating that protein absorption/ deposition occurred throughout the membrane.
However, the flux data (not shown here) has shown that after protein labeling, the filtrate flux of
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the membrane was very different from the flux of the filtration for protein without a fluorescent
label. The labeling ratio and the prefiltration method is critical to reducing the effect of
fluorescent dye on virus filtration performance. In the latter experiments, the labeling molar ratio
was adjusted from 1/10 to 1/1000.
a.

Filtration

Cross section

Top

Bottom

Filtration

Cross section

b.

Top

Bottom

Figure 5.4 Top, bottom, and cross-sectional images of Filter V membrane after filtration of
fluorescently labeled (a) MVM and (b) mAb A. DyLight 488 NHS Ester dye (green) was used
to label the protein and DyLight 633 NHS Ester dye (red) was used for labeling MVM virus.
The fluorescently labeled MVM (with DyLight 633 ) and mAb A (with DyLight 488 )
were spiked into a mAb A solution in 20 mM sodium phosphate buffer at pH 6.0 with 200 mM
NaCl, then filtered through a double-layer Filter V. The overlay of the figures captured from the
top, bottom and the cross-section (Z-stack) of the top layer and the bottom layer are shown in
Figure 5.5. As is shown in red signals, a small number of large virus aggregates are captured in
the large porous section of the first layer, while most of the viruses are captured at the bottom
section (with smaller pore size) of the first layer. In the second layer, a very small number of
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viruses are present in the topper section (can only be seen from the Z stack figure). In contrast,
showing with the green signal, there is a smaller amount of protein aggregates captured in the
macroporous section of the 1st layer, while a large number of proteins are captured at the bottom
of the first layer (together with the viruses). However, In the second layer, a greater amount of
proteins are captured at both the top and the bottom of the filter. These results can explain why
filtration with a single-layer filter module has more virus breakthrough than the double-layer
membrane module.
st

1 Layer
Top view

Virus

Protein

Overlay

Bottom view

Virus

Protein

Overlay

a.
Figure 5.5 The top and the bottom views of a Filter V membrane’s (a) first and (b) second layer
after filtration of fluorescently labeled MVM and mAb A. DyLight 488 NHS Ester dye (green)
was used to label the protein and DyLight 633 NHS Ester dye (red) was used for labeling MVM
virus. (c) the A stacking images showing the cross-section view of the membranes are shown as
well.
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Figure 5.5 (Cont.) The top and the bottom views of a Filter V membrane’s (a) first and (b)
second layer after filtration of fluorescently labeled MVM and mAb A. DyLight 488 NHS Ester
dye (green) was used to label the protein and DyLight 633 NHS Ester dye (red) was used for
labeling MVM virus. (c) the A stacking images showing the cross-section view of the
membranes are shown as well.
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Figure 5.5 (Cont.) The top and the bottom views of a Filter V membrane’s (a) first and (b)
second layer after filtration of fluorescently labeled MVM and mAb A. DyLight 488 NHS Ester
dye (green) was used to label the protein and DyLight 633 NHS Ester dye (red) was used for
labeling MVM virus. (c) the A stacking images showing the cross-section view of the
membranes are shown as well.
5.4 Conclusions
Virus filtration experiments were conducted with the single-layer membrane module of a
commercial virus filter, which is commonly used with a module comprises of two layers of
membranes. The objective of the work is to understand the effect of membrane structure on the
flux declining behavior and the virus retention capability. Compared to the double-layer filter,
which is robust in MVM clearance, the single-layer membrane provided a much lower virus
reduction. Also, the runs with lower fluxes had shown more virus breakthrough.
Besides, fluorescently labeled MVM virus and a monoclonal antibody, mAb A, were
spiked into mAb A solution and filtered through the commercial virus filter (double-layered) to
visualize the location of the proteins and the viruses. It was found that most of the viruses are
captured at the bottom of the first layer membrane, while proteins are captured across the entire
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membranes, with more of them accumulated at the second layer. This result is in line with the
virus clearance results obtained from the single-layer filtration experiments.
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Chapter 6 Conclusions and Future Direction
6.1 Conclusions and Discussion
Virus clearance is critical to the manufacturing of mammalian cell culture-based
biopharmaceuticals since the potential virus contamination could not only bring health risk to the
patients but also lead to tremendous economic and regulatory loss. As an integral part of the
downstream purification process, virus filtration is a dedicated step for virus clearance, removing
both retrovirus and parvovirus based on a size-exclusion mechanism. However, the filter
capacity is limited due to the pre-mature fouling of the membrane. Besides, reductions in virus
retention had been observed in some instances. To better understand the underlying mechanism
of flux decay over the course of virus filtration and the factors that could cause virus
breakthrough, in this work, a systematic analysis was made to understand the effects of solution
conditions, protein molecules, and filter type on filtrate flux and the virus retention of virus
filters. The results and conclusions obtained in the previous chapters are summarized in this
chapter and developed into a decision tree (Figure 6.1), which is based on the properties of the
feed solution, solution condition, and protein properties to aid in choosing the right virus filter
while minimizing the material needed in the VF assessment studies.
6.1.1 The Factors that Influence Virus Filter Flux and Capacity
The downstream processing of biopharmaceuticals involves multiples steps, including
Protein A and ion-exchange chromatography, low pH virus inactivation, and the buffer exchange
with UF/DF, during which solution condition varies to achieve the highest efficiency for each
step. The virus filtration is mostly located at the end of the entire purification train. However, the
location can be adjusted if the adjustment can increase the virus filter capacity. Thus, it is
essential to understand how the solution condition affects membrane fouling behavior.
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Fc-fusion protein is a single complex of protein composed of the Fc-domain of an
immunoglobulin G and a protein (or a polypeptide) with unique biological activity. Because of
the unique molecular structure of Fc-fusion proteins, the purification processes developed for
traditional monoclonal antibodies do not always deliver the best purifying efficiency for Fcfusion proteins. Thus, in Chapter 2, the effect of solution conditions (buffer type and salt
concentration) and virus filter properties were systematically studied in the presence of an Fcfusion protein, spiked with MVM. The combined pore-blocking and cake filtration model was
successfully applied to describe the flux reduction trend of all the three commercial virus filter in
various solution conditions. According to this model, the initial flux decline through a membrane
is caused by pore blockage by the physical deposition of large aggregates on the membrane
surface (Ho & Zydney, 2000). Fluid still can flow through the blocked area, only with the
increasing resistance to the flow over the blocked region while additional protein is convected to
the membrane surface. However, this model was initially developed for a microfiltration
membrane, which has a much larger pore size than virus filters. Because virus filtration
membranes have a unique membrane structure with a macroporous structure facing the feed and
selective layer at the bottom. Thus, even with a good fitting, it does not mean the fouling occurs
exactly by pore-blockage and cake formation. In addition, this model was developed based on
the classical fouling model, which assumes all the pores are uniform, cylindrical, and straight.
However, virus filters have pore size varying along with the depth of the filter, and pores with
torturous interconnected structures. This model is mechanistic, thus, cannot be applied to predict
the flux declining behavior of a filter. However, this combined pore blockage and cake filtration
is a useful phenomenological model.
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Diffusion interaction parameter, 𝑘𝐷 can be used to predict reversible intermolecular
interactions between proteins. In Chapter 4, DLS was used to measure the hydrodynamic
diameter and the diffusion coefficient of a mAb in various solution conditions to see how the
solution conditions affect 𝑘𝐷 . Also, we observed that a lower filtrate flux is correlated with a
stronger attractive intermolecular force ( a more negative 𝑘𝐷 value). This is likely due to the
increased viscosity of the solution caused by stronger intermolecular electrostatic interactions.
These results demonstrated evidence that choosing the solution conditions, which increase
the protein solubility and reduce the attractive intermolecular forces, can improve virus filter
capacity. Also, biophysical tools, such as DLS, can help with making the right decision as well.
6.1.2 The Factors that Influence Virus Retention of a Virus Filter
During virus filtration, the reduction of virus retention could happen. Multiple theories were
brought up to explain the underlying mechanism of virus breakthroughs, such as the internal
virus polarization and small pore blockage model. We have investigated how the protein
molecule, virus filter type, and the solution conditions affect virus retention and see if the current
theories can explain the experimental results. According to the ‘small ore blockage model,’ the
LRV decline happens during virus filtration due to the selective plugging of smaller pores by
impurities and foulants, leading to the viruses getting through the remaining larger pores (Bolton,
et al., 2005). The small pore blockage model predicts that virus breakthrough tends to happen
more easily when there is more flux decline. However, it was observed in this work that more
decline of virus retention occurred when the filtrate fluxes are higher in one of the virus filters.
According to the ‘internal virus polarization model,’ LRV declines arise from an accumulation of
the phage in the reservoir (upper) layer within the membrane (Jackson, et al., 2014). However, it
was seen in Chapter 3 that the accumulated amount of virus loaded onto the membrane is not
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directly correlated to the reduction of LRV. Thus, the observation was inconsistent with the
model.
Process disruption could lead to an LRV reduction. Our results have shown that a more
extended process hold can lead to more virus breakthroughs, indicating that it is better to reduce
the length of process interruption in manufacturing. One hypothesis is that trapped viruses can
move to larger pores due to Brownian motions under the no pressure-conditions, leading to virus
breakthrough. To better understand the relations between virus breakthrough, filtrate flux, and
the transmembrane pressure, a series of virus filtrations at different fluxes were done under
constant flux.
Comparison between the filtration with one layer membrane and two-layer membranes was
conducted. Filtration with a two-layer membrane gives a similar flux pattern to the filtration with
one layer membrane during the filtration of a monoclonal antibody spiked with MVM. However,
much more virus breakthrough observed in the filtration with one layer membrane (Chapter 6).
To examine the virus retention behaviors and the location of protein and virus within a
membrane, confocal optical microscopy imaging was done. It was seen that the virus was
captured mostly at the bottom of the first layer filter while the protein was observed all across the
membranes. This indicates that when the hydraulic conductance increase of transport pathway
decrease can lead to an increased breakthrough of viruses. The images obtained in this work only
can be a reference to show the location of viruses or proteins in the membrane while not
providing quantitative information. There is some limitation in using fluorescent dye labeling
and confocal imaging studies. As multiple factors influence the capturing of the fluorescent
signal from the protein or virus, such as the particle concentration, dye quantum yield,
microscope optical filters, laser power, wavelength. Thus, a more systematic study with confocal
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imaging should be done in the future to get more quantitative information about particle
capturing in a membrane.
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Figure 6.1 A decision tree for developing an efficient virus filtration process.
A decision tree was made based on the results obtained in this dissertation to select the
most effective virus filter for a process (Figure 6.1). Planova™ BioEx provides a robust virus
clearance with high transmembrane pressure (45 psi), while Planova™ 20N provides a stable but
relatively low filtrate flux. Besides, Planova™ 20N is also more susceptible to virus
breakthrough in some conditions. When the feed protein has a hydrophobic nature (such as an
Fc-fusion protein), the filters with more hydrophobic base membranes, Viresolve® Pro and
Planova™ BioEx, foul easier when the solution ionic strength is higher as salt promotes
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hydrophobic interactions. In addition, when the solution pH is close to the isoelectric point of the
protein, they tend to be neutral in charge and form aggregates. Thus, choosing Planova™ 20N is
a better choice. However, in other conditions, Viresolve® Pro will be a better choice, as it
provides a robust virus clearance and a high permeability.
Overall, this decision tree can guide us in choosing the right filter for an efficient process
in an industrial setting. According to the information provided by the membrane manufacturers,
the batch-to-batch variability can cause an up to 10% difference in water permeability. To reduce
this variance, the filtrate flux was normalized to the buffer flux for each run in this work.
However, it is worth mentioning that most of the experiments were done only one run (n=1) due
to the limited amount of feed protein provided. Thus, the statistical significance of the different
performances is worth further studies.
6.2 Recommendation and Future Direction
The results shown in this dissertation provided useful insights for understanding the
fundamental mechanisms that cause flux decline and virus reduction of virus filters. This
information can be used to design an efficient virus filtration membrane and a unit operation
with high filter capacity and high virus reduction in the downstream processing of
biopharmaceuticals. Membrane structure plays a critical role in virus filtration. A composite
membrane, with a steep pore size gradient, with a large porous structure made from polymer
providing support and mechanistic stability, and a selective skin layer made from more
hydrophilic structure providing virus retention will make a more successful virus filter.
As is shown in this dissertation, the filtrate flux and the virus breakthrough of a virus filter
are greatly affected by solution conditions; however, those are also a function of other factors,
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such as the filter type and protein molecules. Even though a few different filters and different
molecules were used in this study, how exactly those factors affect filtrate flux was not
profoundly looked into. In recent years, several studies have used fluorescently labeled
nanoparticles, confocal imaging, and gold nanoparticles, scanning electron microscopy to look
into the structure of the virus filter and the locations of particles with different sizes. Those
studies provided great insights for understanding particle distribution within the filters. However,
considering the difference between the characteristics of nanoparticles and actual proteins (or
viruses), finding ways to look at the locations of virus particles or protein molecules and their
interactions within the membrane would provide greater insights. We have obtained some
preliminary data from experiments done with fluorescently labeled proteins and MVM virus in a
commercial virus filter. A more systematic study can be built on those results to understand the
underlying mechanism better.
Continuous processing (CP) had been successfully applied to multiple industries. However,
due to the sensitive nature of the protein-based therapeutics, they are manufactured in a batchbased processing mode. CP has been getting increasing attention from biopharmaceutical
manufacturers and is believed to be the next evolutionary step for biotechnology. Compared to
traditional manufacturing, CP presents multiple advantages, such as increased efficiency,
reduced space and cost, and stable product quality. Over the past decades, many new
technologies are developed to apply in continuous processing, such as the perfusion bioreactor,
alternating tangential flow filtration (ATF), and periodic counter-current chromatography (PCC)
system. Implementing virus filtration into a continuous processing train is somewhat complicated
as it has to deliver at least 4 logs LRV, meanwhile, maintain a reasonable capacity. As the
chromatography steps are conducted in a constant flux mode, virus filtration also should be
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adapted to operate at constant flux. Flux can affect the performance of the virus filter. In the
future, the effect of the flux and the corresponding pressure should be studied separately, for
example, by applying high pressure at the filter inlet while controlling the flux at the outlet using
a pump. In addition, the effect of intermediate washing steps (resulted from washing steps of
chromatographies) on virus filter flux and virus retention should also be looked into since the
washing steps could redistribute the particles trapped inside the virus filters, thus could
potentially increase virus breakthrough or decrease reversible membrane fouling. Currently, the
virus filter assessment studies are done in a batch mode. A new spiking and assessing strategy
should be designed to meet the needs of continuous processing, such as the ‘in-line spiking’ etc
(Johnson, Brown, Lute, & Brorson, 2017).
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